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The objective of this thesis was to investigate the chemotherapeutic potential 
of a group of compounds with an indole core structure as isoprenylcysteine carboxyl 
methyltransferase (Icmt) inhibitors. Ras proteins contain a C-terminal CaaX motif 
which direct the proteins through a three-step post-translational process termed 
prenylation, in which Icmt catalyzes the last step methylation of the C-terminal 
prenylcysteine. Inhibition of Icmt has multiple impacts on cellular signaling processes 
which ultimately leads to cell death.  
The lead Icmt inhibitor, cysmethynil, was identified from a screen of a diverse 
chemical library of ~10,000 compounds. A structure activity relationship (SAR) study 
was first carried out on the indole core compounds discovered from the library. 
Different methods were employed in this study, namely the (i) principal component 
anaylsis (PCA) and partial least squares projection to latent structures (PLS), (ii) 
multiple linear regression and (iii) comparative molecular field analysis (CoMFA). 
All three approaches complement each other, and identified the steric factor to be 
important for activity. Improved activity was predicted by incorporation of a bulky 
side chain at position 1 of the indole ring while a smaller substituent at the position 5 
phenyl ring was preferred for Icmt inhibition activity.  
Lead optimization efforts guided by the SAR results were performed together 
with conventional analogue design approach. The compounds synthesized were 
classified according to (i) substitution on position 1 (Series 1), (ii) alteration at 
position 5 (Series 2), and (iii) modification of the acetamide side chain at position 3 
(Series 3: tertiary amides, Series 4: amines and Series 5: homologues and 
bioisosteres). A 6th series consisted of compounds with modification made at more 
than one position (1, 3 and/or 5). The synthesized compounds were evaluated for Icmt 
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inhibition activity and effects on the viability of human breast cancer cells. Based 
Icmt inhibitory activity, it was found that the position 3 subsituent was important for 
activity, as demonstrated by the complete loss of activity in compounds lacking a 
substituent at this position. Further evaluation of other variation at this position 
elucidated the importance of a H bond acceptor property at position 3. Optimal length 
and flexibility is also necessary for activity, as seen in the loss of activity for the 
shortened homologue. Although presence of substituents at position 1 and 5 was also 
important for activity, omission of either substituent only resulted in a drop in activity 
rather than a complete loss of activity. The need for a bulky substituent at position 5 
as discovered in the previous QSAR study was verified, as seen by the drop in activity 
when a shorter side chain such as the 5-carbon isoprenyl moiety was incorporated.  
Good correlation was observed between the Icmt inhibition and 
antiproliferative activities. The SAR of the antiproliferative activity observed was the 
same as that of the Icmt inhibitory activity, with the exception that the amine 
analogues (Series 4) were significantly more potent than the other series.  
Computational methods were employed to analyze the results from the 
biological evaluation, specifically the Icmt inhibitory activity, on the 47 compounds 
synthesized. A pharmacophore model was first developed from the Icmt inhibition 
data, identifying aromatic and hydrophobic groups as the main features of the indole 
based Icmt inhibitors, and a H bond acceptor group as the only polar feature in the 
model. Other reported Icmt inhibitors were screened against the model and 5 out of 
the 14 screened were found to comply. Further validation could be carried out by 
actual determination of the biological activity of prospective library screen hits. 
QSAR analysis was also carried out on the same set of biological data using multiple 
linear regression, MOE’s AutoQsar and Sybyl’s CoMFA/CoMSIA. The models 
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complement each other and also agreed with the pharmacophore model, where size 
and hydrophobicity was determined to be the main contributor to activity. 
Visualization of the steric field from CoMFA identified that substituent at position 1 
and 5 provides the bulk important for activity.  
To better understand the consequences of Icmt inhibition, the amino analogues 
identified as the most potent inhibitors thus far, were selected for further detailed 
biological evaluation. Prior studies have demonstrated that inhibition of Icmt by 
cysmethynil has resulted in various downstream effects such as cell cycle arrest and 
induction of autophagy, resulting in cell death. Investigation of these biological 
consequences were conducted on the selected amine analogues and they were found 
to be able to demonstrate the same effects, with some analogues showing activity 
more prominently and at much lower doses.  
In conclusion, the indole analogues are effective as Icmt inhibitors and are 
potentially useful as chemotherapeutic agents. The lead optimization effort has 
elucidated the amine analogues as Icmt inhibitors with significantly improved activity 
in cell-based studies. These compounds may be used for further investigation of the 
outcome of Icmt inhibition and subsequent pre-clinical studies. However, there are 
some limitations in these compounds due to their high lipophilic nature (ClogP > 5). 
Issues may arise in pre-clinical studies due to difficulties in formulating the 
compound into a dosage form that can be administered into the test animals. One 
possible approach to circumvent this problem is to identify new leads with different 
scaffolds that maybe less lipophilic and more drug-like. The pharmacophore model 
generated using the synthesized library of compounds may be useful in this aspect, 
where it can be used to screen against database of lead-like or drug-like compounds 
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that can be readily obtained for biological evaluation. A new lead compound may also 
assist in our quest to further understand the consequences of Icmt inhibition. 
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CHAPTER 1 INTRODUCTION 
1.1. OVERVIEW OF POST-TRANSLATIONAL PRENYLATION OF 
PROTEINS 
Many proteins are subjected to a range of chemical modifications after they 
are synthesized. These modifications are termed post-translation modifications and 
may involve the attachment of other functional groups (by acylation, phosphorylation, 
glycosylation, glycation, prenylation among others) or peptides (eg. ubiquitination) to 
the original protein, a change in the chemical nature of a specific amino acid (for 
example deamination of arginine to give citrulline) or changes in structure like the 
formation of disulfide bridges between cysteine residues. These modifications can 
have a significant impact on the biological activity of the protein. Over the past 
decade, post-translational modification of proteins by isoprenoid lipids, a process 
termed prenylation, has been widely investigated due in part to its central role in the 
subcellular localization and function of a group of proteins characterized by a 
carboxy-terminal tetrapeptide (CaaX) motif, where “C” is cysteine, “a” is an aliphatic 
amino acid and “X” represents an unspecified amino acid.1-2 The presence of this 
motif on a protein triggers three sequential post-translational modifications which are 










































Figure 1-1. Post-translational modification of CaaX proteins.2-3  
In the first step of CaaX protein processing, an isoprenoid residue, farnesyl 
(15-carbon) or geranylgeranyl (20-carbon), is attached by a thioether linkage to the 
cysteine of the CaaX sequence.3 This reaction is catalyzed by protein 
farnesyltransferase (FTase) or protein geranylgeranyltransferase type I (GGTase-I). 
Generally, when X is methionine, serine, glutamine or alanine, the protein is a 
substrate of FTase, whereas if X is leucine, it is processed by GGTase-I.2, 4 The nature 
of the X residue does provide some guidance as to whether the CaaX sequence is 
farnesylated or geranylgeranylated but it is still best to rely on experimental 
confirmation.5 There are some CaaX proteins that are substrates of both FTase and 
GGTase-I, for example, K-Ras, RhoB and RhoH.4 After prenylation, the modified 
CaaX protein moves from the cytosol to the endoplasmic reticulum where it 
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associates with the cellular membrane presumably by inserting its lipophilic 
isoprenoid side chain into the phospholipid bilayer. It is then recognized by an 
endoprotease termed Ras converting enzyme 1 (Rce1), an integral ER membrane 
protein, that removes the last three amino acids (-aaX) from the C-terminus.6 This 
brings the newly exposed -carboxylate anion of the prenylcysteine residue in close 
proximity to the negatively charged phospholipids in the membrane. Likely due in 
part to minimize the electrostatic repulsion, the terminal carboxylate group is 
converted to a methyl ester in a reaction catalyzed by isoprenylcysteine carboxyl 
methyltransferase (Icmt), which like Rce1 is a membrane bound protein located in the 
endoplasmic reticulum.7-8 Unlike the preceding steps, methylation by Icmt is 
potentially reversible9 but a specific methylesterase catalyzing this step has yet to be 
identified. The sequence of reactions involved in the post-translational prenylation of 
CaaX proteins enhances the lipophilic character of otherwise hydrophilic proteins and 
promotes their ability to associate with membranes and to engage in specific protein-
protein interactions.3 
About 280 potential CaaX proteins were identified during the sequencing of 
the human and mouse genomes but less than half of these proteins were proposed to 
undergo post-translational prenylation.10 It appears that the processing enzymes do 
not recognize a particular CaaX sequence or fail to gain access to certain terminal 
carboxyl groups.11 An important class of CaaX proteins that are processed by 
prenylation are the Ras proteins, which play essential roles in controlling several 
crucial signaling pathways that regulate normal cellular proliferation. Ras proteins 
function as binary molecular switches that alternate between two states, an inactive 
state in which Ras is in complex with guanosine 5’-diphosphate (GDP) and an 
activated state in which it is bound to guanosine 5’-triphosphate (GTP).12 The 
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equilibrium between these states is regulated by two proteins: guanine nucleotide 
exchange factors (GEFs) which promote activation by enhancing the release of GDP 
and the binding of GTP, and GTPase activating proteins (GAPs) which promote 
inactivation by accelerating the intrinsic GTPase activity of the Ras proteins.13 In the 
activated state, Ras proteins trigger an array of cellular messengers that transduce key 
signals regulating cell proliferation,14 migration15 and apoptosis.16 Mutations in Ras 
genes frequently involve the loss of intrinsic Ras GTPase activity and insensitivity to 
Ras-GAPs.17 The aberrant Ras proteins retain constitutive activity and participate in 
unregulated signaling that result in the malignant transformation of cells.18-19 Ras 
mutations are found in approximately 30% of all human tumors, notably pancreatic, 
colon, lung and hematological malignancies.17, 20 In these tumors, the activated Ras 
protein contributes significantly to several aspects of the malignant phenotype 
including the deregulation of tumor-cell growth, angiogenesis, programmed cell death 
and invasiveness.21 For this reason, targeting Ras proteins and its network of 
signalling pathways is viewed as a viable and promising strategy for developing 
therapies against cancer. Unfortunately targeting Ras per se, with the aim of blocking 
its activity, has not yet been a feasible option.22 A more tenable approach that has 
been undertaken in recent years is to divert Ras from its subcellular locations (plasma 
membrane, endoplasmic reticulum, Golgi apparatus) by interfering with the enzymes 





1.2. CAAX PROCESSING ENZYMES AS TARGETS IN ONCOGENESIS 
1.2.1. Inhibitors of FTase 
Of the enzymes involved in post-translational prenylation, FTase is the 
preferred target for therapeutic intervention. The primary reasons for targeting FTase 
are that the enzyme catalyzed the first and rate-limiting step in CaaX processing, it is 
soluble and can be readily purified, and FTase processes fewer substrates compared to 
Rce1 or Icmt, which can translate to less toxicity from an FTase inhibitor.23 In 
addition, the major Ras proteins implicated in oncogenesis, H-, K- and N-Ras, are all 
substrates of FTase. Several FTase inhibitors have been developed24 and some 
members have advanced to clinical trials.25-26 Unfortunately, the overall results have 
not been encouraging, possibly because under conditions of FTase inhibition, N-Ras 
and K-Ras which are the isoforms most commonly involved in human cancers, are 
substrates of GGTase-I and the geranylgeranylated Ras proteins retained biological 
activity.27 Nonetheless, the FTase inhibitor lonafarnib (Figure 1-2a) has showed good 
activity against hematological cancers28 and there is evidence to suggest that another 
inhibitor tibifarnib (Figure 1-2b) affects targets that are downstream of Ras.29 
 
Figure 1-2. Structures of selected FTIs. (a) Lonafarnib (SCH66336)28, (b) 
Tipifarnib (R15777)29 
a)       b)  


















1.2.2. GGTase-I inhibitors 
The finding of alternate prenylation of Ras proteins has led to increased 
attention being paid to GGTase-I inhibitors, along with growing evidence that 
geranylgeranylated proteins are involved in oncogenesis and other disease states.  
Several GGTase-I inhibitors have since been described (Figure 1-3).30-34 Recent 
findings that the majority of Rho proteins are modified by FTase and not GGTase-I5 
may mean that GGTase-I inhibitors can be used in combination with other anti-cancer 










Figure 1-3. Structures of small molecule GGTIs. a) Structure of GGTI-DU40, 
optimized by Pharmaceutical Product Development (PPD) discovery from a novel 
inhibitor identified from a diverse chemical library30 b) Core structures of GGTIs 
identified from a library of allenoate-derived compounds34 i) tetrahydropyridine ring 
core, ii) dihydropyrrole ring core. 
1.2.3 Inhibitors of the post-prenylation enzymes: Rce1 and Icmt   
Interest in the inhibitors of the post-prenylation enzymes Rce1 and Icmt have 
only recently intensified.11 Initially, there have been concerns regarding the 
effectiveness of inhibiting these enzymes since essentially all FTase and GGTase-I 
substrates are substrates of Rce1 and Icmt. Thus, inhibition of Rce1 and Icmt may 
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have widespread effects on cellular functions and may cause significant toxicity in 
normal cells.  Indeed, disruption of either the Rce1 or Icmt genes in mice has resulted 
in embryonic lethality.35-36 Additionally, Ras proteins that do not undergo post 
prenylation processing retain partial localization and function, calling into question 
whether targeting these enzymes will have sufficient impact on the function of 
oncogenic CaaX proteins to impair cancer growth.37-38 Mammalian genomes encode 
only one member of the Icmt class of methyltransferases, and Icmt lacks homology 
compared to any other protein methyltransferases.39 Additionally only a single gene 
has been identified in encoding a Rce1-like protein in vertebrates, which implies that 
Rce1 is the only enzyme involved in the processing of prenylated substrates.40-41 Both 
enzymes are distinct in their structure and mechanism from other proteases and 
methyltransferases, a point that should favour the development of specific inhibitors. 
Despite concerns with the effectiveness and safety issues in targeting these enzymes, 
with their unique properties and critical roles they have emerged as promising drug 
targets in cancer chemotherapy. 
 
1.2.3.1. Rce1 inhibitors 
Rce1 inhibitors have not been widely investigated, but some interesting 
compounds have emerged from recent studies. A small number of non-peptidic, non-
prenylic compounds have been investigated as inhibitors of Rce1.42 These compounds 
are regarded as product analogues of the farnesyltransferase reaction as they mimick 
the structure of the farnesylated CaaX peptide. This has led to the proposal that they 
may function as substrate-based inhibitors of Rce1. As it turned out, most of the 
compounds inhibited FTase but not all inhibited Rce1. The more promising 
compounds could serve as lead structures for the further development of Rce1 
inhibitors with anti-cancer potential. One such member is shown in Figure 1-4a. 
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Several halomethylketones which are classic protease affinity labeling agents 
have been identified as non-specific Rce1 inhibitors.43 The introduction of a S-
farnesylcysteine moiety greatly enhanced specificity for Rce1 as seen in BFCCMK 
(Figure 1-4b)41 and further functionalization yielded peptidyl acyloxymethyketones 
(AOMKS) that were dual inhibitors of yeast Rce1 and Icmt.44 A screen of compounds 
in the National Cancer Institute (NCI) Developmental Therapeutics Program 
Diversity Set Compound Library for small molecule inhibitors of yeast and human 
Rce1 yielded nine members of which five inhibited both Rce1 and Icmt while the 
remaining four were fairly specific inhibitors of Rce1.45 Interestingly, the most 
specific Rce1 inhibitor (Figure 1-4c) is prone to colloid aggregation which is 
normally observed among promiscuous inhibitors.46 It remains to be determined if this 
interferes with its Rce1 inhibitory activity. Potential Rce1 inhibitors should be 
screened for effects on cardiac function as it is known that deletion of Rce1 caused 
mortality in mice due to cardiomyopathy.47 
 
 
Figure 1-4. Structures of selected Rce1 inhibitors. a) An example of a non-peptidic, 
non-prenylic Rce1 inhibitor42 b) BFCCMK,41 c) Most promising compound reported 








b)       c)   















1.2.3.2. Icmt inhibitors 
Three classes of Icmt inhibitors have been reported to date. The first are the 
product-based inhibitors typified by S-adenosylhomocysteine (SAH) and compounds 
that increase intracellular SAH.48-49 Icmt catalyzes the transfer of a methyl group from 
the endogenous methyl donor S-adenosylmethionine (SAM) to the isoprenylated 
CaaX proteins (Figure 1-5). In the process, SAM is converted to SAH which binds to 
and functions as a feedback competitive inhibitor of Icmt.50 SAH hydrolase catalyzes 
the hydrolysis of SAH to adenosine and homocysteine. This reaction is reversible and 
the reverse reaction to give SAH is energetically more favourable. Product-based 
inhibitors are likely to be non-specific as other cellular methyltransferases are also 
inhibited by SAH.51 However, the recent finding that methotrexate, one of the most 
established drugs in cancer chemotherapy, targets Icmt through an elevation of SAH 
is of particular interest.52 Methotrexate inhibits nucleotide biosynthesis by its 
antifolate activity.  Depletion of 5-methyltetrahydrofolate by methotrexate blocks the 
methylation of homocysteine to form methionine. The accumulated homocysteine 
reacts with adenosine to give SAH which in turn inhibits cellular methyltransferases.  
Investigations showed that methotrexate inhibits Icmt with an IC50 value of 7.5 M, 
causes the mislocalization of Ras proteins, reduces signalling through Ras pathways 
and has no effect on Icmt -/- cells.52 These findings lend support to the view that Icmt 










Figure 1-5. Inhibition of Icmt by SAH and compounds that increase intracellular 
SAH. 
The second class of inhibitors is derivatives of the substrate prenylcysteine (N-
acetyl-S-farnesyl-L-cysteine, AFC or N-acetyl-S-geranylgeranyl-L-cysteine, AGGC) 
which can function as competitive inhibitors of Icmt. A well-studied example of 
substrate-based inhibitor is the functionalized derivatives of AFC (Figure 1-6).53-55 
As these compounds are structural mimics of the C-terminal prenylcysteine of 
processed CaaX proteins, and are processed by Icmt to yield their methylated 











Figure 1-6. Structures of (a) minimal substrate of Icmt and (b) substrate based 
inhibitors.53 a) N-acetyl-S-farnesyl-L-cysteine (AFC) (1) and N-acetyl-S-
geranylgeranyl-L-cysteine (AGGC) (2) b) An isobutenyl biphenyl derivative of AFC.  
a)       
 
 





































The third class of inhibitors is a miscellaneous class of small molecules that 
have been identified by high throughput screens. The screening of marine sponges 
and plants have yielded promising compounds with in vitro Icmt inhibitory IC50 
values of 2 -30 M) (Figure 1-7).57-59 These compounds have yet to be evaluated on 
cell-based assays but their varied scaffolds may be promising leads for drug 















Figure 1-7. Structures of reported natural product inhibitors. a) Spermatinamine 
from marine sponge Pseudoceratina sp.57; b) Aplysamine 6 from marine sponge 
Pseudoceratina sp.59; c) Hovea parvicalyx extracts58  
Thus far, cysmethynil (2-(1-octyl-5-m-tolyl-1H-indol-3-yl)acetamide is the 
most potent and extensively investigated Icmt inhibitor (Figure 1-8). This compound 
was discovered during a screen of a chemically diverse library comprising of over 
10,000 compounds.60 It is a competitive inhibitor with respect to the isoprenylated 
cysteine substrate but a non-competitive inhibitor with respect to the methyl donor 
SAM.61 Inhibition has been shown to be time-dependent, involving an initial rapid 
association with the enzyme followed by a slow isomerization to give a tighter 
enzyme-inhibitor complex.61 Cancer cells treated with cysmethynil caused 













































mislocalization of Ras, impaired growth factor signaling and blocked anchorage-
independent growth of human colon cancer cells which was reversed by over-
expression of Icmt.60 Subsequent investigations showed that cysmethynil is able to 
control tumor growth in a xenograph mouse model of prostate cancer, to trigger G1 
arrest in PC3 prostate cancer cells and to induce autophagic cell death.62 The dual 
effects of cysmethynil on cell cycle and atutophagic cell death may arise from its 
ability to reduce mTOR signaling due to reduced Ras and Rheb activities.62 







Figure 1-8. Structure of Cysmethynil with numbering system used in this thesis. 
 
1.3 STATEMENT OF PURPOSE 
Of the various CaaX processing enzymes, there is consensus that Icmt is a 
promising druggable target with good potential in drug discovery. There are various 
reasons to support this viewpoint. The post-prenylation processing enzymes Rce1 and 
Icmt may be more attractive targets than the prenylation enzymes (FTase, GGTase-I) 
because they are less likely to disrupt the biological activities of the prenylated CaaX 
proteins, although as noted above this may also impact their effectiveness. However, 
there is increasing evidence that attenuation but not elimination of CaaX protein 
function can offer a more attractive means of therapeutic intervention.63-64 In addition, 













blocking Rce1 activity. Inactivation of Icmt inhibits K-Ras induced 
myeloproliferative diseases in mice65 while inactivation of Rce1 accelerates the 
progression of myeloproliferative disease caused by oncogenic K-Ras.66 These 
findings provide support for Icmt as a preferred therapeutic target compared to Rce1. 
Additionally, the inhibition of Icmt by cysmethynil has led to widespread downstream 
effects (cell cycle arrest, autophagy) that contributed to cell death.62 The unexpected 
finding that methotrexate, one of the most effective anticancer drugs available, also 
inhibited Icmt52 thus further strengthens the rationale for targeting Icmt. 
As mentioned in Section 1.2.3.2, cysmethynil is the most effective and widely 
investigated Icmt inhibitor to date. There is, however, very limited information on the 
structural features of cysmethynil that are associated with its inhibitory activity.  
Without this information, it would be difficult to improve or optimize the activity or 
to propose novel lead compounds that are superior to cysmethynil. Thus, one 
objective of this thesis is to carry out a detailed analysis of structure-activity 
relationships relating to the inhibitory activity of cysmethynil.  
Cysmethynil was identified through the screening of a diverse chemical library 
comprising of over 70 subfamilies derived from different scaffolds.60 The sub-family 
to which it belongs consists of some 70 indole derivatives with different substituents 
on the 5-phenyl ring and the indole nitrogen (position 1) but retained the same 
acetamide side chain (position 3) as cysmethynil. These compounds have been 
evaluated for in vitro Icmt inhibition67 and they constitute a valuable database from 
which important clues may be derived relating to the optimal substitutions at positions 
1 and 5 of the indole ring.  As such an analysis has not been carried out, it is pursued 
here with the aim of determining the critical features for activity at these positions. 
The inhibitory activities of the compounds in this indole library range from IC50 
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values 2 M to more than 50 M.67 As these variations did not result in more potent 
inhibitors (nanomolar IC50 values), it may be that positions 1 and 5 are not key sites 
affecting inhibitory activity. The acetamide side chain at position 3 which is retained 
in all the compounds and has not been altered thus far, and hence is considered as a 
promising site for modification. To investigate this hypothesis, modifications to the 
acetamide side chain will be explored in this investigation. Conventional analogue 
design strategies such as homologation, bioisosteric replacement and variation of 
substituents68 will be employed for this purpose. The option of structure-based design, 
a design strategy based on the 3D structure of the biological target obtained by X-ray 
or NMR, cannot be pursued because the structure of the membrane bound Icmt has 
not been elucidated. Thus, a series of indole derivatives will be synthesized with 
modifications at (i) positions 1 and 5. The study is guided by the analysis of SAR 
from the previously evaluated indole library and (ii) position 3 based on analogue-
based changes of the acetamide side chain. The compounds have been evaluated for in 
vitro Icmt inhibitory activity and effect on the viability of a cancer cell line. With this 
information on hand, it became possible to derive a pharmacophore model (which is 
the ensemble of steric and electronic features necessary for biological response) for 
Icmt activity, and to analyze SAR in descriptive and quantitative terms.     
Cysmethynil has poor water solubility and has been noted to have strong 
plasma protein binding properties. These are features that can compromise its 
pharmacokinetic profile. When cysmethynil was assessed for its drug-likeness by 
established guidelines like the Lipinski Rules69 or the additional rules introduced by 
Veber and co-workers,70 non-compliance was found for certain properties, namely 
lipophilicity (too high) and flexibility (large number of rotatable bonds). Hence, an 
important objective of the design strategy is to incorporate functionalities that would 
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reduce lipophilicity, enhance polar surface area and limit flexibility. A reduction in 
lipophilicity and an increase in polar area are common design strategies aimed at 
reducing binding to plasma proteins.71  It is of interest to determine how far this could 
be achieved without compromising biological activity. 
Post prenylation is a process that affects a broad range of CaaX proteins and 
the biological consequences of Icmt inhibition remain to be fully understood. 
Cysmethynil has been shown, at least in prostate cancer cells, to arrest the cell cycle 
at the G1 phase, to have no effect on apoptosis and to activate the authophagic 
pathway leading to cell death.62 Thus, another objective of this thesis is to determine 
if other Icmt inhibitors (besides cysmethynil) affect cancer cells in the same way.    
In summary, it is hypothesized that the anticancer activity of cysmethynil can 
be enhanced by modifying its acetamide side chain and by incorporating 
functionalities with “drug-like” or “lead-like” features into the molecule. The 
hypothesis will be investigated by synthesis of target compounds, evaluation of their 
Icmt inhibitory activities and effect on cell viability, and computational analysis of the 




CHAPTER 2: QUANTITATIVE STRUCTURE ACTIVITY 
RELATIONSHIP (QSAR) OF INDOLOACETAMIDES AS 
INHIBITORS OF ICMT 
2.1. INTRODUCTION 
In this chapter, the Icmt inhibitory activities of the indole library from which 
cysmethynil was identified were analyzed for a better understanding of the structural 
requirements for activity at positions 1 (indole N) and 5 (phenyl ring) of the indole 
template. Three levels of analysis were undertaken. First, the results were analyzed by 
projection methods, namely principal component analysis (PCA) and partial least 
squares projection to latent structures (PLS). The purpose was to identify the 
physicochemical descriptors that were important determinants of activity. Second, 
multiple linear regression was applied to derive an appropriate equation relating 
activity to physicochemical descriptors. Third, a comparative molecular field analysis 
(CoMFA) was carried out to provide a visual means of interpreting the structure-
activity relationships (SAR) derived from the above mentioned approaches. 
 
2.2. METHODS 
The indole library consisted of 72 compounds and each compound was drawn 
and energy minimized using the Sybyl 7.0 standard Tripos force field (Tripos Inc, St 
Louis, MO, USA). Several descriptors representing size, electronic and lipophilic 
characteristics were collected from forcefield minimized structures of the compounds.   
The following descriptors were determined with Sybyl 7.0 (ClogP/CMR and QSAR 
with CoMFA modules): ClogP, area, volume, polar surface area, polar volume, molar 
refractivity and the Hansch  values.  N substituent was determined from ClogP compound – 
ClogP compound without N substituent   and  phenyl was determined from ClogP compound – ClogP 
compound without phenyl ring. The following descriptors were determined using Molecular 
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Modeling Pro Plus Version 6.2.3 (Chemsoftware). Sterimol parameters (L1,B1,B5), 
highest occupied molecular orbital (HOMO), lowest unoccupied molecular orbital 
(LUMO), dipole moment, Hammett constant (aromatic) of the group on the 5-phenyl 
ring, inductive constant (*) of the group attached to the indole nitrogen. In total, 20 
descriptors were collected for each compound. 
PCA and PLS were carried out on SIMCA-P+ version 11 (2005) (Umetrics 
AB, Umea, Sweden) with default settings. Descriptors were not transformed to 
logarithmic values for the analysis. Multiple linear regression and Pearson correlation 
analysis were carried out on SPSS for Windows 14.0 (SPSS Inc., Chicago, IL, USA). 
CoMFA was performed with the Sybyl 7.0 molecular modeling software 
(Tripos Inc., St. Louis, MO). The compounds were built using fragments in the Sybyl 
database and geometry-optimized with the standard Tripos force field with a distance 
dependent dielectric function until a root mean square (rms) deviation of 0.001 
kcal/mol Å was achieved. The partial atomic charges required for the electrostatic 
interaction were computed using the Gasteiger-Huckel method. The most active 
compound (cysmethynil, 1D) was chosen as the template on which other molecules 
were aligned based on the shared indole ring. CoMFA steric and electrostatic 
interaction fields were calculated at each lattice intersection point of a regularly 
spaced grid of 2.0 Å. The grid pattern, generated automatically by the Sybyl/CoMFA 
routine, extended 4.0 Å units in X, Y and Z directions beyond the dimensions of each 
molecule. The steric term, which represented van der Waals (Lennard-Jones) 
interaction, and the coulombic term, which represented electrostatic interactions, were 
calculated with the standard Tripos force field. An sp3 carbon atom with a van der 
Waals radius of 1.52 Å and +1.0 charge was used as the probe to calculate the steric 
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and electrostatic fields. Values of the steric and electrostatic fields were truncated at 
30 kcal/mol.  
 
2.3. RESULTS AND DISCUSSION 
2.3.1. The indole database 
The structures of the 72 compounds in the indole database are in Table 2-1. In 
this series, modifications centred on the substituted 5-phenyl ring and the side chain 
attached to the indole N. Eight different substituents were present on the 5-phenyl 
ring: m-methyl, p-methyl, m-fluoro, o-methoxy, m-ethoxy, m-chloro-p-fluoro, m,m-
bistrifluoromethyl and p-phenoxy. Nine different side chains were attached to position 
1: isobutyl, cyclopropylmethyl, n-hexyl, n-octyl, benzyl, 3’-trifluoromethylbenzyl, 2’-
naphthylmethyl, 3’-phenoxypropyl and 4’-tert-butylbenzyl. There were also 
compounds with no subsituent on the indole N (R2 = H).  










No R1 R2 pIC50 
1A1 m-tolyl isobutyl 4.80 
1B1 m-tolyl cyclopropylmethyl 5.04 
1C1 m-tolyl n-hexyl 5.13 
1Db m-tolyl n-octyl 5.68 
1E m-tolyl benzyl 5.19 
1G1 m-tolyl 3’-trifluoromethylbenzyl 5.10 
1H1 m-tolyl 2’-naphthylmethyl 4.76 
1I1 m-tolyl phenoxypropyl 4.00 
1J1 m-tolyl H 4.00 
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Table 2-1. (cont’d) 
No R1 R2 pIC50 
2A1 m-fluorophenyl isobutyl 5.43 
2B1 m-fluorophenyl cyclopropylmethyl 4.83 
2C1 m-fluorophenyl n-hexyl 4.89 
2D m-fluorophenyl n-octyl 5.62 
2E m-fluorophenyl benzyl 4.97 
2F1 m-fluorophenyl 4’-tert-butylbenzyl 5.30 
2G1 m-fluorophenyl 3’-trifluoromethylbenzyl 5.24 
2I1 m-fluorophenyl phenoxypropyl 4.00 
2J1 m-fluorophenyl H 4.40 
3A1 p-tolyl isobutyl 5.01 
3B1 p-tolyl cyclopropylmethyl 4.95 
3C1 p-tolyl n-hexyl 5.13 
3D p-tolyl n-octyl 4.97 
3G1 p-tolyl 3’-trifluoromethylbenzyl 5.19 
3H1 p-tolyl 2’-naphthylmethyl 4.71 
3J1 p-tolyl H 4.00 
4A1 m-ethoxyphenyl isobutyl 5.21 
4B1 m-ethoxyphenyl cyclopropylmethyl 5.19 
4C1 m-ethoxyphenyl n-hexyl 5.18 
4D m-ethoxyphenyl n-octyl 5.66 
4E m-ethoxyphenyl benzyl 5.11 
4F1 m-ethoxyphenyl 4’-tert-butylbenzyl 4.90 
4G1 m-ethoxyphenyl 3’-trifluoromethylbenzyl 5.31 
4H1 m-ethoxyphenyl 2’-naphthylmethyl 5.08 
4I1 m-ethoxyphenyl phenoxypropyl 4.00 
4J1 m-ethoxyphenyl H 4.00 
5A1 o-methoxyphenyl isobutyl 4.66 
5B1 o-methoxyphenyl cyclopropylmethyl 4.79 
5C1 o-methoxyphenyl n-hexyl 5.09 
5D o-methoxyphenyl n-octyl 5.22 
5E o-methoxyphenyl benzyl 4.88 
5G1 o-methoxyphenyl 3’-trifluoromethylbenzyl 5.21 
5H1 o-methoxyphenyl 2’-naphthylmethyl 4.53 
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Table 2-1. (cont’d) 
No R1 R2 pIC50 
5I1 o-methoxyphenyl phenoxypropyl 4.00 
5J1 o-methoxyphenyl H 4.00 
6A1 m-chloro-p-fluorophenyl isobutyl 5.04 
6B1 m-chloro-p-fluorophenyl cyclopropylmethyl 5.24 
6C1 m-chloro-p-fluorophenyl n-hexyl 5.03 
6D m-chloro-p-fluorophenyl n-octyl 5.15 
6E m-chloro-p-fluorophenyl benzyl 4.98 
6F1 m-chloro-p-fluorophenyl 4’-tert-butylbenzyl 5.12 
6G1 m-chloro-p-fluorophenyl 3’-trifluoromethylbenzyl 5.21 
6I1 m-chloro-p-fluorophenyl phenoxypropyl 4.00 
6J1 m-chloro-p-fluorophenyl H 4.00 
7A1 m,m-bis(trifluoromethyl)phenyl isobutyl 4.59 
7B1 m,m-bis(trifluoromethyl)phenyl cyclopropylmethyl 4.00 
7D m,m-bis(trifluoromethyl)phenyl n-octyl 4.43 
7E m,m-bis(trifluoromethyl)phenyl benzyl 4.48 
7F1 m,m-bis(trifluoromethyl)phenyl 4’-tert-butylbenzyl 4.53 
7G1 m,m-bis(trifluoromethyl)phenyl 3’-trifluoromethylbenzyl 4.00 
7H1 m, m-bis(trifluoromethyl)phenyl 2’-naphthylmethyl 4.00 
7I1 m,m-bis(trifluoromethyl)phenyl phenoxypropyl 4.00 
7J1 m,m-bis(trifluoromethyl)phenyl H 4.00 
8A1 p-phenoxyphenyl isobutyl 5.23 
8B1 p-phenoxyphenyl cyclopropylmethyl 4.00 
8C1 p-phenoxyphenyl n-hexyl 4.00 
8E p-phenoxyphenyl benzyl 5.03 
8G1 p-phenoxyphenyl 3’-trifluoromethylbenzyl 4.00 
8H1 p-phenoxyphenyl 2’-naphthylmethyl 4.00 
8I1 p-phenoxyphenyl phenoxypropyl 4.00 
8J1 p-phenoxyphenyl H 4.00 
aDetermination of pIC50 (-log IC50 where IC50 is the concentration required to inhibit 




Descriptors for size, lipophilicity, electronic and hydrogen bonding capacity 
were collected for each compound. Size parameters were given by area, volume, polar 
volume and Sterimol parameters. The Sterimol parameter L1 measured the substituent 
length along the axis formed by the bond between the substituent and the atom to 
which it was attached. B1 was the shortest radius perpendicular to the L1 axis and B5 
was the longest possible radius perpendicular to L1.72 Lipophilicity was reflected by 
ClogP and Hansch  values for the phenyl substituent(s) (Ph) and the N substitutent 
(N). HOMO, LUMO, dipole moment, Hammett constants aromatic and * and molar 
refractivity were electronic properties. Molar refractivity was also indicative of the 
size of the molecule. Polar surface area provided an indication of hydrogen (H) 
bonding capacity. The descriptors for each compound are listed in Table A1-1 of 
Appendix 1.  
The pIC50 values for Icmt inhibition have been determined 67 and are provided 
in Table 2-1. In the original report, compounds with IC50 values that exceeded 50 M 
were not accurately determined.  For the purpose of SAR analysis, three IC50 values 
(50, 100 or 200 M) were assigned in turn to these weak inhibitors and for each IC50 
value, a PCA/PLS model was generated. The best model evaluated on the basis of 
regression coefficient R2Y and cross-validated correlation coefficient (Q2) was 
obtained when the IC50 value was 100 M. Therefore, this value was assigned to 
compounds that had IC50 values greater than 50 M.  
 
2.3.2. Analysis by Projection Methods PCA and PLS 
Projection methods are widely employed for establishing structure-activity 
relationships (SAR). The most commonly employed methods are PCA and PLS. In 
PCA, a large set of descriptors are reduced to a smaller set derived from the linear 
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combination of the original descriptors. These are called principal components (PC) 
and they summarize information residing in the original data so that relationships 
between compounds and descriptors may be analyzed.73 PLS is a regression extension 
of PCA and serves to identify the principal components that concurrently explain the 
variance in the descriptor set and maximize their correlation to the dependent variable 
(biological activity). The advantage of PLS is that it still works in circumstances 
where the descriptors are highly correlated to each other or where there are missing 
descriptor values. 
When the data set of 72 compounds and their descriptors were analyzed by 
PCA, a significant three-component model was obtained.  The properties captured by 
these components explained 72 % (R2Y =0.72) and predicted 54 % (Q2 = 0.54) of the 
structural differences in the compounds. The loading plot of the components was next 
examined to identify descriptors that contributed to each component. In terms of 
relevance to the model, the 1st component is the most important, followed by the 2nd 
and 3rd component. Thus only the loading plot of the 1st and 2nd PC was examined 
(Figure 2-1). In this plot, descriptors located at the ends of the axes contributed 
significantly to the respective PC while those found near the origin made lesser 
contributions. In Figure 2-1, size (volume, area, molar refractivity, Sterimol 
parameters of the N-substituent) and lipophilicity (ClogP) were important contributors 
to the 1st PC whereas HOMO and several characteristics of the substituted 5-phenyl 
ring, namely  Ph,  Ph and the Sterimol width parameter of the ring (PB1) contributed 
significantly to the 2nd PC. Interestingly, the 1st component encoded properties of the 
N-substituent whereas the 2nd component received inputs from the substituted 5-
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positions, with the N-substituent making a bigger contribution to the overall 
physicochemical profile of the compounds.  
 
 
Figure 2-1. Loading plot of first and second principal components (p[1], p[2]) of 
72 compounds and 20 descriptors. 
Next the score plot of the two components was examined to see how the 
compounds were distributed with respect to the 1st and 2nd components (Figure 2-2).  
An obvious feature of this plot was the location of compounds without an N-
substituent (codes ending in “J1”) at the lower left quadrant of the plot (Figure 2-2, 
Box I), with many members found outside the Hotelling ellipse which demarcated the 
95% confidence region for the model. The separation of the “J1” compounds from the 
rest implied that their properties were clearly different from the other compounds.  
Furthermore since compounds without an N-substituent were also the least active in 
their respective classes, it may imply that the properties captured by these principal 
components were relevant for Icmt inhibitory activity. Other than the “J1” 
compounds, the other compounds did not show obvious clustering based on the type 
of N-substituent. However, some compounds were found grouped together based on 
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2-2, Box II and III). There was no obvious reason why they were found together. The 
compounds prefixed with 7 had two trifluoromethyl (CF3) groups on the phenyl ring 
and they were among the weakest compounds in the series. Coincidentally they were 
also found near the edge of the Hotelling ellipse. The compounds prefixed with “5” 
had an o-methoxy group on the phenyl ring and were distinguished by being the only 
compounds in the library with an ortho substituent on the phenyl ring. 
 
Figure 2-2. Score plot of principal components t1 versus t2 for compounds (n = 
72, 20 descriptors). Compounds are identified in Table 1. The solid line ellipse 
corresponds to the confidence region based on Hotelling T2 (0.05). I) Compounds 
identified by ‘5’ have o-methoxyphenyl group on the phenyl ring, II) compounds 
identified by ‘7’ have m,m-bis(trifluoromethyl) groups on the phenyl ring, and III) 
compounds identified by ‘J1’ have no substituent on the indole N. These sets of 
compounds are isolated from the rest. 
Next, PLS was used to develop a projection model for predicting biological 
activity from the principal components. First, a model was generated with all 
compounds and parameters.  It was only satisfactory, with R2Y = 0.68 and Q2 = 0.49.  
The model was improved by removing 2 compounds that had large differences 
between the observed and predicted values (compounds 3E and 8D) and descriptors 







phenyl) or were duplicated by existing descriptors (volume, surface area, Ph).  The 
resulting model (A) had R2Y of 0.72 and Q2 of 0.60. A test set of 12 compounds was 
arbitrarily selected from the 70 compounds and used to predict the activities of the 
remaining compounds. The level of predictability, as measured by the root mean 
square of prediction (RMSEP), was satisfactory at 0.48. The coefficient plot of the 
model was then examined (Figure 2-3). This plot provided information on the 
descriptors that made the largest contribution to activity (reflected by the length of the 
bar) as well as how it affected activity (directly correlated or inversely correlated).  As 
seen from Figure 2-3, the model identified the following descriptors (in order of 
decreasing importance) as contributors to activity: polar surface area, polar volume > 
lipophilicity of phenyl ring (Ph) > width parameters B1, B5 of the N substituent and 
N > Sterimol L1 of N substituent. The plot also illustrated the contrasting 
requirements of the N and phenyl ring substituents, namely that for good Icmt 
inhibitory activity, the N-substitutent must be lipophilic and bulky (large width 
dimensions) whereas the substituted phenyl ring should have substituents that were 
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Figure 2-3. Coefficient plot for PLS model derived from 70 compounds and 14 
descriptors, based on the first component. Descriptors with positive coefficients are 
directly related to activity, while those with negative coefficients are inversely related. 
Magnitude of parameter indicates its relative contribution to the model. CLOGP = 
computed log P; pi Ph2 = Hansch constant π of substituted phenyl ring; pi N = 
Hansch constant π of N-substituent; PSA = polar surface area, PV = polar volume; 
CMR = molar refractivity; HOMO = highest occupied molecular orbital; LUMO = 
lowest unoccupied molecular orbital; PL1, PB1, PB5 = sterimol parameters of phenyl 
ring; NL1, NB1, NB5 = sterimol parameters of N-substituent. 
2.3.3. Analysis by Multiple Linear Regression  
The dataset used to derive the PLS model was analyzed by stepwise multiple 
linear regression (MLR)72 to determine which descriptors would be identified as the 
main contributors to activity and if there was any overlap with those determined by 
PLS. The analysis yielded Equation 2-1 which identified polar surface area (PSA), 
polar volume (PV), Sterimol parameter B1 of the substituted phenyl ring and 
lipophilicity contribution of the substituted phenyl ring (Ph) as important contributors 
to activity. 
pIC50 = 10.23 ( 0.55) – 0.016 ( 0.003)* PSA -  0.010 ( 0.002)* PV 
- 0.835 ( 0.195) * PB1 - 0.190 ( 0.056) *  Ph. 
…(2-1) 




When the coefficients in Equation 2-1 were standardized, the relative 
contribution of each parameter was PSA (most important) > PV > PB1 > Ph.  The 1st 
three parameters were significant at p < 0.001 whereas Ph was significant at p = 
0.001.   
When the models derived from MLR and PLS were compared, the following 
observations were made. First, both models identified polar surface area, polar 
volume and Ph as important contributors to activity. That these properties were 
inversely correlated to activity was also recognized in both models. Second, the 
Sterimol and lipophilicity parameters of the N-substituent were conspicuously absent 
from the MLR equation although they were important in the PLS model. A possible 
explanation may be that these Sterimol parameters were captured by polar surface 
area (PSA) to which they were significantly correlated as seen from the Pearson 
correlation coefficients (Table 2-2). Third, the breadth parameter of the phenyl ring 
(PB1) was recognized in Equation 2-1 but not the PLS model. PB1 was significantly 
correlated to HOMO and LUMO (p < 0.0001) but these descriptors were not 
identified by the PLS model. 
 
  
Table 2-2. Pearson Correlation Coefficients of Parameters employed in developing Equation (2-1) 
  PSA PV N Ph NL1 NB1 NB5 PL1 PB1 PB5 HOMO LUMO CLOGP CMR 
PSA Pearson Correlation 1.000              
 Sig. (1-tailed) 0.000              
PV Pearson Correlation 0.309** 1.000             
 Sig. (1-tailed) 0.005 0.000             
πN Pearson Correlation -0.713** -0.335** 1.000            
 Sig. (1-tailed) 0.000 0.002 0.000            
πPh Pearson Correlation 0.039 -0.253* -0.030 1.000           
 Sig. (1-tailed) 0.374 0.017 0.402 0.000           
NL1 Pearson Correlation -0.473** -0.288** 0.781** -0.048 1.000          
 Sig. (1-tailed) 0.000 0.008 0.000 0.347 0.000          
NB1 Pearson Correlation -0.918** -0.185 0.734** -0.010 0.631** 1.000         
 Sig. (1-tailed) 0.000 0.062 0.000 0.469 0.000 0.000         
NB5 Pearson Correlation -0.802** -0.259* 0.959** -0.009 0.658** 0.803** 1.000        
 Sig. (1-tailed) 0.000 0.015 0.000 0.471 0.000 0.000 0.000        
PL1 Pearson Correlation 0.143 -0.125 -0.039 0.813** -0.008 -0.002 -0.026 1.000       
 Sig. (1-tailed) 0.119 0.152 0.375 0.000 0.472 0.494 0.414 0.000       
PB1 Pearson Correlation -0.145 -0.241* 0.026 0.499** 0.003 0.001 0.034 0.029 1.000      
 Sig. (1-tailed) 0.116 0.022 0.416 0.000 0.489 0.498 0.391 0.406 0.000      
PB5 Pearson Correlation 0.220* 0.179 -0.003 0.281** -0.041 0.009 0.021 0.271* -0.097 1.000     
 Sig. (1-tailed) 0.034 0.069 0.492 0.009 0.370 0.469 0.433 0.012 0.213 0.000     
HOMO Pearson Correlation -0.217* 0.125 0.191 -0.350** 0.179 0.381** 0.206* 0.011 -0.616** 0.072 1.000    
 Sig. (1-tailed) 0.037 0.153 0.058 0.002 0.071 0.001 0.045 0.463 0.000 0.278 0.000    
LUMO Pearson Correlation 0.220* 0.179 -0.263* -0.442** -0.100 -0.084 -0.309** -0.118 -0.613** 0.019 0.574** 1.000   
 Sig. (1-tailed) 0.034 0.071 0.014 0.000 0.208 0.245 0.005 0.167 0.000 0.437 0.000 0.000   
CLOGP Pearson Correlation -0.578** -0.425** 0.824** 0.542** 0.630** 0.613** 0.802** 0.428** 0.305** 0.158 -0.038 -0.471** 1.000  
 Sig. (1-tailed) 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.096 0.379 0.000 0.000  
CMR Pearson Correlation -0.479** -0.117 0.779** 0.332** 0.625** 0.638** 0.818** 0.371** 0.044 0.321** 0.202* -0.350** 0.843** 1.000 
 Sig. (1-tailed) 0.000 0.168 0.000 0.002 0.000 0.000 0.000 0.001 0.359 0.003 0.048 0.002 0.000 0.000 
Correlation is significant at the 0.01 (**) and 0.05 (*) levels (1-tailed) respectively. 
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Taken together, the results of the PLS and MLR analyses supported the 
requirement for a small polar surface area for activity. Polar surface area was strongly 
correlated to the dimensions (NL1, NB1, NB5) and lipophilicity (N) of the N-
substituent as seen from their Pearson correlation coefficients in Table 2-2. In 
contrast, the properties (PL1, PB1, PB5, Ph) of the group on 5-phenyl were poorly 
correlated to polar surface area. Thus, compounds with small polar surface areas were 
likely to be those with lipophilic N-substituents. As for the dimensions of the N-
substituent, Figure 2-3 suggests that the breadth dimensions (NB1, NB5) of the 
substituent had a greater role than its length (NL1). This would explain the 
consistently poor activity of compounds with a phenoxypropyl side chain attached to 
the indole N. This side chain was as long as the n-octyl side chain but lacked its 
conformational flexibility. Thus substituents that were conformationally restricted 
may fare less well than those of similar length but greater flexibility.    
The PLS and MLR analyses also supported the requirement for a less 
lipophilic and sterically more compact substituted phenyl ring at position 5. It was 
noted that phenyl rings substituted with m,m-bistrifluoromethyl (compounds prefixed 
with “7”) and p-phenoxy (compounds prefixed with “8”) were generally poor 
inhibitors possibly because these subsituents were more lipophilic and bulkier than 
substituents like methoxy, methyl, fluoro or ethoxy.  
    
2.3.4. Comparative Molecular Field Analysis (CoMFA)  
From the preceding sections, it was deduced that there were different 
requirements for activity at position 1 (indole N) and the substituted 5-phenyl ring.  
At position 1, the substituent should be lipophilic and conformationally flexible 
whereas the phenyl ring at position 5 should be substituted with less lipophilic and 
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less bulky subsituents. Support for this finding was also found from comparative 
molecular field analysis (CoMFA). 
 
 
Figure 2-4. Alignment of the 72 compounds. Figure created with PyMOL (DeLano 
Scientific, Palo Alto, CA, USA). 
CoMFA is a widely employed tool for the analysis of 3-dimensional 
quantitative structure-activity relationships (3D QSAR).74 3D-QSAR is based on the 
premise that the properties of a molecule are related to its 3D structure, namely its 
overall size, shape and electronic properties. In conventional QSAR, the contributions 
of individual moieties or substituents are summed up to give the final property 
“value” of the compound. In CoMFA, steric and electrostatic interaction fields are 
measured around a series of aligned structures (Figure 2-4) and these are related to 
the activity of the compounds. By comparing the steric and electrostatic fields for 
different molecules against their activity, it is possible to define interactions that are 
desirable or undesirable and to visualize these interactions. Several caveats should be 
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noted when employing CoMFA. With reference to the present exercise, it was 
assumed that the forcefield minimized conformation was the active conformation, 
since the latter had not been established for the compounds under investigation. 
Second, the molecules were aligned based on the indole core which was common to 
all compounds. The preferred method is to use the pharmacophore as a basis of 
alignment, but since this has not been established, it could not be applied. 
For alignment, three compounds (8A1, 3E ,8D) were omitted because of their 
large residual values. The remaining 69 compounds were divided into a training set (n 
= 56) and a test set (n = 13). Compounds in these sets covered the same range of 
activity and were well represented in terms of the type of substituents on the indole 
nitrogen and phenyl rings. The statistical parameters of the best CoMFA model 
derived from the training set is given in Table 2-3. The model had a favorable cross-
validated q2 of 0.646 (a q2 value greater than 0.3 is considered significant) and a non 
cross-validated r2 of 0.868 with a low standard error of estimate (SEE) of 0.209. The 




Table 2-3. Summary of CoMFA Analysis of Training Set (n = 56) 
 
Cross validated correlation coefficient, q2 
 
0.646 
Standard error of prediction (SEP) 0.342 
Number of Componentsa 7 
Non cross-validated correlation coefficient, r2 0.868 
Standard error of estimate (SEE) 0.209 
F value 44.91 
Field Contributions 
               Steric 







a Optimum number of components obtained from cross-validated PLS analysis.  This 
number of components is also used in the final non cross-validated analysis.  
 
b Predictive r2 is based only on the 13 compounds not included in the training set.  It is 
determined from r2pred = [SD – PRESS] / SD where SD = sum of the squared 
deviations between IC50 values of compounds in test set and mean IC50 values of 
training set molecules, and PRESS is sum of the squared deviations between predicted 
and actual IC50 values for every member in the test set.  
 
In CoMFA, the steric contours were color-coded green and yellow. Green 
indicated regions where steric bulk was favoured for activity whereas yellow 
indicated regions where steric bulk was not favoured for activity. The steric contours 
of the model displayed a swathe of green at the proximal and distal ends of the N 
substituent. A yellow patch was interspersed between these green zones (Figure 2-5). 
The inference was that there were two optimal lengths of the N substituent 
corresponding to a short group that would occupy the proximal green patch and a 
longer group that filled the distal green patch. The 3’-trifluromethylbenzyl and n-octyl 
groups were examples of optimal short and long substituents. On the other hand, the 
phenoxypropyl group extended beyond the proximal green zone and occupied the 
sterically disfavoured yellow zone. Interestingly, the presence of two optimal lengths 




Figure 2-5. Steric map from the CoMFA model showing the alignment based on 
indole ring as shown in Figure 2-4. Green contours represent areas where steric bulk 
will enhance activity, and yellow contours highlight areas which should be kept 
unoccupied for increased activity. 
As for the 5-phenyl ring, only sparse yellow contours were found in its 
vicinity.  The inference was that the steric nature of the substituted phenyl ring was of 
lesser importance, in spite of deductions from PLS and MLR that less bulk was 
preferred at this position. 
The electrostatic field contribution (32 %) to model B was far less than the 
steric field contribution (68 %) (Table 2-3), which agreed with earlier SAR findings 
that proposed a greater steric influence on activity. Not unexpectedly, the electrostatic 
field contours of model B were sparsely distributed at both positions (Figure 2-6). 
Electrostatic field contours were color-coded red (more negative charge was 




Figure 2-6. Electrostatic map from the CoMFA model showing the same 
alignment as in Figure 2-4. Blue contours represent regions where an increase in 
positive charge will enhance activity, and red contours highlight areas where more 
negative charge is favoured. 
2.4. CONCLUSIONS 
Distinct approaches were used to analyze the structure-activity relationship of 
the library of indoleacetamides from which cysmethynil was identified. The 
approaches were complementary and served to give a definitive picture of the 
structural requirements at the indole N and the substituted phenyl ring. The main 
findings were: 
(i) Steric factors played a greater role than electrostatic factors in determining 
activity.  
(ii) There were contrasting steric and lipophilic requirements at the two 
positions. The side chain attached to the indole N should be lipophilic and possess 
bulk as implied from the Sterimol width parameters (B1 and B5). The latter also 
implied that flexible side chains with a greater “sweep” of conformational space were 
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preferred to those that were less flexible. In contrast, the group(s) on the 5-phenyl ring 
should be of limited lipophilicity and bulkiness. 
(iii) There were two optimal lengths for the side chain attached to the indole 
N: a short chain typified by 3’-trifluoromethylbenzyl and a longer chain that 
corresponded to n-octyl. Side chains that fell between these two optimal lengths were 
likely to give rise to poor activity.   
These findings contribute to the definition of the pharmacophore for Icmt 
inhibitory activity but in its present state, but the study was incomplete because only 
modifications at two positions could be considered due to availability of data. A more 
comprehensive picture would emerge when the SAR of the acetamide side chain was 
known (Chapter 4). In any case, the study provided useful guidelines for structural 




CHAPTER 3: DESIGN AND SYNTHESIS OF 
CYSMETHYNIL ANALOGUES 
3.1. INTRODUCTION 
The design and synthesis of cysmethynil analogues are described in this 
chapter. Modifications to the indole N and the 5-phenyl ring were directed by the 
SAR described in Chapter 2. Modifications to the acetamide side chain at position 3 
of cysmethynil were guided by conventional analogue design approaches which are 
elaborated in the following paragraphs. The routes for the synthesis of target 
compounds are also described in this chapter.   
 
3.2. RATIONALE OF DESIGN 
3.2.1. Drug-like character of synthesized compounds 
The term “drug-like” refers to those properties of a target compound that will 
favour its transition to a successful therapeutic agent. These are properties related to 
the pharmacokinetic (absorption, distribution, metabolism, excretion) profile of the 
compound and its toxicological potential. Awareness of the role played by drug-
likeness in the development of new chemical entities was aroused by the seminal 
publication of Lipinski and coworkers69 which laid the basis for the Lipinski’s Rule of 
Five (Ro5). Briefly, these rules stated that a target compound was likely to have poor 
absorption or permeation if it had more than 5 hydrogen (H) bond donors (expressed 
as the sum of all OH and NH groups), more than 10 H bond acceptors (expressed as 
the sum of all O and N atoms), Log P (where P is partition coefficient) that exceeded 
5 and a molecular weight that was greater than 500. These rules did not apply to 
compounds that were substrates of biological transporters such as P-glycoprotein. 
Moreover, compounds that violated one or more conditions need not necessarily be 
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penalized with poor absorption because the number of rules broken and the degree to 
which they crossed threshold values should be taken into account. Other guidelines 
for deducing drug-like properties of a compound followed in the wake of the Lipinski 
Rules. One of the better known additions was that proposed by Veber and co-
workers.70 Their guidelines, based on more than 1100 drug candidates tested in rats, 
proposed that molecular flexibility ( 10 rotatable bonds) and polar surface area ( 
140 Ǻ2 or  12 total H bond acceptors and donors) were important determinants of 
oral bioavailabilty. Unlike the Lipinski Rules, there was no mention of molecular 
weight.  
The drug-likeness of cysmethynil was assessed by the guidelines given by 
Lipinski and Veber. Cysmethynil has a molecular weight of 376.53, 2 H bond donor 
groups, 3 H bond acceptor groups, 10 rotatable bonds and a ClogP of 7.0 (Figure 3-
1). The main concern here was the high partition coefficient (ClogP = 7) and number 
of rotatable bonds that was close to the stated limit. However, the Lipinski Rules 
applied a simple counting of number of O and N atoms as a means of identifying H 
bond acceptors but based on chemical principles, the indole and amide N atoms 
should not be recognized as H bond acceptors because their lone pairs are delocalized 
and not available for H bonding. Hence cysmethynil has very limited H bonding 
capacity and is likely to have poor water solubility. Thus, one objective of this 
investigation was to propose less lipophilic/more soluble cysmethynil analogues for 














Figure 3-1. Evaluation of drug-like character of cysmethynil. Arrow = rotatable 
bond; circle = H bond acceptor; box = H bond donor. ClogP = 7.0 as determined by 
ChemDraw Ultra, Version 10, Cambridgesoft. 
 
3.2.2. Modifications at position 5 
In the original indole library, the 5-phenyl ring was substituted with 8 different 
groups (m-methyl, p-methyl, m-fluoro, o-methoxy, m-ethoxy, m-chloro-p-fluoro, m,m- 
bistrifluoromethyl, p-phenoxy) and the SAR (Chapter 2) proposed that good activity 
was associated with small and not overly lipophilic groups. With this in mind, the 
following modifications were proposed for the 5- phenyl ring: 
i) Introduction of a m-methoxy substituent: This compound had a predicted 
activity, pIC50 value of 5.57 based on equation (1) (Section 2.3.3) and 5.52 based on 
the CoMFA model (Section 2.3.4) which were comparable to cysmethynil (pIC50 
value of 5.72 and 5.32 respectively).  Moreover, compounds with o-methoxy and m-
ethoxy on the 5-phenyl ring were already represented in the indole library and found 
to have good activities.   
ii) Synthesis of o, m and p-methyl derivatives: The methyl substituent had the 
desired features of lipophilicity and size that were required for activity. Except for o-




(Table 2-1 of Chapter 2) and they were generally of equivalent activity. The 
inclusion of the o-isomer would complete the picture of how substitution at different 
positions of 5-phenyl affected activity.   
iii) Omission of the phenyl ring: The omission of the 5-phenyl ring of 
cysmethynil reduced ClogP to 4.6.  In comparison, omission of the n-octyl side chain 
of cysmethynil caused a more drastic reduction in ClogP to 2.8. As seen from the 
indole library, compounds without the n-octyl side chain were inactive regardless of 
the substituted 5-phenyl ring. The removal of the n-octyl side chain might have 
caused too large a fall in lipophilicity, resulting in complete loss of activity. A lesser 
decrease in lipophilicity brought about by omitting the phenyl ring could have a more 
favourable effect on activity.  
 
3.2.3. Modifications at position 1 
The SAR described in Chapter 2 indicated that the side chain at this position 
should be lipophilic and flexible. Two optimal lengths were proposed, corresponding 
to the m-trifluoromethylbenzyl and n-octyl moieties. Measurement of the distance 
from the indole N to the most distal non-H atom in these side chains showed that they 
corresponded to 6.7 Ǻ and 10.5 Ǻ respectively (Figure 3-2). The equivalent distance 
in the p-phenoxyphenyl side chain (associated with low activity) was 8.6 Ǻ and this 
led to the proposal that side chains of intermediate lengths (like p-phenoxyphenyl) 
would be less active. In order to verify these claims, two side chains were introduced 
at the indole N of cysmethynil: isoprenyl (3-methylbut-2-ene) and geranyl (3,7-

































Figure 3-2. Length of side chains at position 1 in cysmethynil and its m-
trifluromethylbenzyl, isoprenyl and geranyl analogues.  Measurements were made 
on forcefield minimized structures on MOE (Molecular Operating Environment 
2008.10, Chemical Computing Group).  
If the SAR held true, then the estimated chain length of the isoprenyl analogue 
suggested it should be active. The outcome of the geranyl analogue was uncertain as 
its length was between that of n-octyl and p-phenoxyphenyl. The synthesis and 
evaluation of these compounds would provide the necessary verification. 
 
3.2.4. Modification of the acetamide side chain at position 3 
No modification has been reported at position 3 of cysmethynil. As the crystal 
structure of Icmt was not available, a structure-based approach to SAR could not be 
pursued. Thus modifications were based on conventional analogue-based methods as 
discussed in the following paragraph. 
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i) Omission of the acetamide side chain: The acetamide side chain was the 
only polar functionality in cysmethynil. It provided 2 H bond donor groups (-NH2) 
and one H bond acceptor group (carbonyl oxygen of amide). Removing the acetamide 
side chain would give a more lipophilic compound (ClogP of 8.7) with no H bond 
capability. Its activity would provide useful information on the importance of these 
features for activity.   
ii) Homologation: The carbon side chain linking the primary amide moiety to 
the indole ring was lengthened or shortened by one carbon atom. These changes 
affected lipophilicity to a small extent but had a greater effect on flexibility, especially 
that of the shorter homologue. As seen in Figure 3-3, the primary amide is now 
directly linked to the ring and electron delocalization from the indole N to the amide 
carbonyl would restrict the flexibility of the side chain. 
 





Figure 3-3. Restricted flexibility of the C-3 side chain in the shortened 
homologue of cysmethynil. 
iii) Conversion to tertiary and secondary amides: The purpose of this 
modification was to assess the role of H bond donor groups for activity. The tertiary 
amide had no H bond donor capability while the secondary amide retained one H 
bond donor group. Lipophilicity would be expected to increase as predicted from the 
ClogP values, with the likely exception of the N-methylpiperazine analogue, as the 




Table 3-1. ClogPa of secondary and tertiary amide analogues of cysmethynilb 
Side chain at C-3 ClogP 











CH2CON NCH3  
9.3c 
 
a Determined with ChemDraw Ultra Version 10.0, CambridgeSoft.   
b Sidechain attached to position 3, Figure 3-1 
c N-CH3 of ring is protonated at physiological pH. 
 
iv) Conversion to amines: Replacing the acetamide functionality with an 
amine had the effect of reducing the lipophilic character of the compound because the 
amino group would be ionized at pH 7.4. In its ionized state, the amino group would 
not be a H bond acceptor. If the amine is tertiary in nature, H bond donor properties 
would be absent as well. The amino side chains targeted for synthesis are given in 
Figure 3-4. 
 








Figure 3-4.  Amino analogues of cysmethynil targeted for synthesis (side chain at 
position 3) 
v) Isosoteric replacement: Isosteres are groups or functionalities that share 
chemical and physical similarities. These similarities may result in isosteres having 





The most common reason to replace an amide/carboxamide moiety with an isosteric 
group was its pharmacokinetic liability. Many examples of isosteric transformation of 
the carboxamide were found in the area of peptidomimetic design.76 Thus there is a 
wide choice of isosteres for the carboxamide moiety and the following functionalities 


















Figure 3-5. Isosteric replacement of the acetamide side chain of cysmethynil. 
The methyl and ethyl esters mimicked both the substrate and product of Icmt 
catalysis. The minimal substrate of Icmt was identified to be N-acetyl-S-farnesyl-L-
cysteine.53 In the proposed ester analogues of cysmethynil, the n-octyl side chain 
would resemble the prenyl side chain of the substrate whereas the ester moiety 
mimicked the product of Icmt catalysis (methyl ester of cysteine). The combined 
features of substrate and product found in the ester analogues might enhance their 
affinity for Icmt. In the retro (reverse) amide and sulphonamide analogues, the H 
bond donor NH group was now located nearer the indole ring rather than at the distal 
end of the side chain whereas the H bond acceptor (carbonyl or sulphonyl oxygen 
atoms) group was shifted further from the ring.  If the amide moiety of cysmethynil 
was involved in H bonding interactions, the displacement of these groups in the 




3.2.5. Classification of target compounds 
The target compounds were classified into 6 series according to the 
modifications made at positions 1, 3 and 5. Series 1 consisted of compounds with only 
variations at the 5-phenyl ring while retaining the n-octyl and acetamide sidechains 
(Table 3-2). In 1-7 and 1-8, the 5-phenyl ring was omitted and replaced with either H 
or F. The ClogP values were determined with ChemDraw Ultra Version 10.0 
(CambridgeSoft UK). 








1-1 m-tolyl 7.0 
1-2 o-tolyl 6.7 
1-3 p-tolyl 7.0 
1-4 3-methoxyphenyl 6.4 
 
Compound R1 ClogP
1-5 3-ethoxyphenyl 7.0 
1-6 phenyl 6.5 
1-7 -H 4.6 
1-8 -F 4.8 
 
 
In Series 2, the n-octyl side chain was omitted or replaced by other side 
chains.  No change was made to the rest of the molecule (Table 3-3).   
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2-3  5.0 
2-4  7.0  
 
Series 3 consisted of compounds that had a secondary or tertiary amide side 
chain at position 3 while retaining n-octyl and m-tolyl at positions 1 and 5 
respectively (Table 3-4). 





3-1 -H 8.7 
3-2 -CH2CONHCH3 7.2 
3-3 -CH2CON(CH3)2 7.5 






3-6 CH2CON  
10.3 




Series 4 is similar to Series 3 except that the acetamide side chain was 
replaced by a secondary or tertiary amino function (Table 3-5). ClogP values were for 
the non-ionized (free base, non-protonated) state of the amino side chains. 
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Table 3-5. Structures and ClogP values of Series 4 compounds. 
Compound R3 ClogP 
4-1 -CH2NH2 7.6 
4-2 -CH2N(CH3)2 8.5 
4-3 -CH2N(C2H5)2 9.6 
4-4 -CH2N(i-C3H7)2 10.2 
4-5 -CH2N(n-C3H7)2 10.6 
4-6 -CH2NCH3(i-C3H7) 9.4 
 
Compound R3 ClogP 








4-10 CH2N O  8.4 
 
 
Like Series 3 and 4, only modifications were made to the acetamide side chain 
in Series 5 (Table 3-6). These were homologation and isosteric replacement. 
Table 3-6. Structures and ClogP values of Series 5 compounds. 
Compound R3 ClogP 
5-1 -CONH2 7.4 
5-2 -CH2CH2CONH2 7.8 
5-3 -CH2COOCH3 8.4 
 
Compound R3 ClogP 
5-4 -CH2COOC2H5 8.9 
5-5 -CH2NHCOCH3 7.5 
5-6 -CH2NHSO2CH3 7.4 
 
 
The final Series 6 comprised compounds that were modified at two or more 
positions (Table 3-7). They were divided broadly into those with n-octyl and 
isoprenyl side chains at position 1. At position 3, the acetamide side chain was 
retained in a few members but most had amino functionalities. At position 5, the 











Compound R1 R2 R3 ClogP 
6-1 o-tolyl n-C8H17 -CH2N(C2H5)2 9.3 



























6-11 3-methoxyphenyl n-C8H17 -CH2CON(C2H5)2 8.0 
6-12 3-ethoxyphenyl n-C8H17 -CH2CON(C2H5)2 8.5 
aNo phenyl ring, substituent is directly attached to indole C-5 
Except for cysmethynil (1-1), the other 46 compounds were novel.  Half of the 
compounds were synthesized by the candidate: these were the compounds in Series 1 
(except 1-8), Series 2, Series 3 (except 3-2, 3-7), 4-1 and 4-3 in Series 4, Series 5 
(except 5-6) and 6-11, 6-12 in Series 6. The remaining compounds were synthesized 
by a post-doctoral fellow in the supervisor’s laboratory, Dr Suresh Kumar Gorla.   
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3.3 CHEMICAL CONSIDERATIONS 
3.3.1 Series 1 and 2 
The following reaction scheme (Scheme 3-1) was adopted for the synthesis of 
compounds in Series 1 (with substituted 5-phenyl ring) and Series 2. For 1-8, the 
same reactions were carried out on 5-fluoro-1H-indole-3-carbaldehyde but without 






Scheme 3-1. Synthesis of Series 1 and 2 compounds60.  Reagents and conditions: (a) 
(i) NaBH4, NH2CHO-MeOH, rt (ii) KCN, 100 °C;  (b) KOH, t-BuOH, reflux;  (c) 
substituted phenylboronic acid, Pd(PPh3)4, NaHCO3, EtOH/toluene, reflux; (d) R’-X 
(X = halogen), NaH, DMF, rt  53-58°C. 
In the first step, the aldehydic group in 5-bromo-1H-indole-3-carbaldehyde 
was converted to the nitrile 1 in a stepwise process that involved reduction of the 
aldehyde to an alcohol by sodium borohydride (NaBH4), followed by displacement of 
the alcoholic OH by the cyanide ion. The reduction of the aldehydic carbonyl group 
by NaBH4 proceeded by the transfer of a H atom together with the pair of electrons 
from the B-H bond to the electron deficient carbon atom of the C=O group (Figure 3-
6). The resulting oxyanion helped to stabilize the electron deficient BH3 by adding to 
its empty p orbital to generate a tetravalent boron anion again. The latter could 
transfer a second hydrogen (with pair of electrons) to another molecule of aldehyde. 






























this rarely happened. The alcohol was not isolated but reacted in situ with the 
nucleophilic cyanide anion. The reaction occured via the more polarizable carbon 
































Figure 3-6. Reaction mechanisms involved in the formation of the nitrile 1. 
Nitrile 1 was hydrolyzed under basic conditions to give the carboxamide 2.  
Mechanistically, the reaction proceeded by a nucleophilic attack by the hydroxide 
anion on the carbon atom of the nitrile which was positively charged due to the 
greater electronegative character of N. A hydroxyimine anion (strong base) was 
formed and it deprotonated a water molecule.  The hydroxyimine tautomerized to give 






























1 2  
 
Figure 3-7. Reaction mechanisms involved in the hydrolysis of nitrile 1 to give 
the amide 2. 
The preparation of 2-(5-substituted phenyl-1H-indol-3-yl)acetamides involved 
the Suzuki coupling reaction between 2 and an appropriately substituted 
phenylboronic acid in the presence of a palladium catalyst. The palladium catalyst 
used in this reaction was tetrakis(triphenylphosphine)palladium (0) in which 
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palladium existed in its lower and nominally electron rich oxidation state (represented 
as Pd(0)Ln).  The catalytic cycle began with the rate limiting oxidative addition of the 
bromoindole 2 to Pd(0) to give the Pd(II) intermediate (Figure 3-8). Reaction of the 
phenylboronic acid with base led to the formation of borate which was transmetallated 
with the Pd(II) intermediate to afford the Pd(Ar)(Ar’) complex. The latter underwent 
reductive elimination to form the C-C bond with the concomitant regeneration of the 








Figure 3-8. Mechanism of Suzuki Coupling.77 
The mechanism of transmetallation had been investigated in detail and 
evidence suggested two different pathways for this process (Figure 3-9). The first 
involved exchange of hydroxide with bromide to generate palladium hydroxide that 
was transmetallated with the phenylboronic acid through a 4-centred transition state.  
The alternative pathway was when the borate complex reacted with the cationic Pd(II) 




























































Figure 3-9. Mechanism of transmetallation.77 
In the final step, the indole N was N-alkylated in the presence of sodium 
hydride which deprotonated the indole NH to generate a indolyl anion. The latter was 






Figure 3-10. Mechanism of N-alkylation of 2-(5-substituted phenyl-1H-indol-3-yl) 
acetamides. 
3.3.2. Series 3 
The tertiary amides of Series 3 were synthesized by N-alkylating the indole N 
of 5-bromo-1H-indole-3-acetic acid to give 2-(5-bromo-1-octyl-1H-indol-3-yl)acetic 
acid 3. The carboxylic acid was converted to the acid chloride with thionyl chloride 
(Scheme 3-2). The acid chloride was reacted in situ with the secondary amine or 
heterocyclic amine to give the corresponding amide. Subsequently, the 5-m-tolyl 
functionality was added by the Suzuki coupling reaction. The conversion of a 
carboxylic acid to acid chloride with thionyl chloride resulted from the strongly 
electrophilic sulphur atom in the latter. An unstable and highly electrophilic 
















chloride and gaseous products. The conversion of the acid chloride to amide involved 
a nucleophilic substitution at the carbonyl group by the amine. A similar route was 






















Scheme 3-2. Synthesis of Series 3 compounds. Reagents and conditions: (a) 
C8H17Br,  NaH, DMF, rt  53-58°C (b) (i) SOCl2, benzene, reflux, (ii) 2° 
amine/heterocyclic amine, THF; (c) m-tolyl boronic acid Pd(PPh3)4, NaHCO3, 
EtOH/toluene, reflux. 
3.3.3. Series 4  
















Scheme 3-3. Synthesis of Series 4 compounds. Reagents and conditions: (a) R-Br, 
NaH, DMSO; (b) substituted phenylboronic acid, DME, Pd(PPh3)4, K2CO3; (c) (i) aq. 
CH2O, 2o amine (R”H),  ZnCl2, EtOH, rt, 3 h. 
The amino side chain was introduced in the final step (c) by a Mannich 
reaction. Formaldehyde and the secondary amine reacted to form an iminium cation. 
The -excessive indole ring reacted with the iminium ion as a nucleophile at its 






























































Figure 3-11. Mechanism of the Mannich reaction. 
The primary amine 4-1 was prepared by another route, similar to that used to 
prepare the retroamide 5-5 and sulphonamide 5-6.  It is discussed in Section 3.3.4. 
 
3.3.4. Series 5 
Scheme 3-4 outlined the synthesis of the retroamide 5-5, sulphonamide 5-6 
and the short chain homologue 5-1 of cysmethynil. The primary amine 4-1 was 
involved as an intermediate for the synthesis of 5-5 and 5-6. Starting from 5-bromo-
1H-indole-3-carbaldehyde, sequential functionalization at positions 5 and 1 were 
carried out as described earlier (Section 3.3.1). The carbonyl group of 1-octyl-5-(m-
tolyl)-1H-indole-3-carbaldehyde was reacted with hydroxylamine to give a mixture of 
E and Z oximes which were not separated. The oxime was then reduced to give the 
primary amine 4-1. The reduction was initially attempted with sodium borohydride 
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but the yield of 4-1 was improved when nickel chloride was added, possibly due to 
the greater electrophilicity of the carbonyl carbon in the presence of nickel chloride. 
4-1 was acetylated with acetylchloride in the presence of triethylamine to give the 
retroamide 5-5 or sulphonylated with methane sulphonyl chloride in the presence of 

















































Scheme 3-4. Synthesis of compounds 5-1, 5-5 and 5-6. Reagents and conditions: (a) 
C8H17Br, NaH, DMF; (b) m-tolylboronic acid, EtOH/DME, Pd(PPh3)4, K2CO3; (c) 
NH2OH.HCl, Py, EtOH; (d) NiCl2.6H2O, MeOH, NaBH4; (e) CH3COCl, CH2Cl2, 
Et3N; (f) CH3SO2Cl, THF, Et3N; (g) KMnO4, acetone; (h) (i) SOCl2, benzene, reflux, 
(ii) NH3 (g), THF.  
Starting from 1-octyl-5-(m-tolyl)-1H-indole-3-carbaldehyde, the short 
homologue of cysmethynil (5-1) was prepared by oxidation of the aldehyde to  a  
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carboxylic acid which was then converted to an acid chloride with thionyl chloride, 
followed by reaction with  gaseous ammonia to give the desired product. 
The synthesis of the long chain homologue of cysmethynil 5-2 is shown in 
Scheme 3-5. The reaction started with 2-(5-bromo-1H-indol-3-yl) acetic acid which 
was converted to its methyl ester and then reduced with lithium aluminium hydride to 
give the alcohol. The alcoholic OH group was displaced by cyanide and hydrolyzed to 
give the primary amide. One difference was that the alcoholic OH had to be activated 
by conversion to a methane sulphonyl ester to enhance its leaving group ability. It was 
then reacted with KCN to give the nitrile. The conversion of the nitrile to amide and 
functionalization at positions 5 and 1 were carried out as described in Section  3.3.1.  
 
 
Scheme 3-5. Synthesis of compound 5-2. Reagents and conditions: (a) MeOH, 
H2SO4, reflux (1 h),  (b) LiAlH4, THF, rt (30 min), (c) (i) TEA, MsCl, CH2Cl2, 0 °C 
(30 min), (ii) KCN, DMSO, 100 °C (d) KOH, t-BuOH, reflux (3 h)  (e) m-
tolylboronic acid, Pd(PPh3)4, NaHCO3, EtOH/toluene, reflux (1-6 h) (f) bromooctane, 
NaH, DMF, rt (1.5 h) 53-58 °C (3-6 h) 
The bioisosteric esters of cysmethynil (5-3, 5-4) were also prepared starting 
from 2-(5-bromo-1H-indol-3-yl) acetic acid. The latter was functionalized at positions 
1 and 5 and then converted to the methyl or ethyl ester by an acid catalyzed 




























































R = CH3 , C2H5
a b c
 
Scheme 3-6. Synthesis of compounds 5-3 and 5-4. Reagents and conditions: (a) 
C8H17Br, NaH, DMSO; (b) m-tolylboronic acid in EtOH, DME, Pd(PPh3)4, K2CO3;   
(c) R-OH, cat. H2SO4.  
3.3.5. Series 6  
The compounds in this Series were synthesized following earlier procedures.  
The amines 6-1, 6-2, 6-4 to 6-7, 6-9 and 6-10 were prepared by the Mannich reaction 
starting from 5-bromo-1H-indole (Scheme 3-3), indole or 5-fluoro-1H-indole with 
appropriate functionalization at positions 1 and 5. Scheme 3-1 was used for the 
synthesis of the primary amide 6-8 starting with 5-fluoro-1H-indole-3-carbaldehyde. 
The tertiary amides 6-11 and 6-12 were synthesized following the reaction sequences 
described in Scheme 3-2, except that Suzuki coupling was carried out with 3-
methoxyphenylboronic acid and 3-ethoxyphenylboronic acid, instead of 3-
methylphenylboronic acid. 6-3 was synthesized from 5-bromo-1H-indole by N-
alkylation with 1-chloro-3-methylbut-2-ene to introduce the isoprenyl side chain, 




3.4. EXPERIMENTAL  
3.4.1. General Details 
Reagents (synthetic grade or better) were obtained from commercial suppliers 
(Sigma-Aldrich Chemical Company Inc, Singapore; Alfa Aesar, MA, USA) and used 
without further purification.  1H (300 MHz) and 13C (75 MHz) spectra were measured 
on a Bruker Spectrospin 300 Ultrashield spectrometer magnetic resonance 
spectrometer. Chemical shifts were reported in ppm and referenced to TMS or  
residual deuterated solvents (CDCl3 δH 7.26 ppm, DMSO-d6  δH  2.50 ppm; CD3OD 
δH  3.31 ppm) for 1H spectra and residual CDCl3 ( C 77.16 ppm) and DMSO-d6  ( C 
39.52 ppm) for proton decoupled 13C NMR spectra.  Coupling constants (J) were 
reported in Hertz (Hz). Reactions were routinely monitored by thin layer 
chromatography (TLC) on pre-coated plates (Silica Gel 60 F254, Merck) with 
ultraviolet light as visualizing agent. Column chromatography was carried out with 
Silica Gel 60 (0.04–0.063 mm).  Nominal mass spectra were captured on an LCQ 
Finnigan MAT equipped with an atmospheric pressure chemical ionization (APCI) 
probe and m/z values for the molecular ion were reported. Accurate mass was 
determined using a Finnigan Mat 95/XL-T spectrometer equipped with an electron 
spray ionization probe (ESI). Purity of final compounds were verified by combustion 
analysis (C and H) on a Perkin Elmer PRE-2400 Elemental Analyzer or by reverse 
phase high performance liquid chromatography (HPLC) carried out on a Waters Delta 
600 liquid chromatography system, using an Agilent Zorbax Eclipse XDB-C18 
column (4.6 mm × 150 mm, 5 μm) on two different solvent systems (isocratic mode), 
details of which are given in Table A2-1. Compounds synthesized by the candidate 
are reported in this section while those prepared by Dr Suresh are described in 
Appendix 2.  
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2-(5-Bromo-1H-indol-3-yl) acetonitrile (1).60 To a solution of 5-bromo-1H-
indole-3-carbaldehyde (4.5 mmol, 1 equiv.) in formamide-methanol (NH2CHO-
MeOH; 1:1, v/v; 200 mL) was added sodium borohydride (NaBH4; 13.5 mmol, 3 
equiv.) and the mixture was stirred for 0.5 h. To the reaction mixture was added 
potassium cyanide (KCN; 45 mmol, 10 equiv.) and the whole mixture was refluxed 
on an oil bath at 100 °C for 2.5 h with stirring. After cooling to room temperature, 
brine was added and the mixture was extracted with chloroform (CHCl3), washed 
with brine, dried over anhydrous sodium sulphate (Na2SO4), and evaporated under 
reduced pressure to give the nitrile 1. Recrystallization from ethanol (EtOH)/water 
gave needle-like white crystals. Yield: 81 %; 1H NMR (300 MHz, CD3OD): δ 3.73 (s, 
2 H), 7.19-7.33 (m, 3 H), 7.69 (s, 1 H); MS (APCI): m/z 236.1 [M + H]+. 
2-(5-Bromo-1H-indol-3-yl)acetamide (2).60 Nitrile 1 (3.5 mmol, 1 equiv.), 
was refluxed in tertiary butanol (t-BuOH;10 mL) containing finely powdered 85% 
potassium hydroxide (KOH; 28 mmol, 8 equiv.) for 3 h. The reaction mixture was 
cooled to room temperature, diluted with water, and acidified with 1 M hydrochloric 
acid (HCl). The resulting suspension was filtered under reduced pressure. The filter 
cake was washed with water then dried in vacuo. The product was isolated as an off-
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white solid. Yield: 89 %; 1H NMR (300 MHz, DMSO-d6): δ 3.44 (s, 2 H), 7.15-7.38 
(m, 4 H), 7.73 (s, 1 H), 11.07 (s, 1 H); MS (APCI): m/z 254.1 [M + H]+. 
General procedure for preparation of 2-(5-(substituted phenyl)-1H-
indole-3-yl)acetamides (3).  To a suspension of bromoindole 2 (2 mmol, 1 equiv.) in 
anhydrous toluene (40 mL) in an ice bath was added 
tetrakis(triphenylphosphine)palladium (0) (Pd(PPh3)4; 5.7 mol%). The bright yellow 
suspension was stirred for 0.5 h, after which was added in one portion a solution of 
substituted phenylboronic acid (3 mmol, 1.5 equiv) in absolute EtOH (10 ml) 
followed immediately by a saturated aqueous solution of sodium bicarbonate 
(NaHCO3; 25 mL). After refluxing for 1-6 h, the biphasic mixture was cooled to room 
temperature and then poured into a solution of brine. The organic phase was separated 
and the aqueous phase was extracted with ethyl acetate (EtOAc). The organic extracts 
were combined, dried (anhydrous Na2SO4), the drying agent was removed by 
filtration and the filtrate was concentrated under reduced pressure to give the crude 
product 3, which was used without further purification for the N-alkylation reaction. 
2-(5-m-Tolyl-1H-indol-3-yl)acetamide (2-1).60 Off-white solid (purified by 
column chromatography using EtOAc/ dichloromethane (CH2Cl2) as eluate); Yield: 
80 %; 1H NMR (300 MHz, CDCl3): δ 2.44 (s, 3 H), 3.79 (s, 2 H), 7.14 (d, J 6 Hz, 1 
H), 7.20 (s, 1 H), 7.31 (t, J = 15 Hz, 1 H), 7.43-7.52 (m, 4 H), 7.78 (s, 1 H), 8.25 (s, 1 
H); 13C NMR (75 MHz, CDCl3): δ 21.5, 32.9, 109.7, 111.6, 117.1, 122.6, 124.2, 
124.5, 127.3, 127.4, 128.1, 128.6, 134.0, 135.8, 138.3, 142.0, 174.1; MS (APCI): m/z 
265.2 [M + H]+. 
General procedure for preparation of 2-(1-substituted-5-(substituted 
phenyl)-1H-indol-3-yl)acetamides (1-1 to 1-7 and 2-2 to 2-4). To a stirred 
suspension of sodium hydride (NaH, 60% dispersion in mineral oil; 3 mmol, 1.5 
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equiv.) in anhydrous dimethylformamide (DMF; 5 ml) in ice bath was added 
dropwise a solution of the crude acetamide 3 (2 mmol, 1 equiv.) in anhydrous DMF 
(10 mL) over a period of 10 min. After stirring at room temperature for 1.5 h, the 
alkyl or arylalkyl halide (1-bromooctane for 1-1 to 1-7, trifluromethylbenzylbromide 
for 2-2, 1-chloro-3-methylbut-2-ene for 2-3 and geranyl bromide for 2-4; 6 mmol, 3 
equiv.) was added dropwise over 5 min. The reaction mixture was then heated in an 
oil bath at 53-58°C for 3-6 h, after which it was cooled to room temperature and 
poured into ice water. The suspension was stirred 10 min and extracted with diethyl 
ether (Et2O). The organic extracts were combined, washed with brine, and dried 
(anhydrous Na2SO4). The drying agent was removed by filtration and the filtrate was 
concentrated under reduced pressure to give the crude alkylated product. The crude 
product was purified by flash silica gel column chromatography by elution with 
EtOAc/CH2Cl2 to give compounds 1-1 to 1-7 and 2-2 to 2-4. 
2-(1-Octyl-5-m-tolyl-1H-indol-3-yl)acetamide (Cysmethynil, 1-1).60 Off-
white solid, mp 62-65 ˚C; Yield: 77 %; 1H NMR (300 MHz, CD3OD,): δ 0.92 (t, J 
=15 Hz, 3 H), 1.29-1.35 (m, 10 H), 1.88 (t, 2 H, J = 15 Hz), 2.42 (s, 3 H), 3.70 (s, 2 
H), 4.20 (t, J = 15 Hz, 2 H), 7.12 (d, J = 9 Hz, 1 H), 7.21-7.32 (m, 2 H), 7.37-7.48 (m, 
4 H), 7.80 (s, 1 H); 13C NMR (75 MHz, CD3OD): δ 13.6, 20.8, 22.8, 27.2, 29.5, 29.6, 
30.6, 32.1, 32.6, 46.3, 108.6, 110.0, 117.3, 121.5, 124.5, 127.1, 127.6, 128.2, 128.7, 
131.1, 133.1, 136.6, 138.4, 143.0, 177.0.  MS (APCI): m/z 377.5 [M+H]+.  
2-(1-Octyl-5-o-tolyl-1H-indol-3-yl)acetamide (1-2). Off-white solid; Yield: 
63 %; 1H NMR (300 MHz, CDCl3): δ 0.85 (t, J = 15 Hz , 3 H), 1.27-1.34 (m, 10 H), 
1.85 (t, J = 15 Hz, 2 H), 2.30 (s, 3 H), 3.72 (s, 2 H), 4.09 (t, J = 15 Hz, 2 H), 7.12 (d, J 
9 Hz, 1 H), 7.21-7.32 (m, 5 H), 7.37-7.48 (m, 3 H), 7.80 (s, 1 H) 13C NMR (75 MHz, 
CDCl3): δ 14.1, 20.6, 22.6, 27.0, 29.1, 29.1, 30.3, 31.7, 32.9, 46.5, 107.7, 109.1, 
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119.2, 123.8, 125.7, 126.8, 127.3, 127.6, 130.3, 130.3, 133.5, 135.5, 135.6, 142.6, 
174.3; MS (APCI): m/z 377.3 [M + H]+. 
2-(1-Octyl-5-p-tolyl-1H-indol-3-yl)acetamide (1-3). Off-white solid, mp 
123-128 ˚C; Yield: 75 %; 1H NMR (300 MHz, CDCl3): δ 0.85 (t, J = 15 Hz, 3 H), 
1.26-1.33 (m, 10 H), 1.83 (t, J = 12 Hz, 2 H), 2.40 (s, 3 H), 3.76 (s, 2 H), 4.09 (t, J = 
12 Hz, 2 H), 7.07, (s, 1 H) , 7.24 (d, J = 6 Hz, 2 H), 7.38 (d, J 6 Hz, 1 H), 7.48-7.55 
(m, 3 H), 7.75 (s, 1 H) 13C NMR (75 MHz, CDCl3): δ 14.0, 21.0, 22.6, 27.0, 29.1, 
29.1, 30.2, 31.7, 32.9, 46.5, 107.9, 109.9, 117.0, 121.8, 127.2, 127.2, 127.8, 129.4,  
129.4, 133.2, 135.9, 136.2, 139.2, 174.3; MS (APCI): m/z 377.3 [M + H]+. 
2-(5-(3-Methoxyphenyl)-1-octyl-1H-indol-3-yl)acetamide (1-4). Off-white 
solid, mp 89-91 ˚C; Yield: 26 %; 1H NMR (300 MHz , CD3OD): δ 0.91 (t, J = 12 Hz, 
3 H), 1.29-1.34 (m, 10 H), 1.88 (t, J = 12 Hz, 2 H), 3.71 (s, 2 H), 3.87 (s, 3 H), 4.20 (t, 
J = 12 Hz, 2 H), 6.87 (d, J = 6 Hz, 1 H), 7.17-7.44 (m, 6 H), 7.82 (s, 1 H). 13C NMR 
(75 MHz, DMSO-d6): δ 14.9, 15.7, 23.0, 27.3, 29.6, 29.7, 30.9, 32.2, 33.3, 46.5, 56.1, 
109.9, 111.0, 112.6, 113.4, 118.3, 120.1, 121.4, 129.0, 129.1, 130.9, 131.8, 136.6, 
144.4, 160.7, 174.2; MS (APCI): m/z 393.5 [M + H]+. 
2-(5-(3-Ethoxyphenyl)-1-octyl-1H-indol-3-yl)acetamide (1-5). Off-white 
solid, mp 74-76 ˚C; Yield: 74 %; 1H NMR (300 MHz, DMSO-d6): δ 0.90 (t, J = 12 
Hz, 3 H), 1.05-1.15 (m, 6 H), 1.27-1.31 (m, 10 H), 1.84 (t, J = 9 Hz, 2 H), 3.40-3.48 
(m, 4 H), 3.87 (s, 3 H), 3.88 (s, 2 H), 4.19 (t, J = 15 Hz, 2 H), 6.87 (d, J = 6 Hz, 1 H), 
7.14-7.44 (m, 6 H), 7.83 (s, 1 H); 13C NMR (75 MHz, DMSO-d6): δ 15.0, 15.8, 23.1, 
27.4, 29.7, 29.8, 31.0, 32.2, 33.3, 46.5, 64.0, 110.1, 111.0, 113.0, 114.0, 118.4, 120.0, 
121.4, 128.9, 129.2, 130.8, 131.8, 136.6, 144.4, 160.0, 173.8; MS (APCI): m/z 407.4 
[M + H]+. 
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2-(1-Octyl-5-phenyl-1H-indol-3-yl)acetamide (1-6). Off-white solid, mp 74-
76 ˚C; Yield: 70 %; 1H NMR (300 MHz, CDCl3): δ 0.85 (t, J = 15 Hz, 3 H), 1.26-1.31 
(m, 10 H), 1.84 (t, J = 12 Hz, 2 H), 3.77 (s, 2 H), 4.10 (t, J = 15 Hz, 2 H), 7.07 (d, J = 
6 Hz, 1 H), 7.28-7.34 (m, 2 H), 7.40-7.52 (m, 3 H), 7.63 (d, J 6 Hz, 2 H), 7.77 (s, 1 
H); 13C NMR (75 MHz , CDCl3): δ 14.1, 22.6, 27.0, 29.1, 29.1, 30.3, 31.7, 32.9, 46.5, 
108.0, 110.0, 117.3, 121.9, 124.9, 126.5, 127.3, 127.3, 128.7, 128.7, 133.2, 136.0, 
142.1, 174.3; MS (APCI): m/z 363.6 [M + H]+. 
2-(1-Octyl-1H-indol-3-yl)acetamide (1-7). Off-white solid, mp 74-76 ˚C; 
Yield: 65 %; 1H NMR (300 MHz, CDCl3): δ 0.85 (t, J 12 Hz, 3 H), 1.25-1.31 (m, 10 
H), 1.81 (t, J = 15 Hz, 2 H), 3.73 (s, 2 H), 4.07 (t, J = 15 Hz, 2 H), 7.06 (s, 1 H), 7.12 
(t, J = 15 Hz, 1 H), 7.22 (t, J = 12 Hz, 1 H), 7.34 (d, J = 9 Hz, 1 H), 7.57 (d, J = 6 Hz, 
1 H); 13C NMR (75 MHz, CDCl3): δ 14.0, 22.6, 27.0, 29.1, 29.1, 30.2, 31.7, 32.9, 
46.4, 107.6, 109.7, 118.9, 119.5, 122.0, 127.2, 127.4, 136.5, 174.3; MS (APCI): m/z 
287.5 [M + H]+. 
2-(5-m-Tolyl-1-(3-(trifluoromethyl)benzyl)-1H-indol-3-yl)acetamide (2-2). 
Off-white solid; Yield: 35 %; 1H NMR (300 MHz , CDCl3): δ 2.43 (s, 3 H), 3.79 (s, 2 
H), 5.38 (s, 2 H), 7.13 (d, J = 9 Hz, 2 H), 7.30 (t, J = 18 Hz, 2 H), 7.41-7.50 (m, 5 H), 
7.54 (d, J = 6 Hz, 2 H) 7.79 (s, 1 H); 13C NMR (75 MHz , CDCl3): δ 28.7, 37.8, 51.5, 
99.6, 100.3, 106.3, 110.5, 111.2, 112.0, 112.2, 114.4, 114.8, 115.0, 115.4, 116.1, 
116.5, 119.7, 121.5, 123.0, 123.2, 126.0, 152.1; MS (APCI): m/z 423.4 [M + H]+. 
2-(1-(3-Methylbut-2-enyl)-5-m-tolyl-1H-indol-3-yl)acetamide (2-3). Off-
white solid; Yield: 62 %; 1H NMR (300 MHz, CDCl3): δ 1.79 (s, 3 H), 1.84 (s, 3 H), 
2.43 (s, 3 H), 3.75 (s, 2 H), 4.68 (d, J = 6 Hz, 2 H), 5.37 (t, J = 15 Hz, 1 H), 7.05-7.15 
(m, 2 H), 7.30-7.51 (m, 5 H), 7.75 (s, 1 H) 13C NMR (75 MHz, CDCl3): δ 18.0, 21.6, 
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25.7, 33.0, 44.2, 108.0, 110.0, 117.3, 119.5, 121.9, 124.5, 127.2, 127.4, 128.0, 128.1, 
128.6, 133.4, 136.0, 136.9, 138.3, 142.1, 174.4; MS (APCI): m/z 333.4 [M + H]+. 
(E/Z)-2-(1-(3,7-dimethylocta-2,6-dienyl)-5-m-tolyl-1H-indol-3-
yl)acetamide (2-4). Amber oil; Yield: 45 %; 1H NMR (300 MHz, CDCl3): δ 1.59 (s, 3 
H), 1.66 (s, 3 H), 1.80 (s, 3 H), 2.10 (t, J = 21 Hz, 4 H), 2.43 (s, 3 H), 3.65 (s, 2 H), 
4.70 (d, J = 6 Hz, 2 H), 5.04 (t, J = 9 Hz, 1 H), 5.39 (t, J = 6 Hz, 1 H), 7.05-7.15 (m, 2 
H), 7.30-7.51 (m, 5 H), 7.75 (s, 1 H); 13C NMR (75 MHz, CDCl3): δ 16.4, 17.7, 21.5, 
25.7, 26.2, 32.9, 39.4, 44.1, 107.9, 110.1, 117.2, 119.3, 121.9, 123.6, 124.4, 127.2, 
127.4, 128.1, 128.6, 131.9, 133.4, 136.0, 138.3, 140.4, 140.7, 142.8, 174.5. MS 
(APCI): m/z 401.5 [M + H]+. 
 
3.4.3. Synthesis of Series 3 compounds 




2-(5-Bromo-1-octyl-1H-indol-3-yl)acetic acid (4). Compound 4 was 
synthesized according to the method described in Roy et al.78 To a stirred suspension 
of NaH (60% dispersion in mineral oil, 138 mmol, 5 equiv.) in tetrahydrofuran (THF; 
100 mL) at 0 °C was added a solution of 2-(5-bromo-1H-indol-3-yl)acetic acid (27.7 
mmol, 1 equiv.) in THF (50 mL). The mixture was stirred for 30 min at 0 °C after 
which a solution of 1-bromooctane (83.1 mmol, 3 equiv.) in THF (50 mL) was added 



















3-3 to 3-64 5a-d
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which it was stirred for another 4 h. The reaction mixture was then cooled to 0 °C and 
excess NaH was carefully destroyed by the slow addition of MeOH with vigorous 
stirring, followed by cold water until a clear yellow solution was obtained. Et2O (100 
mL) was added, the aqueous phase was separated, acidified with 6 M HCl, and 
extracted with sufficient CH2Cl2. The combined organic extracts were dried 
(anhydrous Na2SO4) and concentrated in vacuo. The crude product was purified by 
column chromatography with hexane/EtOAc as a . Yield: 64 %; 1H NMR (300 MHz, 
CDCl3): δ 7.71 (s, 1 H), 7.26 (d, J = 2.1 Hz, 1 H), 7.16 (d, J = 8.7 Hz, 1H), 7.07 (s, 1 
H), 4.03 (t, J = 7.2 Hz, 2 H), 3.73 (s, 2 H), 1.79 (t, J = 9.9 Hz), 1.28-1.24 (m, 10 H), 
0.86 (t, J = 6.3 Hz).  13 C NMR (75 MHz, CDCl3): δ 177.3, 134.8, 129.2, 128.0, 124.5, 
121.5, 112.5, 110.9, 105.6, 46.5, 31.7, 30.7, 30.1, 29.1, 29.0, 26.9, 22.5, 14.0. 
General procedure for the synthesis of 2-(5-bromo-1-octyl-1H-indol-3-yl)-
N-substituted acetamides (5). A mixture of acetic acid 4 (1 mmol, 1 equiv.) and 
thionyl chloride (SOCl2; 2 mL, 27 equiv.) were refluxed for 4 h in dry benzene (5 
mL), after which excess SOCl2 and benzene were  removed by distillation in vacuo to 
give the corresponding acid chloride.  The acid chloride was dissolved in dry THF (4 
ml) and added dropwise to a stirred solution of the amine in dry THF at 0-5 ºC. The 
reaction mixture was stirred at the same temperature for 1 h after which THF was 
removed in vacuo and the residue extracted with CH2Cl2 and dried (anhydrous 
Na2SO4).  Removal of the solvent under reduced pressure gave the desired amide 
which was purified by column chromatography with EtOAc/hexane as eluting 
solvents. 
2-(5-bromo-1-octyl-1H-indol-3-yl)-N,N-
dimethylacetamide (5a). Yield: 38%; 1H NMR (300 MHz, 







8.7 Hz, 1 H), 7.05 (s, 1 H), 4.01 (t, J = 7.2 Hz, 2 H), 3.72 (s, 2 H), 3.40 (s, 6 H), 1.77 
(t, J = 6.9 Hz, 2 H), 1.25-1.23 (m, 10 H), 0.86 (t, J = 6.6 Hz, 3 H); 13C NMR (75 
MHz, CDCl3): δ 171.2, 134.8, 129.3, 127.4, 124.3, 121.4, 112.3, 110.8, 107.2, 46.4, 
37.8, 35.6, 31.7, 30.6, 30.1, 29.1 (2C), 26.9, 22.5, 14.0. 
2-(5-bromo-1-octyl-1H-indol-3-yl)-N,N-
diethylacetamide (5b). Yield: 38 %; 1H NMR (300 MHz, 
CDCl3): δ 7.70 (s, 1 H), 7.25 (d, J = 8.1 Hz, 1 H), 7.15 (d, J 
= 8.7 Hz, 1 H), 7.05 (s, 1 H), 4.01 (t, J = 7.2 Hz, 2 H), 3.72 (s, 2 H), 3.40 (q, J = 6.9 
Hz, 2 H), 3.34 (q, J = 7.5 Hz, 2 H), 1.77 (t, J = 6.9 Hz, 2 H), 1.25-1.23 (m, 10 H), 
1.13 (t, J = 6.9 Hz, 3 H), 1.11 (t, 3 H, J = 6.9 Hz), 0.86 (t, J = 6.6 Hz, 3 H); 13C NMR 
(75 MHz, CDCl3): δ 170.3, 134.8, 129.3, 127.3, 124.2, 121.3, 112.2, 110.8, 107.7, 
46.4, 42.4, 40.2, 31.7, 30.5, 30.1, 29.12, 29.10, 26.9, 22.5, 14.3, 14.0, 12.9.  
2-(5-Bromo-1-octyl-1H-indol-3-yl)-1-(pyrrolidin-1-
yl)ethanone (5c). This compound was not characterized.  
 
2-(5-bromo-1-octyl-1H-indol-3-yl)-1-(piperidin-
1-yl)ethanone (5d). Yield: 38 %; 1H NMR (300 MHz, 
CDCl3): δ 0.86 (t, J = 6.9 Hz, 3 H), 1.23-1.25 (m, 10 H), 
1.36 (t, J = 6.9 Hz, 2 H), 1.55 (t, J = 6.9 Hz, 4 H), 1.77 (t, J = 6.9 Hz, 2 H), 3.39 (t, J 
= 5.4 Hz, 2 H), 3.58 (t, J = 5.4 Hz, 2 H), 3.75 (s, 2 H), 4.02 (t, J = 6.9 Hz, 2 H), 7.01 
(s, 1 H), 7.16 (d, J = 8.7 Hz, 1 H), 7.26 (d, J = 8.7 Hz, 1 H), 7.71 (s, 1 H); 13C NMR 
(75 MHz, CDCl3): δ 14.0, 22.5, 24.4, 25.5, 26.3, 26.9, 29.11, 29.14, 30.1, 30.8, 31.7, 
42.8, 46.4, 47.3, 107.6, 110.8, 112.3, 121.4, 124.3, 127.2, 129.2, 134.8, 169.4. 
General procedure for the synthesis of the tertiary amides (3-3 to 3-6). 

















Li et al.79 To a solution of the acetamide 5 (1 mmol, 1 equiv.) in 4 ml 
dimethoxyethane (DME) was added Pd(PPh3)4 (0.05 mmol, 0.05 equiv.) followed by 
stirring under argon for 15 min. A solution of m-tolylboronic acid (1 mmol, 1 equiv.) 
in 1.5 ml EtOH was added and stirring was continued for another 15 min. A solution 
of 2 M aqueous sodium carbonate (Na2CO3; 4 mL) was added and the mixture was 
refluxed for another 5 h under argon. On cooling, the organic solvent was removed 
under reduced pressure, the resulting suspension was extracted with CH2Cl2 and dried 
(anhydrous Na2SO4). The residue obtained on removal of the solvent was purified by 
column chromatography on silica gel with EtOAc/hexane as eluting solvents.   
N,N-dimethyl-2-(1-octyl-5-m-tolyl-1H-indol-3-yl)acetamide (3-3). Amber 
oil; Yield: 48 %; 1H NMR (300 MHz, CD3OD): δ 0.91 (t, J = 12 Hz, 3 H), 1.27-1.31 
(m, 10 H), 1.86 (t, J = 9 Hz, 2 H), 2.42 (s, 3 H), 3.10 (s, 6 H), 3.90 (s, 2 H), 4.18 (t, J 
= 15 Hz, 2 H), 7.09-7.13 (m, 2 H), 7.29 (t, 1 H), 7.40-7.48 (m, 4 H), 7.83 (s, 1 H); 13 
NMR (75 MHz, CD3OD):  δ 13.6, 20.8, 22.8, 27.1, 29.5, 29.6, 30.6, 32.1, 32.5, 35.2, 
37.6, 46.3, 107.8, 110.0, 117.5, 121.5, 124.5, 127.1, 127.7, 128.0, 128.7, 128.9, 133.0, 
136.6, 138.4, 143.1, 172.0; HRMS (ESI): m/z 405.2943 (calcd for [C27H36N2O + H]+: 
405.2828) 
N,N-diethyl-2-(1-octyl-5-m-tolyl-1H-indol-3-yl)acetamide (3-4). Amber oil; 
Yield: 38 %; 1H NMR (300 MHz, CDCl3): δ 0.89 (t, J = 12 Hz, 3 H), 1.13-1.15 (m, 6 
H), 1.26-1.30 (m, 10 H), 1.85 (t, J = 12 Hz, 2 H), 2.44 (s, 3 H), 3.33-3.44 (m, 4 H), 
3.84 (s, 2 H), 4.11 (t, J = 15 Hz, 2 H), 7.08-7.14 (m, 2 H), 7.26-7.48 (m, 5 H), 7.78 (s, 
1 H); 13C NMR (75 MHz, CDCl3): δ 14.1, 14.3, 20.8, 21.6, 22.6, 27.0, 29.3, 29.4, 
30.8, 31.8, 32.8, 40.1, 42.7, 46.4, 108.4, 109.6, 117.2, 121.4, 124.5, 126.7, 127.0, 
128.1, 128.2, 128.5, 132.7, 135.7, 138.1, 142.6, 170.9; HRMS (ESI): m/z 433.3194 




Amber oil; Yield: 46 %; 1H NMR (300 MHz, CD3OD): δ 0.91 (t, J = 15 Hz, 3 H), 
1.27-1.31 (m, 10 H), 1.84-1.96 (m, 6 H), 2.42 (s, 3 H), 3.49 (t, J = 15 Hz, 2 H), 3.60 
(t, J = 15 Hz, 2 H), 3.84 (s, 2 H), 4.19 (t, J = 12 Hz, 2 H), 7.09-7.15 (m, 2 H), 7.32 (t, 
J = 12 Hz, 1 H), 7.40-7.48 (m, 4 H), 7.83 (s, 1 H); 13C NMR (75 MHz, CD3OD): δ 
13.6, 20.8, 22.8, 24.5, 26.2, 27.1, 29.5 (2C), 30.6, 32.1, 32.5, 46.4, 50.2, 52.0, 107.8, 
110.0, 117.5, 121.5, 124.5, 127.1, 127.7, 128.0, 128.7, 128.9, 133.1, 136.6, 138.4, 
143.1, 172.0; MS (APCI): m/z 431.4 [M + H]+. 
2-(1-octyl-5-m-tolyl-1H-indol-3-yl)-1-(piperidin-1-yl)ethanone (3-6). 
Amber oil; Yield: 28 %; 1H NMR (300 MHz , CD3OD): δ 0.90 (t, J = 12 Hz, 3 H), 
1.26-1.29 (m, 10 H), 1.47-1.57 (m, 6 H), 1.84 (t, J = 12 Hz , 2 H), 2.42 (s, 3 H), 3.51-
3.58 (m, 4 H), 3.90 (s, 2 H), 4.18 (t, J = 15 Hz, 2 H), 7.09-7.12 (m, 2 H), 7.32 (t, J = 
15 Hz, 1 H), 7.40-7.48 (m, 4 H), 7.85 (s, 1 H); 13C NMR (75 MHz, CD3OD): δ 13.6, 
20.8, 22.8, 24.5, 25.9, 26.4, 27.1, 29.5, 29.6, 30.7, 31.6, 32.1, 43.3, 43.4, 46.2, 108.4, 
110.0, 117.4, 121.5, 124.5, 127.1, 127.4, 128.0, 128.6, 128.7, 133.1, 136.6, 138.4, 
143.0, 171.6; HRMS (ESI): m/z 445.3351 (calcd for [C30H40N2O + H]+: 445.3141). 
 
3.4.4. Synthesis of Series 4 compounds (4-1 and 4-3) 
 (1-Octyl-5-m-tolyl-1H-indol-3-yl)methanamine (4-1). Synthesis of 4-1 is 

















5-Bromo-1-octyl-1H-indole (6). Compound 6 was synthesized according to 
the method described in Na et al.80 NaH (60% in mineral oil dispersion, 6 mmol, 1.2 
equiv.) was added to a stirred solution of 5-bromo-1H-indole (5 mmol, 1 equiv.) in 
anhydrous dimethylsulfoxide (DMSO) at room temperature. After 1 h of stirring at 
the same temperature, 1-bromooctane was added and the mixture stirred for another 3 
h. Distilled water was added to the reaction mixture which was then extracted with 
CH2Cl2. The organic layer was washed with brine, dried (anhydrous Na2SO4) and 
evaporated under reduced pressure. The residue was purified by column 
chromatography with EtOAc/hexane as eluting solvents. Yield: 92 %; 1H NMR (300 
MHz, CDCl3): δ 0.82 (t, J = 6.9 Hz, 3 H), 1.20-1.24 (m, 10 H), 1.76 (t, J = 6.9 Hz, 2 
H), 4.03 (t, J = 7.2 Hz, 2 H), 6.37 (d, J = 3 Hz, 1 H), 7.04 (d, J = 3 Hz, 1H), 7.17 (s, 1 
H), 7.21 (d, J = 1.2 Hz, 1 H), 7.69 (d, J = 1.5 Hz, 1 H); 13C NMR (75 MHz, CDCl3) δ 
14.0, 22.5, 26.9, 29.1(2C), 30.1, 31.7, 46.5, 100.4, 110.7, 112.4, 123.3, 124.0, 128.8, 
130.1, 134.6.  
1-Octyl-5-m-tolyl-1H-indole (3-1). Indole 6 was reacted with m-tolylboronic 
acid as described for the synthesis of amide 3-3 (Section 3.4.3). The product was 
isolated as an amber oil. Yield: 85 %; 1H NMR (300 MHz, CD3OD): δ 0.91 (t, J = 18 
Hz, 3 H), 1.20-1.30 (m, 10 H), 1.85 (t, J = 15 Hz, 2 H), 2.41 (s, 3 H), 4.17 (t, J = 12 
Hz, 2 H), 6.48 (d, J = 3 Hz, 1 H), 7.10 (d, J = 6 Hz, 1 H), 7.20 (d, J = 3 Hz, 1 H), 7.31 
(t, J = 15 Hz, 1 H), 7.40-7.45 (m, 4 H), 7.76 (s, 1 H); 13C NMR (75MHz, CD3OD): δ 
13.6, 20.8, 22.8, 27.1, 29.4, 29.5, 30.6, 32.1, 46.4, 101.3, 109.8, 119.2, 121.1, 124.4, 
127.0, 128.0, 128.7, 128.9, 129.8, 133.0, 136.2, 138.4, 143.2; MS (ESI): m/z 320.3 [M 
+ H]+.  
N-ethyl-N-((1-octyl-5-m-tolyl-1H-indol-3-yl)methyl)ethanamine (4-3). 
Diethylamine (1 mmol, 1equiv.), zinc chloride (ZnCl2; 1.5 mmol, 1.5 equiv.), 
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formaldehyde (HCHO; 1 mmol, 36% aq., 1 equiv.), indole 3-1 (1 mmol, 1equiv.) and 
EtOH (3 mL) were stirred together in a round bottom flask for 10 h at room 
temperature. Distilled water was added to the mixture which was made alkaline by the 
addition of 4 M sodium hydroxide (NaOH).  The mixture was extracted with EtOAc, 
the solvent was removed under reduced pressure and the residue purified by column 
chromatography with CH2Cl2/MeOH or EtOAc/hexane as eluting solvents. The 
product was isolated as an amber oil. Yield: 68 %; 1H NMR (300 MHz, CDCl3): δ 
0.84 (t, J = 4.8 Hz, 3 H), 1.08 (t, J = 7.2 Hz, 6 H), 1.28-1.23 (m, 10 H), 1.81 (t, J = 6.9 
Hz, 2 H), 2.41 (s, 3 H), 2.56 (q, J = 6.9 Hz, 4 H), 3.81 (s, 2 H), 4.06 (t, J = 7.2 Hz, 2 
H), 7.04 (s, 1 H), 7.09 (d, J = 6.9 Hz, 1 H), 7.23 (s, 1 H), 7.30 (s, 1 H), 7.44-7.39 (m, 
3 H), 7.88 (s, 1 H); 13C NMR  (75 MHz, CDCl3): δ 142.8, 138.0, 135.7, 132.4, 129.1, 
128.5, 128.2, 127.7, 126.9, 124.5, 121.1, 118.1, 112.3, 109.4, 47.8, 46.6, 46.3, 31.7, 
30.2, 29.2, 29.2, 27.0, 22.6, 21.6, 14.0, 12.1; MS (APCI): m/z 404.9 [M + H]+. Found 
(calcd. for C28H48N2) C 83.12 (83.11), H 9.59 (9.96). 
 

















5-3, 5-47a : R = CH3






 General method for the preparation of alkyl esters of 2-(5-bromo-1-octyl-
1H-indol-3-yl) acetic acid (7). To a solution of acid 4 (4 mmol, 1 equiv.) in 20 mL of 
the required alcohol (MeOH or EtOH) was added 10 drops of concentrated sulphuric 
acid (H2SO4). The mixture was heated under reflux with continuous stirring for 1-1.5 
h. The reaction mixture was then cooled to room temperature and evaporated in 
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vacuo. The residue was treated with a saturated solution of NaHCO3 (50 mL), 
extracted with EtOAc and dried with anhydrous Na2SO4. Removal of the solvent in 
vacuo gave a residue that was purified by column chromatography with CH2Cl2 as 
eluting solvent. 
Methyl-2-(5-bromo-1-octyl-1H-indol-3-yl)acetate (7a). Yield: 95 %; 1H 
NMR (300 MHz, CDCl3): δ 0.86 (t, J = 6 Hz, 3 H), 1.24-1.28 (m, 10 H), 1.78 (t, J = 
6.6 Hz, 2 H), 3.70 (s, 2 H), 3.71 (s, 3 H), 4.01 (t, J = 6.9Hz, 2 H), 7.07 (s, 1 H), 7.16 
(d, J = 8.7 Hz,1H), 7.26 (d, J = 8.7 Hz, 1H), 7.70 (s, 1 H); 13C NMR  (75 MHz, 
CDCl3): δ 14.0, 22.5, 26.9, 29.1, 29.14, 30.1, 30.8, 31.7, 46.4, 52.0, 106.3, 110.9, 
112.4, 121.5, 124.4, 127.8, 129.3, 134.8, 172.2.  
Ethyl-2-(5-bromo-1-octyl-1H-indol-3-yl)acetate (7b). Yield: 95 %; 1H NMR 
(300 MHz, CDCl3): δ 0.86 (t, J = 6.9 Hz, 3 H), 1.24-1.27 (m, 13 H), 1.78 (t, J = 6.6 
Hz, 2 H), 3.68 (s, 2 H),4.01 (t, J =6.9 Hz ,2 H),4.16 (q, J = 6.9 Hz, 2H), 7.07 (s, 1 H), 
7.15 (d, J = 8.7 Hz,1H), 7.25 (d, J = 8.7 Hz, 1H), 7.72 (s, 1 H); 13C NMR (75 MHz, 
CDCl3): δ 14.0, 14.1, 22.5, 26.9, 29.11, 29.15, 30.1, 31.1, 31.7, 46.4, 60.8, 106.5, 
110.8, 112.3, 121.7, 124.3, 127.8, 129.3, 134.8, 171.7.  
Methyl 2-(1-octyl-5-m-tolyl-1H-indol-3-yl)acetate (5-3). The ester 7a was 
reacted with m-tolylboronic acid as described for the synthesis of amide 3-3 (Section 
3.4.3). The product was isolated as an amber oil. Yield: 47 %; 1H NMR (300 MHz, 
CDCl3,): δ 0.85 (t, J = 12 Hz, 3 H), 1.26-1.32 (m, 10 H), 1.82 (t, J = 6 Hz, 2 H), 2.44 
(s, 3 H), 3.70 (s, 2 H), 3.81 (s, 3 H), 4.06 (t, J = 15 Hz, 2 H), 7.11 (d, J = 3 Hz, 2 H), 
7.32-7.37 (m, 2 H), 7.44 (d, J = 6 Hz, 3 H), 7.78 (s, 1 H); 13C NMR (75 MHz, 
CDCl3): δ 14.1, 21.6, 22.6, 27.0, 29.1, 29.2, 30.3, 31.1, 31.8, 46.5, 52.0, 107.0, 109.6, 
117.5, 121.5, 124.5, 127.0, 127.3, 128.1, 128.2, 128.5, 132.8, 135.7, 138.1, 142.6, 
172.6;  MS (APCI): m/z 392.5 [M +H]+. 
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Ethyl 2-(1-octyl-5-m-tolyl-1H-indol-3-yl)acetate (5-4). The ester 7b was 
reacted with m-tolylboronic acid as described for 3-3 (Section 3.4.3). The product 
was isolated as an amber oil. Yield: 38 %; 1H NMR (300 MHz, CDCl3): δ 0.85 (t, J = 
12 Hz, 3 H), 1.19-1.31 (m, 13 H), 1.82 (t, J = 6 Hz, 2 H), 2.43 (s, 3 H), 3.79 (s, 2 H), 
4.06 (t, J = 9 Hz, 2 H), 4.13 (q, J = 21 Hz, 2 H), 7.12 (d, J = 3 Hz, 2 H), 7.32-7.36 (m, 
2 H), 7.44 (d, J = 6 Hz, 3 H), 7.79 (s, 1 H); 13C NMR (75 MHz, CDCl3): δ 14.0, 14.2, 
21.6, 22.6, 27.0, 29.1, 29.1, 30.3, 31.3, 31.7, 46.5, 60.7, 107.2, 109.6, 117.6, 121.4, 
124.5, 127.0, 127.3, 128.2, 128.5, 128.7, 132.7, 135.7, 138.1, 142.6, 172.1; HRMS 





1-Octyl-1H-indole-3-carbaldehyde (8). 5-Bromo-1H-indole-3-carbaldehye 
was reacted with 1-bromooctane as described for the synthesis of indole 6. Yield: 85 
%; 1H NMR (300 MHz, CDCl3):   9.91 (s, 1 H), 8.43 (s, 1 H), 7.66 (s, 1 H), 7.36 (d, 
J =7.5 Hz, 1 H), 7.20 (d, J = 8.7, 1 H), 4.11 (t, J = 7.2 Hz, 2 H), 1.85 (t, J = 6.3 Hz, 2 
H),1.30-1.24 (m,10 H), 0.86 (t, J = 6 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ 184.1, 
138.7, 135.8, 126.8, 126.8, 124.7, 117.3, 116.4, 111.4, 47.4, 32.7, 31.6, 29.6, 29.0, 
































1-Octyl-5-m-tolyl-1H-indole-3-carbaldehyde (9). Aldehyde 8 was reacted 
with m-tolylboronic acid as described for the synthesis of 3-3 (Section 3.4.3).  The 
product was isolated as an amber oil. Yield: 62 %; 1H NMR (300 MHz, CDCl3):   
9.98 (s, 1 H), 8.53 (s, 1 H), 7.66 (s, 1 H), 7.57-7.46 (m, 3 H), 7.39-7.29 (m, 2 H), 7.13 
(d, J = 7.2 H, 1 H), 4.1 (t, J = 8.7 Hz, 2 H), 2.42 (s, 3 H), 1.86 (t, J = 3 H), 1.29-1.24 
(m, 10 H), 0.86 (t, J = 6.6 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ 184.8, 143.7, 
141.6, 138.9, 135.4, 135.1, 129.1, 128.9, 127.1, 119.3, 119.2, 118.5, 116.8, 111.6, 
47.4, 32.7, 31.6, 29.6, 29.0, 26.7, 22.5, 14.0.    
(E & Z)-1-Octyl-5-m-tolyl-1H-indole-3-carbaldehyde oxime (10). 
Compound 10 was synthesized according to the method described in Jansen et al.81 
Aldehyde 8 (1.03 mmol, 1equiv.) was refluxed with hydroxylamine hydrochloride 
(NH2OH.HCl; 2.57 mmol, 2.5 equiv.) and pyridine (2.67 mmol, 2.6 equiv.) in EtOH 
(20 mL).  The reaction was monitored by TLC for the disappearance of 9, which 
occurred after 2 h.  The mixture was cooled to room temperature, diluted with water, 
acidified with 10% HCl and extracted with Et2O. The ethereal layer was washed 
successively with 10% HCl and water, dried (anhydrous Na2SO4) and the solvent 
removed under reduced pressure.  The residue was triturated with petroleum ether and 
filtered to give 10 in 74% crude yield. It was used without further purification for the 
next step. 1H NMR (300 MHz, DMSO-d6): δ 0.81 (t, J = 9 Hz, 3H), 1.22-1.26 (m, 
10H), 1.76 (t, J = 6 Hz, 2 H), 2.39 (s, 3 H), 4.12 (t, J = 15 Hz, 2 H), 7.12 (d, J = 9 Hz, 
1 H), 7.32 (t, J = 15 Hz, 1 H), 7.40-7.44 (m, 2 H), 7.48 (d, J = 12 Hz, 1 H), 7.57 (d, J 
= 9 Hz, 1 H), 7.69 (s, 1 H,), 8.24 (m, J = 12 Hz, 2 H), 10.60 (s, 1 H); 
1-Octyl-5-m-tolyl-1H-indol-3-yl)methanamine (4-1). To a stirred solution of 
nickel chloride (NiCl2.6H2O; 0.76 mmol, 1 equiv.) in MeOH (12 mL) was added 10 
(0.76 mmol, 1 equiv.) and NaBH4 (4.16 mmol, 5.5 equiv.) in one portion. After 5 min 
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of stirring, the black precipitate was removed by vacuum filtration and the filtrate 
concentrated in vacuo to approximately a third of its original volume. It was then 
poured into 20 mL of water containing 3 mL of ammonia solution, extracted with 
EtOAc and dried (anhydrous Na2SO4). The solvent was removed under reduced 
pressure to give 4-1 as a viscous, dark colored oil. Purification using flash silica gel 
column chromatography by elution with CH2Cl2/MeOH yielded the corresponding 
amine 4-1 as an amber oil. Yield: 54 %; 1H NMR (300 MHz, DMSO-d6): δ 0.82 (t, J 
= 9 Hz, 3H), 1.22-1.30 (m, 10H), 1.72 (t, J = 9 Hz, 2 H), 2.39 (s, 3 H), 3.93 (s, 2 H), 
4.12 (t, J = 12 Hz, 2 H), 7.10-7.49 (m, 7 H), 7.87 (s, 1 H,); 13C NMR (75 MHz, 
DMSO-d6): δ 14.0, 21.5, 22.6, 27.0, 29.1, 29.2, 30.3, 31.7, 46.4, 57.6 109.7, 117.2, 
121.5, 124.4, 126.6, 127.1, 127.3, 128.1, 128.5, 132.8, 135.9, 138.1, 142.4; MS 
(APCI): m/z 348.3 [M + H]+.  
  N-((1-octyl-5-m-tolyl-1H-indol-3-yl)methyl)acetamide (5-5). Acetyl 
chloride (0.0.628 mmol, 1 equiv.) was added to a solution of amine 4-1 (0.628 mmol, 
1 equiv.) and triethylamine (0.942 mmol, 1.5 equiv.) in THF (4 mL) at 0 °C. The 
reaction mixture was stirred at room temperature (27oC) for 1 h after which the 
precipitate that formed was removed by vacuum filtration, the filtrate was 
concentrated under reduced pressure and the residue purified by column 
chromatography with CH2Cl2 as eluting solvent. The product was isolated as an 
amber oil. Yield: 65 %; 1H NMR (300 MHz, CDCl3): δ 7.71 (s, 1 H), 7.49-7.05 (m, 6 
H ), 7.01 (s, 1 H),  5.73 (bs, 1 H), 4.49 (d, 2 H, J =  4.8 Hz), 4.04 (t, 2 H,  J = 6.9 Hz), 
2.43 (s, 3 H ), 1.80 (t, 2 H, J = 6.3 Hz), 1.95 (s, 3 H), 1.28-1.24 (m, 10 H), 0.86 (t, 3 
H, J = 7.2 Hz); 13CNMR  (75 MHz, CDCl3) δ 169.9, 142.2, 138.2, 135.9, 133.0, 
128.6, 128.1, 127.5, 127.1, 124.6, 124.4, 121.7, 117.3, 111.3, 109.8, 46.4,  35.1, 31.7, 







































Methyl-2-(5-bromo-1H-indol-3-yl)acetate (11). To a solution of 2-(5-bromo-
1H-indol-3-yl)acetic acid (4 mmol) in 20 mL of MeOH was added 10 drops of 
concentrated sulphuric acid. The mixture was heated under reflux with continuous 
stirring for a period of 1-1.5 h. Following reflux, the reaction mixture was cooled to 
room temperature and evaporated in vacuo. The residue was added with a saturated 
solution of NaHCO3 (50 mL) to neutralize acid, and the resulting alkaline aqueous 
mixture was extracted with EtOAc and dried over Na2SO4. Evaporation of the solvent 
gave a residue which was purified by flash silica gel column chromatography. Elution 
with CH2Cl2 yielded the corresponding ester 11 as an off-white solid. Yield: 89 %; 1H 
NMR (300 MHz, CDCl3): δ 3.66 (s, 3 H), 3.68 (s, 2 H), 7.18-7.21 (m, 4 H); MS 
(APCI), m/z 269.2 [M + H]+.  
2-(5-Bromo-1H-indol-3-yl)ethanol (12). Compound 12 and 13 were prepared 
according to method described in Bascop et al.82 To a solution of ester 11 (4 mmol, 1 
equiv) in anhydrous THF (50 mL) was added lithium aluminium hydride (LiAlH4; 16 
mmol, 4 equiv) in portions with the temperature maintained at 0 °C.  The reaction 
mixture was brought to room temperature and stirred for 30 min. Excess LiAlH4 was 
destroyed by careful addition of a saturated aqueous solution of Na2SO4 with the 
temperature maintained at about 0 °C. The mixture was filtered and the filtrate 
CHAPTER 3 
 75
washed with THF. The combined filtrates were concentrated under reduced pressure, 
the residue was acidified to pH 6 with 10 % HCl and extracted with CHCl3. The 
combined organic layer was dried (anhydrous Na2SO4), filtered, evaporated to dryness 
and purified using flash column chromatography by elution with EtOAc/hexane to 
give the alcohol 12 as an amber oil. Yield: 83 %; 1H NMR (300 MHz, CDCl3): δ 2.97 
(t, J = 18 Hz, 2 H), 3.86-3.93 (m, 2 H), 4.09 (t, J = 21 Hz,1 H), 7.09 (d, J = 3 Hz, 1 
H), 7.22 (d, J = 9 Hz, 1 H), 7.75 (s, 1 H), 8.10 (s, 1 H); MS (APCI): m/z 241.2  [M + 
H]+. 
2-(5-Bromo-1H-indol-3-yl)propanenitrile (13). Methane sulphonyl chloride 
(MsCl, 0.55mL, 2 equiv) was added to a stirred solution of 12 (3.2 mmol, 1 equiv), 
triethylamine (0.9 mL, 2 equiv) and anhydrous CH2Cl2 (20 mL) maintained at 0 °C.  
The reaction mixture was then stirred for 30 min at 0 °C under N2, after which it was 
treated with 2M NaOH and extracted with CH2Cl2. The combined organic layer was 
washed with water, dried (anhydrous Na2SO4) and evaporated to dryness under 
reduced pressure. The residue was dissolved in anhydrous DMSO (20 mL), KCN 
(3.25 mmol, 3 equiv) was added and the reaction mixture was heated at 100 °C in an 
oil bath for 1 h. It was diluted with a water-ice mixture, extracted with chloroform, the 
combined organic layer was washed with water, dried (anhydrous Na2SO4), and 
evaporated to dryness under reduced pressure. The residue was purified by column 
chromatography with CHCl3 as eluting solvent and 13 was obtained as an amber oil. 
Yield: 75 %; 1H NMR (300 MHz, DMSO-d6): δ 2.78 (t, J = 15 Hz, 2 H), 3.58 (t, J = 
12 Hz, 2 H), 7.14-7.17 (m, 2 H), 7.20 (d, J = 27 Hz, 1 H), 7.68 (s, 1 H), 11.01 (s, 1 H); 
MS (APCI): m/z 261.3 [M + H]+. 
2-(5-Bromo-1H-indol-3-yl)propanamide (14).  Amide 14 was prepared from 
the nitrile 13 according to the procedure described for amide 2 (Section 4.3.2). Yield: 
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82 %; 1H NMR (300 MHz, CDCl3): δ 2.44 (t, J = 15 Hz, 2 H), 2.96 (t, J = 15 Hz, 2 
H), 7.09-7.58 (m, 4 H); MS (APCI): m/z 268.1 [M + H]+. 
3-(5-m-Tolyl-1H-indol-3-yl)propanamide (15). Amide 15 was prepared from 
the amide 14 according to the procedure described for amide 3 (Section 3.4.2). Yield: 
50 %; 1H NMR (300 MHz, CDCl3): δ 2.38 (s, 3 H), 2.49 (t, J = 18 Hz, 2 H), 3.02 (t, J 
= 15 Hz, 2 H), 7.12-7.61 (m, 8 H); MS (APCI), m/z 279.4 [M + H]+ 
3-(1-Octyl-5-m-tolyl-1H-indol-3-yl)propanamide (5-2). Amide 5-2 was 
prepared from the amide 15 according to the general procedure described for the 
synthesis of 1-1 (Section 3.4.2). Yield: 77 %; 1H NMR (300 MHz, CDCl3): δ 0.78 (t, 
J = 12 Hz, 3 H), 1.18-1.21 (m, 10 H), 1.69 (t, J = 9 Hz, 2 H), 2.35 (s, 3 H), 2.49 (t, J = 
15 Hz, 2 H), 3.01 (t, J = 15 Hz, 2 H), 3.92 (t, J =15 Hz, 2 H), 6.84 (s, 1 H), 7.02 (d, J 
= 9 Hz, 1 H), 7.22 (d,  J = 12 Hz, 2 H), 7.35-7.38 (m, 3 H), 7.68 (s, 1 H); 13C NMR 
(75 MHz, CDCl3): δ 14.1, 21.0, 21.6, 22.6, 27.0, 29.2, 29.2, 30.3, 31.8, 36.7, 46.3, 
109.7, 113.6, 117.3, 121.4, 124.5, 126.1, 127.1, 128.0, 128.2, 128.6, 132.4, 135.9, 
138.2, 142.6, 175.4; MS (APCI), m/z  = 391.5 [M + H]+.  
 
3.4.6. Synthesis of compounds in Series 6 (6-11, 6-12)  
N,N-Diethyl-2-(5-(3-methoxyphenyl)-1-octyl-1H-indol-3-yl)acetamide (6-
11). Acetamide 5 was reacted with 3-methoxyphenylboronic acid as described for the 
synthesis of 3-3 (Section 3.4.3). The product was isolated as an amber oil. Yield: 80 
%; 1H NMR (300 MHz, CD3OD): δ 0.90 (t, J = 12 Hz, 3 H), 1.05-1.15 (m, 6 H), 1.27-
1.31 (m, 10 H), 1.84 (t, J = 9 Hz, 2 H), 3.40-3.48 (m, 4 H), 3.87 (s, 3 H), 3.88 (s, 2 H), 
4.19 (t, J = 15 Hz, 2 H), 6.87 (d, J = 6 Hz, 1 H), 7.14-7.44 (m, 6 H), 7.83 (s, 1 H); 13C 
NMR (75 MHz, CD3OD): δ 12.4, 13.5, 13.6, 15.7, 22.8, 27.1, 29.5, 29.6, 30.6, 31.4, 
32.1, 40.8, 43.2, 46.3, 54.9, 108.6, 110.0, 111.8, 113.0, 117.5, 119.9., 121.5, 127.5, 
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128.7, 129.8, 132.8, 136.7, 144.6, 160.7, 172.7; HRMS (ESI): m/z 449.3157 (calcd for 
[C29H40N2O2 + H]+: 449.309). 
2-(5-(3-Ethoxyphenyl)-1-octyl-1H-indol-3-yl)-N,N-diethylacetamide (6-
12). Acetamide 5 was reacted with 3-ethoxyphenylboronic acid as described for the 
synthesis of 3-3 (Section 3.4.3). The product was isolated as an amber oil.  Yield: 74 
%; 1H NMR (300 MHz, CD3OD,): δ 0.91 (t, J = 15 Hz, 3 H), 1.05-1.15 (m, 6 H), 
1.27-1.31 (m, 10 H), 1.46 (t, J 15 Hz, 3 H), 1.85 (t, J = 9 Hz, 2 H), 3.38-3.49 (m, 4 H), 
3.89 (s, 2 H), 4.09-4.19 (m, 4 H), 6.86 (d, J 9 Hz, 1 H), 7.14-7.43 (m, 6 H), 7.83 (s, 1 
H); 13C NMR (75 MHz, CD3OD): δ 12.5, 13.5, 13.6, 14.4, 22.8, 27.1, 29.5, 29.6, 30.6, 
31.4, 32.1, 40.8, 43.2, 46.3, 63.7, 108.6, 110.0, 112.4, 113.7, 117.5, 119.8, 121.5, 




The synthesis, characterization and purification (at least 95 % purity based on 
combustion analysis or reverse phase HPLC) were successfully achieved by several 
reported methods. The compounds were novel and have not been previously reported. 
The compounds synthesized by Dr Suresh were also novel. Compounds 1-8, 




CHAPTER 4: INVESTIGATIONS INTO THE ICMT 
INHIBITORY AND ANTIPROLIFERATIVE ACTIVITIES 
OF SYNTHESIZED COMPOUNDS 
4.1. INTRODUCTION 
This chapter describes the evaluation of the compounds described in Chapter 3 
for inhibition of Icmt. The compounds were also evaluated for their effects on the 
viability of a human breast cancer cell line. Inhibitory activities were expressed in 
terms of IC50 values (concentration required to reduce enzyme activity or proliferation 
of treated cells by 50%) and the results were analyzed to (i) reveal structure activity 
relationships (SAR) in each case, and (ii) ascertain if there was overlap in the 
structural requirements for the two activities. The significance of the findings is also 
discussed.   
 
4.2. EXPERIMENTAL METHODS 
4.2.1. Materials for biological assay 
Sf9 (Spodoptera frugiperda ovarian) membranes containing recombinant Icmt 
were prepared as described previously.52 The human breast cancer cell line, MDA-
MB-231, was purchased from American Type Culture Collection (ATCC, Rockville, 
MD). Streptavidin sepharose beads were purchased from Amersham Biosciences (GE 
Healthcare, UK), S-adenosylmethionine p-toluene sulfonate from Sigma-Aldrich 
(Singapore) and [3H] S-adenosylmethionine (SAM or AdoMet) from Perkin Elmer 
(Waltham, MA). Biotin S-farnesylcysteine (BFC) was synthesized by the Duke Small 
Molecule Synthesis Facility 67 and its purity was assessed by mass spectrometry and 
NMR. CellTiter ® 96 AQueous One Solution was obtained from Promega (Madison 
USA). Suppliers for other reagents were: fetal bovine serum (Hyclone Laboratories, 
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Logan, UT), penicillin and streptomycin (Gibco, Invitrogen, Carlsbad, CA), DMEM 
(Sigma Aldrich, Singapore).  
 
4.2.2. Outline of the Icmt inhibition assay 
Briefly, the assay involved measuring the rate at which Icmt (expressed on Sf9 
membranes) transfered a methyl group from the methyl donor S-adenosyl methionine 
(AdoMet or SAM) to the substrate biotin-farnesyl-L-cysteine (BFC). BFC 
corresponds to the C-terminus of a farnesylated, Rce-1-protetolyzed substrate of Icmt 
and exhibits a Michaelis-Menten constant (Km) of 2.1 M.67 The attached biotin 
moiety facilitated the isolation of the methylated substrate from the reaction mixture 
with the aid of commercially available streptavidin beads. The methyl group that is 
donated to the substrate by AdoMet is radiolabelled with 3H so that its presence in the 
substrate can be measured. In the assay, the enzyme and test compound were first 
incubated to allow binding of the inhibitor to the enzyme. Thereafter, the substrate 
cocktail of BFC and AdoMet was added to effect the Icmt-catalyzed methylation of 
BFC. If the test compound inhibited Icmt, the methylation of BFC would be 
interrupted. The reaction was terminated by adding a surfactant (Tween 20) to break 
up the membrane and release the methylated BFC which was then bound to 
streptavidin beads due to the strong affinity of streptavidin for biotin. Once the 
binding reaction reached an equilibrium (at least 8 hours), the beads were washed to 
remove any unbound radioactive AdoMet. Only the radioactivity emitted from 




4.2.3. Measurement of Icmt activity. 
The method described by Winter-Vann et al60 was followed with some 
modifications. Briefly, the standard reaction mixture contained recombinant Icmt (1.0 
μg of Sf9 membrane protein) in a final total volume of 50 μL buffer A (100 mM 
Hepes buffer pH 7.4, 5 mM MgCl2 and 100 μM EDTA). The test compound 
(dissolved in DMSO, final concentration of DMSO in the assay mixture was 2 % v/v) 
was added and the mixture was incubated at 37 ºC for 20 min. After this time, the 
substrate mixture which comprised of 5 μM BFC and 2.5 μM [3H] AdoMet (15 
Ci/mmol) in buffer A was added to initiate the reaction (37 °C, 20 min). The final 
concentrations of BFC and [3H] AdoMet in the mixture were 1 μM and 0.5 μM 
respectively. The reaction was terminated by the addition of 10% Tween 20 (5 μL) 
and streptavidin beads (10 μL of packed beads) in 500 μL of buffer B which consisted 
of 20 mM NaH2PO4 (pH 7.4) and 150 mM NaCl. The interaction between biotin and 
streptavidin beads was allowed to proceed overnight at 4 °C with gentle agitation. The 
beads were harvested by centrifugation (1000 x g, 5 min) on a tabletop 
microcentrifuge and washed 3x with 500 μL buffer B. The beads were then suspended 
in 500 μL of the same buffer and transferred to scintillation vials (each with 4.5 ml 
scintillation fluid) for the determination of radioactivity. Radioactivity was measured 
on the LS6500 multipurpose scintillation counter (Beckmann Coulter Inc, Fullerton, 
CA) and data captured by the LS6000 data capture/network software version 2.11 
(Beckman Coulter).  
 
4.2.4. Outline of the cell viability assay 
Colorimetric assays based on tetrazolium compounds are commonly employed 
to measure the viability of cells. These assays are based on the ability of 
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mitochondrial reductases of viable cells to reduce the tetrazolium dye to a purple 
product called formazan. Cells use NADPH or NADH produced from normal cellular 
activity to achieve this reduction. When cells lose their viability, the reduction fails to 
occur due to insufficient NADP/NAD. The most common tetrazolium dye employed 
in viability assays is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT). The purple formazan crystals that are formed from the reduction of MTT are 
insoluble and must be dissolved in DMSO for absorbance measurements. In the 
present investigation, a commercial kit (CellTiter 96® AQueous One Solution) that 
contained another tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS] was used. MTS is 
provided together with another reagent phenazine ethosulfate (PES) in the kit. PES 
has enhanced chemical stability which allows it to be combined with MTS to form a 
stable solution. When MTS was reduced to its formazan, it is soluble in the culture 
media. Thus, DMSO need not be added to dissolve the formazan and the assay 
procedure was reduced to an “add-incubate-measure” format. Moreover, there was 
greater flexibility as the plate could be read and returned to the incubator for further 
color development if a longer incubation period was necessary. 
 
4.2.5. Cell Viability Assay 
MDA-MB-231 human breast cancer cells were grown in DMEM 
supplemented with 10% fetal bovine serum, 50 U/ml penicillin and 50 μg/ml 
streptomycin at 37 °C, 5 % CO2. Cells were subcultured at 80-90 % confluency and 
used within 10-25 passages for the assays. For the assay, cells were seeded at 2400 
cells per well in DMEM containing 5 % FBS in 96-well plates for 24 h. Aliquots of 
test compounds (various concentrations, prepared in DMSO stock solutions) were 
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then added to each well (final concentration of DMSO maintained at 0.5 % v/v per 
well) and incubated for 72 h. Control wells contained cells and DMSO at the same 
concentration as those in test wells. At the end of the incubation period, 20 μL of 
CellTiter® 96 AQueous One Solution was added to each well and the plates were 
incubated in the dark for 2 h at 37 °C before absorbance readings at 490 nm were 
taken. Background absorbance readings from blank wells that contained only media 
and DMSO were subtracted from each well. Each condition was determined in 
triplicate. Cell viability was expressed as % of absorbance at 490 nm (treated cells) 
over that of control (untreated) cells. The concentration of test compound required to 
reduce cell growth by 50 % (IC50 value) was determined from the sigmoidal curve 
obtained by plotting % cell viability versus concentration with GraphPad Prism 
(Version 4.0, GraphPad Software, San Diego, CA). IC50 values were the mean of at 
least two separate determinations. 
 
4.3. RESULTS  
Table 4-1 summarizes the IC50 values for Icmt inhibition and antiproliferative 







Table 4-1. IC50 values for Icmt inhibition and antiproliferative activities of test 
compounds. Standard deviations ( SD) are provided for compounds that had more 
than two separate determinations. Values in parentheses are Hill slopes determined 
from dose-response curves constructed with GraphPad Prism. 
 
IC50 (µM) Compound R1 
Icmt inhibition a Antiproliferative activity a 
1-1 m-tolyl 1.5 0.2 [2.3] 21.8 0.8 [9.4] 
1-2 o-tolyl 1.0 [1.8] 21.2 1.1 [9.1] 
1-3 p-tolyl 1.0 [1.0] NAb 
1-4 3-methoxyphenyl 1.9 [2.7] 22.4 1.2 [7.4] 
1-5 3-ethoxyphenyl 1.3 [2.2] 18.7 1.0 [7.6] 
1-6 phenyl 1.8 [2.3] 26.0 1.5 [8.6] 
1-7 -H 6.5 [1.3] 50 4 [4.0] 
1-8 -F 7.0 [1.0] 70 20 [3.1] 
 
 
IC50 (µM) Compound R2 
Icmt inhibition a Antiproliferative activity a 




2.5 [2.4] 17.2 2.3 [3.6] 
2-3  
7.7 [2.4] 28.5 [3.7] 
2-4  













IC50 (µM) Compound R3 
Icmt inhibition a Antiproliferative activity a 
3-1 -H > 100 [NA] > 100 [NA] 
3-2 -CH2CONHCH3 2.1 [1.8] 4.7 [8.7] 
3-3 -CH2CON(CH3)2 1.5 [1.3] 31 [6.5] 
3-4 -CH2CON(C2H5)2 1.4 0.8 [0.7] 27.0 6.7 [2.4] 
3-5 CH2CON
 
1.2 [2.0] 15.6  2.7 [3.0] 
3-6 CH2CON  
1.8  0.8 [0.8] 28.9 5.2 [2.3] 
3-7 CH2CON NCH3  
1.7 [1.8] 19.7 0.9 [16.4] 
4-1 -CH2NH2 0.7 [2.2] 2.9 [12.7] 
4-2 -CH2N(CH3)2 1.3 [1.5] 6.8 [31.9] 
4-3 -CH2N(C2H5)2 0.7 0.1 [2.1] 3.6 0.1 [13.0] 
4-4 -CH2N(i-C3H7)2 1.7 [1.0] 20.1 [2.7] 
4-5 -CH2N(n-C3H7)2 0.8 [1.2] 13.0 [6.7] 
4-6 -CH2NCH3(i-C3H7) 0.9 [1.8] 5.3 [12.5] 
4-7 CH2N  
0.5 [1.5] 5.1  1.2 [4.5] 
4-8 CH2N
 
0.7 [2.3] 4.9 0.2 [9.2] 
4-9 CH2N NCH3
 
0.9 [1.8] 6.1 [19.1] 
4-10 CH2N O
 
2.7 [1.2] 24.5 2.3 [6.4] 
5-1 -CONH2 30 [NA] >100 [NA] 







5-3 -CH2COOCH3 76 [NA] >100 [NA] 
5-4 -CH2COOC2H5 >100 [NA] >100 [NA] 
5-5 -CH2NHCOCH3 1.8 [1.6] 30 3 [3.0] 









6-1 o-tolyl n-C8H17 -CH2N(C2H5)2 0.6 0.2 [1.5] 5.5  0.3 [9.9] 
6-2 p-tolyl n-C8H17 -CH2N(C2H5)2 0.6 0.2 [1.7] 3.4 0.1 [11.8] 
6-3 m-tolyl 
 
-H >100 [NA] >100 [NA] 
6-4 m-tolyl 
 









2.0 [1.5] 34 [3.9] 
6-7 -H 
 
-CH2N(C2H5)2 67 [NA] 74 [5.9] 
6-8 -F 
 
-CH2CONH2 69 [NA] >100 [NA] 
6-9 -F n-C8H17 -CH2N(C2H5)2 4.1 [1.6] 7.2 [11.2] 
6-10 -F 
 
-CH2N(C2H5)2 35 6[NA] 32 [6.1] 
6-11 3-methoxy phenyl n-C8H17 -CH2CON(C2H5)2
0.8 [0.6] 52 [1.0] 
6-12 3-ethoxy phenyl n-C8H17 -CH2CON(C2H5)2
1.0 [0.5] 26.8 [1.0] 
 
aMean of two or more separate determinations; The results where SD are not provided 
were from two separate determinations where the difference between independent 
results and the mean were 10-40% (average: 27.3%) for the Icmt inhibition assay and 
2-25% (average: 9.3%) for the antiproliferative assay 




4.3.1. Effect of structural modifcations on Icmt inhibitory activity: Position 5 
Position 5 of cysmethynil (1-1) was occupied by a m-tolyl ring. Changes in the 
substitution pattern of the 5-phenyl ring, namely switching the position of the m-
methyl to o- and p- positions (1-2, 1-3), replacing m-methyl with m-methoxy (1-4) or 
m-ethoxy (1-5), were generally well-tolerated and caused only incremental changes in 
inhibitory activity. An unsubstituted 5-phenyl ring (1-6) fared just as well but 
omitting the ring altogether (1-7) caused a modest 4-fold drop in activity. Introducing 
5-fluoro (1-8) in place of 5-phenyl caused a similar loss of activity. The good 
agreement between the predicted ( 3 M) and experimentally determined (2 M) 
IC50 values of the methoxy analogue (1-4) provided some support for the SAR 
derived in Chapter 2. 
 
4.3.2. Effect of structural modifcations on Icmt inhibitory activity: Position 1 
The compounds in Series 2 exemplified the modifications made at position 1.  
The most notable observation was the 20-fold drop in activity when the n-octyl chain 
was removed (2-1). This was significantly greater than the decrease in activity 
brought about by removing the 5-phenyl ring (1-7). In Section 3.2.3, it was proposed 
that the isoprenyl analogue 2-3 should be active because its length was comparable to 
the m-trifluoromethylbenzyl side chain of 2-2. On the other hand, the activity of the 
geranyl side chain analogue (2-4) was in doubt because of its questionable flexibility 
and length.  As it turned out, the geranyl analogue 2-4 was almost as active as 
cysmethynil while the isoprenyl analogue 2-3 was about 5-fold weaker. Thus, it may 
be that the measured lengths (determined in silico from energy minimized structures) 
were not accurate or that length of side chain was not the main determinant of 
activity. Noting that lipophilicity at this position was highlighted in the SAR 
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described in Chapter 2, the lower activity of the isoprenyl analogue 2-3 could be due 
to its lower lipophilic character (100 fold less than cysmethynil based on ClogP 
values) while the more lipophilic geranyl analogue 2-4 (ClogP of 7) was as potent as 
cysmethynil.  
 
4.3.3. Effect of structural modifcations on Icmt inhibitory activity: Acetamide 
side chain at position 3 
The removal of the acetamide side chain resulted in a compound (3-1) with no 
measurable Icmt inhibitory. This was observed in spite of the significantly greater 
lipophilic character of 3-1 (ClogP 8.7). Thus, the poor Icmt inhibitory activity of 3-1 
must stem from the intrinsic loss of the acetamide functionality and not to 
lipophilicity changes. That the latter did not play a significant role was further seen in 
compounds 3-1 and 3-4 which had very different inhibitory activities (IC50 value of > 
100 M versus 1.4 M) but comparable lipophilicities (ClogP of 8.7 versus 8.6).  
As mentioned in Section 3.2.4, the acetamide moiety can function as H bond 
donor and H bond acceptor. The importance of the H bond donor capability of the 
side chain was investigated in the Series 3 compounds. Conversion of the primary 
amide to a secondary amide (3-2) and various tertiary amides (3-3 to 3-7) reduced the 
number of H bond donor groups. These changes did not dramatically affect inhibitory 
activity which remained within a narrow range of IC50 values (1.2 to 2.1 M) in spite 
of an almost 1000-fold variation in lipophilicity (ClogP varied from 7.2 to 10.3) 
among the compounds. These observations suggested that the H bond donor property 
of the acetamide side chain did not contribute to Icmt inhibition, and that changes in 
the lipophilic character of this functionality had little influence on activity. 
Next, the role of the side chain as a H bond acceptor was investigated by 
removing the carbonyl functionality to give the amines of Series 4. Most of the 
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amines were tertiary amines (4-2 to 4-10) but there was one primary amine (4-1).  
Most notably, only Series 4 yielded compounds that were more potent inhibitors than 
cysmethynil. The increase in potency was modest (no more than 3-fold) and was 
observed for most of the amines (4-1, 4-3, 4-5 to 4-9).  Branching of alkyl groups at 
the basic nitrogen was not a desirable feature was seen from the poor activity of the 
di(isopropyl) amino analogue 4-4 as compare to the di(n-propyl)amino (4-3) and the 
N-methyl-N-isopropylamino (4-6) analogues. The good activities of the heterocyclic 
amines (4-7 to 4-9) in which the substituents on N were cyclized further emphasized 
the need for a “sterically compact” basic centre.  The exception was the morpholino 
analogue 4-10 and this may be due to other factors like its lower basicity owing to the 
presence of the electron withdrawing morpholino oxygen. Taken together, these 
findings showed that omitting the amide carbonyl to give amine analogues of 
cysmethynil generally improved or maintained inhibitory activity. Whether this meant 
that the H bond acceptor properties of the carbonyl oxygen was not required for 
activity remained questionable because the resulting amine could function as a H 
bond acceptor if it was not protonated. Going by the basic character of the amines 
present in the side chain, the protonated form was likely to predominate at 
physiological pH but this need not necessarily mean that the protonates species was 
also the “active” species interacting with the enzyme. 
The compounds in Series 5 were homologues or isosteres of cysmethynil. A 
significant observation was the poor activity of the short chain homologue 5-1 
compared to the longer chain homologue 5-2. A possible explanation may be that the 
side chain at position 3 must have a minimum length (probably equivalent to that 
found in cysmethynil) to interact with a putative residue on the Icmt active site. 
Flexibility may also be an important factor as the side chain of 5-1 had limited 
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flexibility (Section 3.2.4). Thus the poor activity of the short chain homologue may 
be attributed to its less than optimal length and limited flexibility, features that were 
not found in the longer chain homologue.  
Of the isosteres, the esters fared poorly but the retroamide (5-5) and 
sulphonamide (5-6) were as active as cysmethynil. The esters were proposed as 
inhibitors because they resembled both the substrate and product of Icmt. Their poor 
inhibitory activities suggested that this proposal is not tenable. It may be that the 
esters were hydrolyzed under the experimental conditions to give a common (and 
inactive) carboxylic acid intermediate. This would explain the broadly similar IC50 
values of the two compounds for both Icmt inhibition and antiproliferative activities.  
The good activities of the retroamide and sulphonamide derivatives showed 
that shifting the H bond acceptor carbonyl or sulphonyl moieties further away from 
the indole ring did not adversely affect activity. In fact, these two side chains were 
similar to the side chain of the longer homologue 5-2 of cysmethynil in terms of 
length and relative positions of the electron rich carbonyl/sulphonyl moieties. 
 
4.3.4. Effect of structural modifcations on Icmt inhibitory activity: Series 6 
compounds 
Unlike Series 1 to 5, the compounds in Series 6 were modified at two or more 
positions of the indole ring.  A convenient way of discussing this series is to divide it 
into 2 categories, namely those with n-octyl or isoprenyl at position 1. Of the 
compounds with n-octyl, modifications were made at the 5-phenyl ring (position of 
methyl group, replacement with m-methoxy or m-ethoxy, 5-fluoro in place of 5-
phenyl) and the 3-position (tertiary amide or amine in place of acetamide). The 
inhibitory activities of the resulting compounds closely reflected the trends observed 
in cysmethynil. Thus, 6-1 and 6-2 with diethylamino side chains (IC50 value of 0.6 
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µM) were almost as potent as the amines in Series 4 whereas the inhibitory activities 
of the tertiary amides 6-11 and 6-12 fell within the range of the amide analogues of 
cysmethynil (Series 3). The activity of 6-9 (IC50 value of 4.1 M) was instructive as it 
showed that even with a “preferred” amine side chain at position 3, replacing 5-
phenyl with 5-fluoro reduced activity to almost the same degree as that observed 
when cysmethnil was similarly modified to give 1-8 ( IC50 value of 7.0 M). It may 
be that the n-octyl side chain strongly influenced inhibitory activities in spite of 
modifications at the other two positions. This would explain why activity trends 
closely mirrored those observed for cysmethynil for the octyl analogues. If this was 
true, then compounds with isoprenyl at position 1 should exhibit wider variations in 
their activities. The findings with the isoprenyl analogues are summarized in Figure 
4-1. 
                                        





Figure 4-1. Series 6 compounds with isoprenyl side chain at position 1. Effect of 
modifications on Icmt inhibitory activity. 
Starting with 2-3 (structure shown in Figure 4-1) which had an IC50 value of 
7.7 M, replacing the acetamide side chain with various amino side chains 
(diethylaminomethyl, 6-4, N-piperidinylmethyl, 6-5, N-morpholinomethyl, 6-6) 
resulted in a 3 fold improvement in activity but these amine analogues (IC50 value of 
2.0 to 2.4 M) were generally not as potent as the Series 4 compounds (IC50 value of 
0.5 to 2.7 M). Removing the acetamide side caused the expected large loss in 
(i) 6-7: no 5-Ph with amine side chain 
(ii) 6-8, 6-10: 5-Ph replaced by 5-F with 
amine/amide side chain 
 loss of activity 
6-4, 6-5, 6-6: amide replaced 
with amine side chain 
 activity improved 
6-3: removal of amide side 
chain 
 loss of activitity 
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activity (6-3, IC50 value of > 100 M). Removing the 5-phenyl ring and replacing it 
with 5-fluoro while keeping the acetamide and isoprenyl sidechains intact gave 6-8 
which was largely inactive as an Icmt inhibitor (IC50 value of 69 M). This loss was 
significantly greater than that observed when the 5-phenyl ring of cysmethynil was 
similarly altered to give 1-8 (IC50 value  of 7.0 M). The significantly better activity 
of 1-8 may be attributed to the presence of the n-octyl side chain. The role of n-octyl 
in retaining good activity was further observed in 6-9 and 6-10. 6-9 (IC50 value of 4.1 
M) with an n-octyl side chain was 9 times stronger as an inhibitor compared to 6-10 
(IC50 value of 35 M) which had an isoprenyl side chain.   
 
4.3.5. Effect on cell growth/proliferation.  
The two activities of Icmt inhibition and cell growth inhibition were 
significantly correlated to each other when analyzed by Spearman non-parametric 
correlation analysis (Spearman’s rho = 0.707, significant at 0.001 level, 2-tailed). 
Thus, those compounds with good Icmt inhibitory activities also curtailed cell growth 
and proliferation. However, two differences were noted. First, anti-proliferative IC50 
values were generally an order magnitude higher than Icmt IC50 values.  Second, a 
wider spread was observed for Icmt IC50 values (approximately 100-fold spread in 
IC50 values) compared to antiproliferative IC50 values (about 30-fold spread). These 
differences may be traced to the way the assays were carried out. Icmt activity was 
evaluated by an in vitro assay using Sf9 membranes enriched with the enzyme, 
whereas effect on cell viability involved incubating test compounds for several days 
with human cancer cells. In the latter, compounds must move across the cell 
membrane to gain access to the large number of biological targets in the cell interior.  
Activity would thus be influenced to a greater degree by the permeability 
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characteristics of the test compounds. Moreover, the media for cell culture contained 
components, most notably serum albumin, that could sequester the test compounds by 
adsorption or binding and this could further influence the results. 
4.3.6. Hill slopes of dose response curves for determination of IC50 values 
Dose response curves were constructed for the determination of IC50 values 
for Icmt inhibition and antiproliferative activity. An important feature of the curve 
was the steepness of the slope from which the IC50 value was derived. The steepness 
of the slope was quantified by the Hill slope (Hill coefficient). Briefly, the Hill slope 
is used to measure the cooperativity in a binding process. A value greater than 1 was 
indicative of positive cooperativity where the binding of one ligand facilitated the 
binding of subsequent ligands on the receptor or enzyme complex. Practically, a large 
Hill slope signified that the inhibitory activity of the compound increased much more 
quickly with concentration than would be expected for a classical single site inhibitor. 
For the latter, inhibition may increase from 10% to 90% over a 80-fold concentration 
range. For compounds with steep dose response curves, this increase would occur 
over a narrower 10-fold concentration range. In this investigation, the Hill slopes of 
the test compounds had a wide range, namely 1.0 to 2.7 for Icmt inhibition and 1.0 to 
33 for antiproliferative activity (Table 4-1). Representative dose response curves are 
given in Figure 4-2 and 4-3.   
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Figure 4-2. Inhibition of Icmt by cysmethynil and analogues. Icmt activity was 
measured as the incorporation of [3H] from [3H]AdoMet into the Icmt substrate BFC. 
The assay was performed in the presence of various inhibitors (● – cysmethynil, ■ – 
4-3, ▲ – 6-4).  
 
























Figure 4-3. Antiproliferative activity of cysmethynil and analogues. Cells were 
seeded at 10% confluency in DMEM containing 5% FBS in 96-well plates for 24hr 
prior to treatment with the various inhibitors (● – cysmethynil, ■ – 4-3, ▲ – 6-4) at 
indicated concentrations for 72 hours. 
The phenomenon of steep dose response curves and their significance have 
been discussed at length46, 83-84. Briefly, the appearance of steep dose response curves 
should alert the investigator to 3 possibilities: (i) the presence of multisite binding on 
the target protein, or a multimeric protein complex; that is, several inhibitor molecules 
may bind to one target protein/enzyme complex; (ii) the inhibitor may form 
aggregates (in the range of 50 nm to over 400 nm) and these particles adsorb or 
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absorb the target protein/enzyme thereby inhibiting them; (iii) the enzyme 
concentration is greater than the Kd (equilibrium dissociation constant) value of the 
inhibitor.  In this case, inhibition will be observed only when the concentration of the 
inhibitor approaches that of the enzyme. A steep rise would be observed because of 
the very high inhibitor concentration (> Kd).  
Of these 3 possibilities, the second possibility (colloidal aggregation followed 
by enzyme sequestration) would present  the greatest concern because it would mean 
that the inhibition was non-specific. However, there were several reasons to exclude 
this possibility for the present test compounds. The Icmt assay of cysmethynil was 
investigated with different enzyme concentrations varying from 0.5 to 5 µg protein. 
The change in enzyme concentration did not abolish the steep dose response curves as 
it should have done if there was non-specific inhibition. Moreover, cysmethynil and 
4-3 were investigated for their ability to form micelles and it was found that the 
critical micelle concentrations of these compounds were in the range of 10 to 25 M, 
which exceeded the IC50 Icmt values by at least 10 times. If there was non-specific 
inhibition, a good correlation between Icmt inhibition and antiproliferative activities 
would be unlikely. Furthermore, recent reports that cysmethynil disrupted the cell 
cycle and caused cell death, and that overexpression of Icmt would protect cells from 
these consequences, argue against the operation of a non-specific mechanism.62  Also 
noteworthy in this regard are recent findings that Icmt exists in membranes as a 
homodimer, and the two subunits of the dimer interact such that perturbation of one 
impacts the other (C. Hrycyna, Purdue Univ, personal communication). 
As seen from Table 4-1 and Figure 4-2, the Hill slopes obtained from the 
dose response curves constructed for antiproliferative activities were much larger than 
those observed for Icmt inhibition. The mechanisms proposed by Shoichet and co-
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workers were directed at steep curves obtained in the course of investigating enzyme 
inhibition and may not apply to cell based assays46. A notable observation was that 
increasing the fetal bovine serum concentration in the culture media significantly 
affected the steepness of the dose response curves of cysmethynil, 4-3 and 6-4  
suggesting that binding to serum binding may be a factor contributing to this 
phenomenon, ie. the concentration of inhibitor available for cell entry is less than the 
bulk concentration as a fixed component is bound to serum proteins. 
 
4.3.7. SAR for antiproliferative activity 
A comparison of the SAR for Icmt and anti-proliferative activities is described 
in the following paragraphs: 
(i) Omitting each of the three key functionalities (5-m-tolyl, n-octyl, 
acetamide) of cysmethynil to give 1-6, 2-1 and 3-1 reduced antiproliferative activities. 
Of the three “deletions”, removing the 5-m-tolyl residue had the least effect on 
activity (IC50 value of 50 M) while removing the other two functionalities resulted in 
almost the same degree of loss (IC50 value of >100 M). In contrast, the extent of loss 
in Icmt inhibitory activity was of the order acetamide (3-1, greatest loss of activity 
IC50 value of > 100 M) > n-octyl (2-1, IC50 value of 33 M) > 5-m-tolyl (1-6, IC50 
value of 6.5 M).   
(ii) The Series 1 compounds that had changes made to the substitution of the 
5-phenyl ring retained the same level of antiproliferative activity as cysmethynil (IC50 
value of 21.6 M). Omitting 5-phenyl or replacing it with 5-fluoro caused a larger 
loss in antiproliferative activity. These changes closely paralleled those observed for 
Icmt inhibitory activities.  
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(iii) When n-octyl was replaced with m-trifluoromethylbenzyl, isoprenyl or 
geranyl, Icmt inhibitory activities were decreased (2-2, 2-3) or maintained (2-4). The 
antiproliferative activities of 2-2 and 2-3 were broadly comparable to cysmethynil but 
the geranyl analogue 2-4 (IC50 value of 10.6 M) was now twice as potent. 
Lipophilicity was unlikely to have contributed to the improved antiproliferative 
activity of 2-4. 
(iv) The tertiary amides of Series 3 had comparable antiproliferative activities 
(IC50 value of 15.6 to 31 M) to cysmethynil. The secondary amide 3-2 is of 
particular interest because its antiproliferative IC50 value (4.7 M) was lower than 
expected, given that its Icmt IC50 value (2.1 M) was close to that of cysmethynil.   
(v) The amines of Series 4 had significantly more potent effects on cell 
proliferation (IC50 value of 2.9 to 13.0 M) compared to cysmethynil (IC50 value of 
21.8 M). The least potent amines 4-4 and 4-10 were also those with the weakest Icmt 
inhibitory activities.   
(vi) The antiproliferative activities of the cysmethynil homologues and 
isosteres in Series 5 closely paralleled their Icmt inhibitory activities. Thus, the esters 
(5-3, 5-4) and short chain homologue (5-1) had negligible effect on cell viability 
while the long chain homologue 5-2, retroamide 5-5 and sulphonamide 5-6 were 
almost as potent as cysmethynil. 
(vii) Good agreement was observed between the two activities (Icmt 
inhibition, antiproliferative activity) of the compounds in Series 6. Exceptions were 
found in two cases. First, the antiproliferative activity of 6-11 was lower than 
expected given its good Icmt inhibitory activity. Second, the amines 6-4 and 6-5 with 
isoprenyl side chains had better than expected antiproliferative activities (IC50 value 
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of approximately 4 M) although they inhibited Icmt to almost the same extent as 
cysmethynil.   
 
4.4. DISCUSSION 
One of the objectives of this thesis was to investigate modifications at position 
3 of cysmethynil and to determine if these changes would result in more potent 
inhibitors of Icmt. The compounds in Series 3, 4 and 5 were synthesized and 
evaluated to answer this question. A comparison of the activities of 1-6, 2-1 and 3-1 
clearly showed that the acetamide side chain made a significant contribution to Icmt 
inhibition, which exceeded that of the n-octyl and 5-phenyl functionalities.   
Modifying the acetamide to the retroamide, sulphonamide and various tertiary amides 
retained activity. Varying the length of the primary amide side chain showed that the 
shorter homologue was inactive whereas the longer homologue was as active as 
cysmethynil. The ester analogues (5-3, 5-4) were without activity. Of the many 
modifications made to the acetamide side chain, only the amino analogues resulted in 
improved Icmt inhibitory activities, albeit to a modest degree (approximately 2-3 
fold). The good inhibitory activities of the amino analogues raised the question as to 
whether they interacted with Icmt in their protonated or non-protonated states. There 
was little doubt that the amines were largely protonated at physiological pH because 
they were moderate to strong bases with pKa values that exceeded 7.0. But the 
“active” species interacting with the enzyme need not be the protonated form. Icmt is 
a membrane bound enzyme found in the hydrophobic environment of the endoplasmic 
reticulum. The protonated amine analogue may lose a proton in this environment and 
the species interacting with the enzyme could be the non-protonated amine. If this was 
so, then a H bond acceptor moiety would be a required feature of the side chain. 
CHAPTER 4 
 98
Hence, a tentative SAR profile was proposed, namely that (i) a H bond donor was not 
essential for activity (tertiary amides were not H bond donors but were as active as 
cysmethynil);  (ii) a H bond acceptor moiety was required for activity  (provided by 
the carbonyl oxygen of cysmethynil, the tertiary amides, retroamide 5-5; sulphonyl 
oxygen of sulphonamide 5-6 and the nitrogen lone pair of the amine analogues in 
Series 4) , (iii) a longer or more flexible side chain at position 3 was preferred to a 
shorter side chain (the short chain homologue 5-1 had poor activity). 
Based on the Icmt IC50 values of 1-6, 2-1 and 3-1, the n-octyl side chain was 
ranked after the acetamide side chain in terms of importance for inhibition. The 
contribution of this functionality was closely linked to its lipophilic character as 
replacing n-octyl with less lipophilic residues (m-trifluoromethylbenzyl 2-2 and 
isoprenyl 2-3) reduced activity. The geranyl analogue 2-4 which was as lipophilic as 
cysmethynil (in terms of ClogP) had comparable inhibitory activity. It may be that the 
n-octyl side chain was required to anchor the molecule in the endoplasmic reticulum 
and to bring it close to the membrane bound Icmt. As a related objective of this thesis 
was to seek out more drug-like substitutes to cysmethynil with lower lipophilicities 
and equal or greater potencies, geranyl analogues would not be the preferred choice. 
Rather, isoprenyl analogues would be better alternatives in spite of the relatively weak 
Icmt inhibitory activity of 2-3 (IC50 value of 7.7 M). Indeed, the amino analogues 
with isoprenyl side chains (6-4, 6-5) turned out to be among the more promising 
“drug-like” substitutes to cysmethynil, combining good Icmt inhibitory activity 
(comparable to cysmethynil) with even better antiproliferative activity. Compared to 
selected amine analogues in Series 4 which constituted the other class of drug like 
substitutes, 6-4 and 6-5 were less potent Icmt inhibitors (IC50 Icmt value  2M) but 
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had comparable antiproliferative activities. Compounds in Series 4, 6-4 and 6-5 had 
lower lipophilicities than cysmethynil because of their protonated amino side chains. 
While lipophilicity played a role in influencing inhibitory activity, the 
relationship is not as clear cut as it may appear. Notably, compounds that were more 
lipophilic than cysmethynil did not always turn out to be better inhibitors. This was 
well illustrated by the tertiary amides (3-4 to 3-7) which had ClogP values in the 
range of 8 to 10 (10-1000 times more lipophilic than cysmethynil) but were not better 
Icmt inhibitors than cysmethynil. There were also instances where compounds with 
the same ClogP values (for example 3-1 and 3-4) had very different Icmt inhibitory 
activity.  
The SAR of the 5-m-tolyl ring was investigated in Chapter 2 and the few 
modifications undertaken in this investigation were made with these findings in mind. 
The most striking observation was the relatively small effect on activities when the 5-
phenyl ring was removed altogether (1-7, IC50 Icmt value of 6.5 M, IC50 antiproliferative 
value of 50 M), emphasizing the lesser role of this position in influencing activities. 
From the drug design perspective, this finding could be used as a means of 
modulating drug-like properties without incurring significant loss of activity.   
In general, antiproliferative activities of the test compounds moved in parallel 
with Icmt inhibitory activities. There were a few exceptions, namely 2-4, 3-2, 6-4, 6-5 
(more antiproliferative activity than expected based on IC50 Icmt values) and 6-11 (less 
antiproliferative activity than expected based on IC50 Icmt values). Differences in the 
magnitude and range of IC50 values for these two activities may be attributed to the 
nature of these assays (in vitro versus cell-based). In spite of the good correlation 
between the two activities, it is not known if Icmt is the only cellular target of the test 
compounds and if the arrest of cell growth stemmed solely from its inhibition. 
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Moreover, the mechanism by which Icmt affected cell viability was not well 
understood. Recently, different concentrations of cysmethynil were found to arrest 
cell proliferation (cytostatic) by interfering with the cell cycle at the G1 phase, or to 
kill cells (cytotoxic) by autophagy.62 Thus, while the correlation between IC50 values 
observed here was encouraging, more work needs to be done to understand the 
connection between these two activities. 
 
4.5. CONCLUSION 
The main findings of this chapter are as follows: 
(i) Loss of the acetamide side chain of cysmethynil resulted in a significant 
decrease in Icmt inhibitory activity which was greater than that observed when the n-
octyl side chain or the 5-phenyl ring was omitted from the molecule. Thus, the 
acetamide side chain of cysmethynil made a significant contribution to its Icmt 
inhibitory activity. 
(ii) The H bond acceptor property and length/flexibility were important 
features of the acetamide side chain for Icmt inhibition. 
(iii) The most important contribution of the n-octyl side chain to Icmt 
inhibition may be its lipophilic character. It was proposed that this side chain 
localized the molecule in the endoplasmic reticulum, in proximity to the membrane 
bound Icmt enzyme. Thus for compounds that differed only at this position (n-octyl 
versus isoprenyl), better Icmt inhibitory activity was generally found for the n-octyl 
analogue (for example 4-3 and 6-4; 4-8 and 6-5; 1-8 and 6-8). 
(iv) Modification to the substituted 5-phenyl ring caused only incremental 
changes to Icmt inhibitory activity. It may be a useful position to introduce drug-like 
features to the molecule without causing marked changes to inhibitory activity. 
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 (v) Several amines in Series 4 (4-3, 4-7, 4-8) and Series 6 (6-4, 6-5) were 
more potent than cysmethynil in terms of inhibition of Icmt and antiproliferative 
activities. They were also less lipophilic than cysmethynil. Thus, these compounds 
may be considered as the more drug-like alternatives to cysmethynil.  
(vi) There was a good correlation between Icmt inhibitory and antiproliferative 
activities, but this did not necessarily mean that the compounds only targeted Icmt to 
affect cell viability. A few compounds affected cell growth to a greater extent than 
expected from their Icmt inhibitory activities. It is possible that these compounds 
acted on other targets beside Icmt to arrest cell proliferation. 
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CHAPTER 5:  PHARMACOPHORE MODELING AND 
QSAR 
5.1. INTRODUCTION 
This chapter describes attempts to rationalize the Icmt inhibitory activities of 
the test compounds described in Chapter 3. The first approach was to develop a 
three-dimensional (3D) pharmacophore model for Icmt inhibition based on the 47 
compounds. A 3D pharmacophore represents the relative position of important 
binding groups in space and disregards the molecular structure that holds them in 
place. The 3D pharmacophore for a particular binding site should be common to all 
ligands that bind to it. Hence, it could be used as a screening tool to identify structures 
that share the same pharmacophoric features and thus stand a good chance of 
inhibiting Icmt. The second approach was to identify and quantify physicochemical 
properties that influenced Icmt inhibitory activity. A diverse series of 
physicochemical descriptors were collected for the test compounds and these were 
investigated for correlations to Icmt inhibition by stepwise multiple linear regression 
(MLR) and PLS (partial least squares projection to latent structures) regression.  3D 
quantitative structure activity relationship (QSAR) using comparative molecular field 
analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) 
were also attempted. In Chapter 4, the pIC50 Icmt and pIC50 antiproliferation values were 
found to be highly correlated (Spearman rho coefficient of 0.707, p <0.001). A 
decision was made to model the pharmacophore and SAR based on Icmt inhibitory 
activities rather than cell viability effects based on the reasoning that the effects on 
cell viability might be due to other targets besides Icmt, in spite of the good 
correlation between the two activities.  It is well known that the cellular phenotype is 
complex as it represents the summation of the activity states of several pathways.85 
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Hence, there is a “black-box” quality in cell-based screens that cannot be avoided. For 
this reason, it was decided that the pharmacophore model and SAR would be analyzed 
with respect to a specific target, namely Icmt. 
 
5.2 MATERIALS AND METHODS 
5.2.1. General 
The compound database comprised 47 functionalized indoles described in 
Chapters 3 and 4. The structures of the test compounds were drawn and energy 
minimized using the MMFF94x force field (gradient setting of 0.1 kcal mol-1 Å-1)86-87 
on the software Molecular Operating Environment (MOE, version 2008.1001, 
Chemical Computing Group, Montreal, Canada). Partial atomic charges were 
calculated on the same force field. Eighteen compounds (ten in Series 4 and eight in 
Series 6) had basic amino groups at position 3. These compounds were energy 
minimized in both their protonated and non-protonated states, giving rise to 2 
databases of the 47 compounds, one comprising of the 18 compounds in the non-
protonated states and another with the same compounds represented in their 
protonated states. Several descriptors were collected for these two databases by MOE. 
They are divided broadly into 2D descriptors calculated from connection tables and 
are independent of conformation and 3D descriptors that were dependent on 
conformation. A total of 41 descriptors were used for MLR and PLS regression 
analyses (Table 5-1). Tables A4-1 to A4-4 in Appendix 4 list the descriptors values 
for the two databases.  
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Table 5-1.  Descriptors used for MLR and PLS Regression Analyses a 
2D Descriptors  
1. Physical Properties  
 
Molar refractivity (MR), log P(o/w), SlogP (considers state 
of protonation), van der Waals (vdw) area and volume, 
polar surface area (TPSA), log S (S= aqueous solubility), 
molecular weight 
2. Atom and Bond 
Counts 
 
Number of bonds (b_count), rotatable bonds (b_rotN), 
rotatable single bonds (b_1rotN); Fraction of rotatable 
single bonds (b_1rotR) and rotatable bonds 
(b_rotR).Lipinski’s druglike features (lip_druglike) and 




Number of H bond acceptors (a_acc), donors (a_don), 
hydrophobic atoms (a_hyd), basic atoms (a_base). vdw 
surface areas of H bond acceptors (vsa_acc), donors 
(vsa_don), hydrophobic atoms (vsa_hyd), polar atoms 
(vsa_pol) 
3D Descriptors  
1. MOPAC descriptors Properties calculated using the PM3 Hamiltonian 
(MOPAC): energy (PM3_E), electronic energy 
(PM3_Eele), PM3_HOMO, PM3_LUMO, ionization 
potential (PM3_IP), heat of formation (PM3_HF), dipole 
moment (PM3_dipole) 
2. Potential energy 
descriptors 
 
Potential energy E, solvation energy Esol, bond stretch 
potential energy (Estr), local strain energy (E strain), 
torsion potential energy (E tor), vdw component of 
potential energy (E vdw) 
3. Surface area, 
volume and shape 
descriptors 
Water accessible surface area (ASA), vdw volume 




Water accessible surface areas of hydrophobic atoms 
(ASA_H) and polar atoms (ASA_P); dipole moment 
(dipole) 
 
a Abbreviations are given in parentheses. Information relating to these descriptors as 




5.2.2. Generation of the Pharmacophore Model 
The database of non-protonated test compounds was imported into a molecular 
database in MOE. Up to 500 conformers of each compound were generated with a 
modified version of the Conformation Import module in MOE. Conformation Import 
follows a fragment-based approach to rapidly generate conformers88. Briefly, input 
molecules were dissected into overlapping fragments for which a number of 
conformations were generated by means of stochastic conformational search. The 
results of this search were stored in a fragment conformer library. The fragments of 
this library were then reassembled in a systematic way to yield the final conformers. 
The geometry of final conformer was optimised by the MOE MMFF94x force field 
with a gradient setting of 1.0 kcal mol-1 Å-1. The flexible n-octyl side chain at position 
1 posed a considerable challenge for conformer generation. Therefore, the 
“Conformation Import” method was modified to restrict conformational freedom of 
this group. With the aid of scripts implemented in the MOE scripting language SVL, 
the fragment conformer library was restricted to trans-fragments of the n-octyl 
residue. Butyl fragments (derived from the n-octyl residue) with a dihedral angle of 
θ < 175˚ or θ > 185˚ were removed. Furthermore, indole fragments were modified 
such that the N1 side chains were aligned on the same side of the indole ring. This 
was done by monitoring the respective dihedral angle. All negative C2´–C1´–N1–C2 
dihedral angles (‘prime’ atoms referring to the indole N1 residue atoms, ‘non-prime’ 
atoms referring to the indole ring) were flipped by 180˚. Conformers generated in this 
way had limited conformational freedom for the N1 residues and unrestricted 
conformational freedom for the other residues. 
The pharmacophore model was generated with this conformer library with the 
Pharmacophore Elucidator module in MOE. First, pharmacophoric features were 
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assigned to the test compounds, namely ‘aromatic OR  π ring’, ‘hydrophobic’, ‘H-
bond donor projection point’, ‘H-bond acceptor projection point’, ‘cation’, ‘anion’, 
‘carboxyl bioisostere’, and ‘amidinium bioisostere’. A maximum number of 3 
hydrophobic features and a minimum number of 1 H-bond acceptor projection point 
were specified. These restrictions were imposed to avoid generation of 
pharmacophore models composed of purely hydrophobic/aromatic features. 
Pharmacophoric features were treated as solid spheres with a radius of 1.4 Å. Next, an 
exhaustive search of all pharmacophore queries that induced a good overlay of most 
of the active molecules and separate actives from inactives were performed. Thus 3D 
alignments of selected conformers of the input molecules were generated. The 
plausibility of a pharmacophore was measured by the overlay of actives (goodness of 
3D alignment) and the relationship to activity was measured by its “classification 
accuracy” (ability to separate actives from inactives). Molecules were considered 
actives if IC50 Icmt value of < 5 µM. The results were potential 4-point and 5-point 
pharmacophore models that included at least 90% of the actives. The generated 
pharmacophore hypotheses (734 models) were then sorted by their overlay scores and 
classification accuracies. One model was chosen by manual inspection of the top-
scoring hypotheses according to the abovementioned quality measures (overlay and 
accuracy). This model was subsequently subjected to manual refinement with MOE’s 
Pharmacophore Query Editor. Briefly, the radii of pharmacophoric spheres were 
reduced to 1.2 Å, and their positions were optimized to center on the respective 





5.2.3. Multiple linear regression (MLR) and Spearman correlation analysis 
Multiple linear regression was carried out separately on the two databases of 
non-protonated and protonated test compounds, with descriptors in Table 5-1 as 
independent variables and pIC50 Icmt value as the dependent variable. In each case, 
stepwise regression was carried out in which descriptors were sequentially added to or 
deleted from the equation until the best fit relationships were obtained. A Spearman 
correlation analysis was similarly carried out on pIC50 Icmt value and descriptors.  
Spearman rho values are given in Table A4-5 and A4-6 of Appendix 4. Both MLR 
and correlation analysis were carried out on SPSS for Windows 17.0 (SPSS Inc., 
Chicago, IL, USA). 
 
5.2.4. PLS Analysis 
PLS analysis was carried out separately on the non-protonated and protonated 
compounds using the AutoQSAR module in MOE. PLS identifies the principal 
components (derived by “summarizing” the large number of descriptors into a smaller 
number that represent the main variation in the data set) that can concurrently explain 
the variance in the descriptor set as well as maximize their correlation to biological 
activity.  The option to restrict descriptors to the three most representative members 
was selected in favour of the “Auto” select option which would generate a large 
number of descriptors.  The z factor (threshold value beyond which compounds are 
identified as outliers) was set at the default value of 2.5.   
 
5.2.5. CoMFA Analysis 
The 3D-QSAR model was developed with CoMFA/CoMSIA on the modeling 
software Sybyl 8.0 (Tripos, St Louis, Missouri). Force field minimized structures (of 
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non-protonated members) from MOE were aligned using the best pharmacophore 
model described in Section 5.2.2. Steric, electrostatic, hydrophobic, hydrogen bond 
donor and acceptor potential fields were calculated at each lattice intersection of a 
regularly spaced grid of 2.0 Å. A probe atom with + 1 charge, radius of 1.0 Å and + 1 
hydrophobicity was used for this purpose. A Gaussian type distance dependence was 
considered between the grid point in the lattice and each atom of molecule. The 
attenuation factor () was set at the default value of 0.3. The PLS analysis was used 
to construct and validate the models. Column filtering was set to 2.0 kcal/mol to speed 
up the analyses and reduce background noise. The CoMSIA descriptors served as 
independent variables, while the pIC50 Icmt values served as dependent variable. The 
performance of the models were tested using the leave-one-out (LOO) cross-
validation method. The optimum number of components was used to derive the non-
cross validated model, leading to the highest cross-validated correlation coefficient q2 
and the lowest standard error of estimate (SEE). The predictive power of the 3D 
QSAR model was determined using a test set of 9 compounds (1-4, 1-8, 3-4, 4-5, 4-9, 
6-1, 6-3, 6-5, 6-9) for external validation. The optimization, alignment and all other 
steps of these test set molecules were the same as that of the training set, and their 
activities were predicted using the model derived from the training set.  
 
5.3. RESULTS AND DISCUSSION 
5.3.1. Establishing a pharmacophore model for Icmt inhibition 
A pharmacophore is the ensemble of steric and electronic features necessary to 
ensure the optimal supramolecular interactions with a specific biological target 
structure and to trigger (or to block) its biological response89. It does not represent a 
real molecule or a real association of functional groups. Rather it should be viewed as 
CHAPTER 5 
 109
an abstract concept that embraces the common molecular interaction capacities of a 
group of compounds for their target structure. The pharmacophore can be viewed as 
the largest common denominator shared by a set of active molecules89. 
Pharmacophore modelling is generally applied to achieve the following objectives. 
First, it is used to define relevant pharmacophoric features in a compound that are 
necessary to achieve a desired biological effect. This would help to establish a 
definitive SAR. Second, a pharmacophore model can be used to detect molecules with 
different scaffolds by virtually screening large compound libraries by a technique 
called scaffold hopping. Third, it can be used together with other pharmacophore 
based screens to predict the pharmacological profiles of lead structures in silico. This 
requires deriving pharmacophore fingerprints for different activities. For instance, an 
overlap between an activity fingerprint and a toxicity fingerprint would reduce the 
attractiveness of a particular structure or scaffold.  In this section, pharmacophore 
modelling was used for the elucidation of SAR90-92.  
The pharmacophore model was based on the 47 test compounds and was built 
using the Pharmacophore Elucidator module in MOE. As this module considered 
binary activity class labels (active vs. inactive), an arbitrary activity threshold of 5 µM 
(IC50 Icmt value) was used to classify the compounds. By this criterion, 35 compounds 
(or 74 %) were classified as actives. Conformations were generated and they were 
aligned by the software to give various pharmacophore models. However, the 
generated pharmacophore hypotheses consisted of only hydrophobic and aromatic 
features. These were rejected because they failed to include features related to the 
critical polar side chain at position 3. Furthermore, the computation was carried out 
with settings that assumed an aqueous environment of pH 7.0. Under these conditions, 
the molecules, in particular the 18 compounds with amino groups, would be 
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protonated by the software. As discussed in Section 4.4, while this was 
physiologically “correct”, it did not necessarily mean that these compounds interacted 
with Icmt in their protonated states. Loss of a proton could occur as the molecule 
approached the active site of the enzyme and the final interacting species might be the 
non-protonated state.    Furthermore, if it was assumed that the amide and amine 
derivatives shared the same binding mode to the enzyme, there would be no common 
pharmacophoric feature in their side chains at position 3, if the amino group was 
protonated. The tertiary amides of Series 3 were only H bond acceptors, not H bond 
donors while the protonated amines of Series 4 and 6 were H bond donors and not H 
bond acceptors. On the other hand, if interaction involved the non-protonated amine, a 
common H bond acceptor feature would be present in both amide and amino side 
chains (Table 5-2). With these considerations in mind, it was decided that the test 
molecules would be aligned in their non-protonated states. Furthermore, to avoid 
generating purely hydrophobic/aromatic models, the presence of at least one hydrogen 
bond acceptor feature in the putative model was specified. 
Table 5-2. Hydrogen-bond donating and accepting features in representative side 
chains at position 3 of the indole scaffold.  













H bond donor Yes Yes No 
H bond acceptor Yes Yes Yes 
Protonated amines 





H bond donor Yes  Yes 








H bond donor Yes  No 
H bond acceptor Yes  Yes 
 
However, the 3D alignment of the compounds in the pharmacophore models 
generated this way was poor. It was reasoned that the poor outcomes could arise from 
insufficient conformational sampling of the input molecules contributed to the poor 
3D alignment. Apparently, most conformers focused on geometry variations of the 
flexible n-octyl side chain (seven rotatable bonds) that was present in 36 of the 47 
input molecules (77 %) at the expense of conformational variations of the polar side 
chain at position 3. Therefore, a method was developed that would restrict the 
conformational freedom of the n-octyl side chain. The ‘Conformation Import’ tool in 
MOE was modified to allow only trans-isomers of the n-octyl side chain. 
Furthermore, conformations were restricted to those that had the n-octyl side chain 
oriented towards the same “direction” relative to the indole ring. Conformers 
generated in this way had restricted conformational freedom for the n-octyl sidechain 
but not for other residues on the indole scaffold. In this way, up to 500 conformers 
were generated for each molecule resulting in a total of 23,474 conformers (ca. 499 
per molecule). With this approach, pharmacophore models with good 3D alignments 
and high accuracy were obtained. In total, 734 four-point and five-point 
pharmacophore models were generated by MOE and these were sorted by their 
overlap scores and classification accuracies. The accuracy of the pharmacophore 




TNTPAccuracy  … (5-1)
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In this equation, TP is the number of true positives, TN is the number of true 
negatives, FP is the number of false positives, and FN is the number of false 
negatives. Based on the threshold of IC50 value of < 5 µM for actives, 35 molecules 
were actives while 12 molecules were inactives. The most accurate models (93.6 % 
accuracy) correctly identified all 35 molecules as actives (TP = 35, FN = 0). However, 
the indole ring of 6-9 (the amine with a fluoro group in place of the 5-phenyl) did not 
superimpose with the indole rings of the remaining actives, possibly due to the 
missing phenyl residue on position 5. Hence, the next best models (91.4 % accuracy; 
TP = 34, FN = 1) was selected, where 6-9 was regarded as a false negative. Of the 
remaining molecules, 9 were identified as true inactives (TN) but 3 were deemed to 
be actives in spite of having IC50 Icmt values that exceeded 5 µM (FP = 3). These were 
the isoprenyl analogue 2-3 and the esters 5-3, 5-4.  There was no good reason why the 
isoprenyl analogue 2-3 (IC50 Icmt value of 7.7 M) was classified as a false positive. 
Re-determination of its IC50 value may be necessary. As for the esters 5-3 and 5-4, 
they may be hydrolyzed to give inactive carboxylic acids under the conditions of the 
assay, although the esters were not found to be unstable during their syntheses and 
characterization. A carboxylic acid derivative should be synthesized and evaluated for 
inhibitory activity to provide the needed confirmation.  
The final pharmacophore model consisted of five pharmacophoric features 
(Figure 5-1). These were (i) a hydrophobic feature at position 1, the location of which 
was guided by the shorter isoprenyl and trifluoromethylbenzyl residues, (ii) an 
aromatic feature for a substituent at position 5 of the indole ring, (iii) two aromatic 
features on the fused indole ring, and (iv) H bond acceptor projection point where the 
topological distance was 2 bonds from the ring for amine analogues and 3 to 4 bonds 
from the ring for amide and sulphonamide analogues. Atom exclusion volumes were 
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placed above and below the plane of the indole ring to ensure planarity of the 
aromatic rings (not depicted in Figure 5-1). In some of the proposed models, the side 
chains at position 3 were twisted by 90 degrees which placed the H bond acceptor 
projection point in front of the indole ring at position 2. However, these models were 
not considered due to their lower accuracies. For example, with the H bond acceptor 
feature at this position, the shorter cysmethynil homologue 5-1 (IC50 value of 30 M) 
would be classified as an active compound.  
 
Figure 5-1. Pharmacophore model. A 3D alignment of 34 analogues with Icmt IC50 
value of < 5 µM is shown. Pharmacophoric features are depicted as spheres. Green: 
hydrophobic, orange: aromatic OR π ring, cyan: H-bond acceptor projection point. 
Feature radius: 1.2 Å. Figure created with PyMOL (DeLano Scientific, Palo Alto, CA, 
USA). 
Next, 14 compounds that were known Icmt inhibitors and not structurally 
related to cysmethynil were tested on the pharmacophore to determine if they had the 
same pharmacophoric features as the model. Five compounds were found to comply. 
The features present were the hydrophobic, aromatic (two), and H bond acceptor (one 
or two) (Figure 5-1). Some flexibility was permitted in this screening process in that 
ligands that had only one of the two aromatic features on the indole ring were allowed 
to pass through. Ligands that had more than one H-bond acceptor atom could also 
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potentially match the pharmacophoric feature. As for the remaining 9 Icmt inhibitors 
not identified by the model, this showed that the present model required further 
refinement with additional compounds of greater structural diversity. It could also 
imply that these compounds did not interact with Icmt in the same manner as 
cysmethynil and its analogues, and hence would not be expected to fit into the 
model.93 Ultimately, a true validation of the predictive capabilities of the model could 
only be addressed by prospective library screening to short-list hit compounds and to 
follow up on their inhibitory activities. It should be noted that the present model was 
generated to elucidate the structure-activity relationships of cysmethynil analogues. 
As such it would be more descriptive than predictive in nature. 
 
Figure 5-2. Known Icmt inhibitors with pharmacophoric features that match the 
proposed model. 1: Anderson53, 2: Donelson55; 3, 4, and 5: Buchanan58. Green: 






















5.3.2. Multiple linear regression and correlation analysis 
As mentioned in Section 5.2.1, the test compounds were prepared in their non-
protonated and protonated states and descriptors were collected for both states. Only 
the 18 compounds with amino side chains would be expected to have different 
descriptors. Even then, not all of the descriptors were affected by protonation of the 
basic amino group. An inspection of the descriptors (Tables A4-1 to A4-4) showed 
that the protonated compounds were less lipophilic (SlogP values were about 2 units 
lower than the non-protonated states), more polar (dipole moments of greater 
magnitude) and had larger polar surface areas (captured by the 3D descriptor water 
accessible surface area for polar atoms ASA_P but not van der Waals polar surface 
area of polar atoms). In addition, solvation (Esol) and electrostatic (Eele) energies of 
the protonated species were lower indicating the ease of solvation and electrostatic 
stabilities of these species. Several energy terms calculated by the PM3 Hamiltonian 
function (MOPAC) such as heats of formation, ionization potential, HOMO and 
LUMO were also different. On the other hand, descriptors like area, volume and 
pharmacophore features, were the same regardless of whether the compound was 
protonated or not.   
MLR was carried out separately on the protonated and non-protonated 
databases to determine if different descriptors would be recognized in each instance. 
If this was observed, and more importantly, if the key descriptors identified for the 
protonated species are among those mentioned in the earlier paragraph, this would 
lend support to the view that the compounds were interacting with Icmt in their 
protonated states. But the results should be interpreted with caveats in mind. First, 
only 18 compounds (37 %) could exist in the protonated state and not withstanding 
their strong Icmt inhibitory activities, their input to the MLR equation might be 
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overshadowed by the remaining compounds. Second, the descriptors for H bonding 
used in this analysis did not discriminate adequately between the protonated and non-
protonated states of 18 compounds. For example, the van der Waals surface areas of 
H bond donors and acceptors (vsa_don, vsa_acc) were set at zero for these 
compounds in both databases. This was because the software defined vsa_acc as the 
“approximation of van der Waals surface areas of pure H bond acceptors, not 
counting acidic atoms and atoms that are both H bond donors and acceptors such as 
OH”. Similarly the number of H bond donors (a_don) did not include the protonated 
NH+ because of the software definition for a_don where cations are excluded as 
donors. Hence, protonated and non-protonated members had similar a_don values. 
The exception was the primary amine 4-1 which had a_don = 1 when non-protonated 
state and a_don=0 when protonated. Meanwhile, another interesting finding is that the 
non-protonated amino function had vsa_acc of zero because the van der Waals surface 
area of tertiary amines was approximately calculated to be zero. This prevented 
discrimination of the protonated and non-protonated species.  
MLR with stepwise selection of descriptors yielded 11 models when applied 
to the non-protonated compounds but only 3 models for the protonated compounds.  
In the latter case, the 3rd model (with 3 descriptors) was selected. To facilitate 
discussion and to avoid over-fitting, the model with 3 descriptors (3rd model) was also 
selected for the non-protonated compounds. The MLR equations and statistics are 
given as follows: 
 (i) Equation for non-protonated compounds:  
pIC50 Icmt = 1.232 (0.481) + 0.066 (0.007) * b_count + 0.816 
(0.174) * a_don – 0.029 (0.010) * vsa_acc 
… (5-2)
R2 = 0.662, Standard error of estimate (SEE) = 0.420, F = 28.102 (significant at p < 
0.001). The standard error of each coefficient in the equation is given in the bracket. 
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When the coefficients were standardized, the largest contribution was made by 
b_count (1.00), followed by a_donor (0.633) and vsa_acc (0.318). 
 (ii) Equation for protonated compounds: 
pIC50 Icmt  = -0.692(0.703) + 0.009 (0.001) * VSA +               
0.045 (0.009) * vsa_donor + 0.173 (0.046) *PM3_IP 
… (5-3)
R2 = 0.689, SEE = 0.402, F = 31.78 (significant at p < 0.001). When the coefficients 
were standardized, the largest contribution was made by VSA (0.899), followed by 
vsa_don (0.551) and PM3_IP (0.372). 
Both equations had correlation coefficients (R2) of approximately 0.7 which 
meant that the activities of approximately 70 % of the compounds could be accounted 
by these equations. The F values showed that the models were significant at the level 
of p < 0.001.    
Equation 5-2 identified b_count (number of bonds) as the main contributor to 
activity. The Spearman correlation showed that b_count was significantly correlated 
to several size and lipophilicity parameters, namely molecular weight, van der Waals 
area and volume, water accessible surface area for hydrophobic atoms, SlogP and 
logP. The other two descriptors in Equation 5-2 were a_donor (number of H bond 
donors) and vsa_acc (van der Waals surface area of H bond acceptors). Their 
correlations to activity might suggest that H bond donors were more important than H 
bond acceptors. As mentioned earlier, vsa_acc was defined in such a way that it is 
unable to discrimate the H bond acceptor properties of the tertiary amine analogues 
from non H bond acceptors. Thus vsa_acc may not reflect on the role of H bond 
acceptors per se. Rather it may emphasize the importance of non-polar residues for 
activity. jVsa_acc was significantly correlated to dipole moment and polar surface 
areas (ASA_P, vsa_pol) with Spearman rho values of 0.7-0.8 (p < 0.01), as compared 
to a rho value of 0.437 for number of H bond acceptors (a_acc)   
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For the protonated compounds (Equation 5-3), van der Waals surface area 
(VSA) was the main contributor to activity. It was highly correlated to b_count and 
other size and lipophilicity parameters. Thus, size and lipophilicity were found to be 
the most critical determinants of activity regardless of whether the compound was 
protonated or otherwise. Two other descriptors in Equation 5-3 were van der Waals 
surface area of H bond donors (vsa_don) and ionization potential (PM3_IP). Of these, 
only ionization potential values differed for the protonated and non-protonated amine 
analogues. On protonation, the ionization potentials of the amine analogues increased 
by about 3 units while those of the other compounds remained the same. As for the 
van der Waals surface area of H bond donors (vsa_don), like vsa_acc, it should be 
interpreted with caution. 
Taken together, the MLR described in Equations 5-2 and 5-3 highlighted the 
following points.  First, size and lipophilicity were the most important determinants of 
activity regardless of the protonation state of the compounds. Noting that the 
pharmacophore model had 3 aromatic residues and 1 hydrophobic feature, the 
presence of these descriptors in the equations were not unexpected. Second, H bond 
donor was identified in both equations (a_don in Equation 5-2 and vsa_don in 
Equation 5-3) but the interpretation of its role in activity should be done with 
caution, not least because of the way the terms were defined.  The presence of the H 
bond donor term need not necessarily imply that the protonated amino species of the 
18 compounds were preferred for good activity.  As the protonated ammonium group 
(-NH+) was not recognized as a H bond donor in its definition, a_don values were 
actually the same for both protonated and non-protonated species (except for a_don of 
the primary amine 4-1). Rather, the H bond donor term may reflect on the 
contribution of the amide NH (present in Series 1, the secondary amide 3-2, the 
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reverse amide 5-5), sulphonamide NH in 5-6, and the NH groups in the primary amine 
4-1. Thirdly, ionization potential (PM3_IP) was the only “unique” parameter 
recognized in the MLR for the protonated species (Equation 5-3) but it carried the 
lowest weightage among the three descriptors. In spite of the inclusion of this term in 
Equation 5-3, it was uncertain if interaction with Icmt occurred preferably with the 
protonated species. It may be unreasonable to expect MLR to provide a satisfactory 
answer in view of the caveats mentioned in the earlier paragraph. 
 
5.3.3. PLS regression analysis 
The databases were analyzed by the AutoQSAR module in MOE which used 
PLS to perform the regression analysis. To avoid over-fitting and to have models that 
were “comparable” to those derived from MLR, the number of descriptors was 
restricted to just three. Equations 5-4 and 5-5 were obtained for non-protonated and 
protonated compounds respectively. 
 (i) Equation for non-protonated compounds: 
pIC50 Icmt = 1.46 - 0.00004 * PM3_E + 0.0086 * PM3_HF + 
0.0013 * ASA_P   
… (5-4)
R2 = 0.521, cross validated R2 = 0.414, RMSE = 0.478, cross validated RMSE = 
0.533. Relative importance of descriptors were PM3_E (1.0) > PM3_HF (0.54) > 
ASA_P (0.106)  
 (ii) Equation for protonated compounds: 
pIC50 Icmt  = 1.49 + 0.0138 * VSA + 0.00003 * PM3_E + 
0.0062 * ASA_P   
… (5-5)
R2 = 0.562, cross validated R2 = 0.462, RMSE = 0.457, cross validated RMSE = 
0.512. Relative importance of descriptors were VSA (1.0), followed by PM3_E 
(0.431) and  ASA_P (0.302).  
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The correlation coefficients R2 were not as good as those obtained by MLR as 
the activities of only 50 % of the test compounds could be accounted for by the 
descriptors in either equation. Increasing the number of descriptors to 5 for each 
regression equation improved R2 to ≈ 0.7 but the two most important descriptors in 
each case (protonated and non-protonated species) were similar to those identified in 
Equations 5-4 and 5-5. Hence, it was decided that the analysis would be based on the 
latter equations. 
Equation 5-4 showed that the total energies calculated using the PM3 
Hamiltonian (PM3_E) had the greatest effect on activity.  Its relationship to the pIC50 
value was inverse, indicating that compounds with low total energies were associated 
with improved activities. The Spearman rho values showed that total energies were 
inversely correlated (p< 0.01) to size parameters, namely b_count, molecular weight 
and van der Waals area. Thus the inverse relationship between the pIC50 value and 
total energy implied that better activity was found in larger and more lipophilic 
compounds.  This agreed with the MLR-derived equation (Equation 5-2) where 
b_count was the main contributor to activity. The heats of formation measured by 
PM3 Hamiltonian (PM3_HF) ranked 2nd in terms of contribution. The Spearman rho 
values were again scrutinized to give a better understanding of the significance of this 
parameter. The heats of formation were inversely correlated to dipole moments and 
van der Waals surface areas of polar atoms (p < 0.01). Thus, two terms (PM3_E and 
PM3_HF) in equation 3 emphasize on the importance of size, diminished polarity and 
lipophilicity for good activity. On the other hand, the presence of the ASA_P term 
(water accessible surface area of polar atoms) in Equation 5-4 showed that the polar 
component was a small but important contributor to activity.   Taken together, both 
the analysis by MLR (Equation 5-2) and PLS (Equation 5-4) identified size and 
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lipophilicity as important determinants of inhibitory activity. Both approaches gave a 
smaller role to polar surface areas which encoded the H bond capabilities of the test 
compounds.  
Turning to Equation 5-5 which was derived by PLS for the protonated 
species, it was striking that two descriptors in this equation (PM3_E and ASA_P) 
were related to polarity as compared to one descriptor (VSA) that favoured size and 
lipophilicity.  VSA was, however, still the main contributor to Equation 5-5, in 
keeping with the other equations (Equations 5-2, 5-3, 5-4) where size and 
lipophilicity were the main determinants of activity.  The presence of ASA-P in 
Equation 5-5 was notable as it was the only descriptor that was “unique” to the 18 
protonated compounds in this database. Therefore, both approaches (MLR and PLS) 
identified unique descriptors for the protonated species in the regression equations 
(Equations 5-3 and 5-5). Whether this meant that interaction with Icmt occurred 
preferentially with the protonated states of the 18 amino analogues, most of which had 
exceptionally good Icmt inhibitory activities, remained an open question. But the 
results conveyed that a more representative analysis was obtained when the 
compounds were analyzed in their protonated states. Equations 5-3 and 5-5 
recognized the importance of the amino groups for activity by identifying parameters 
that were unique to these groups. Furthermore, in Equation 5-5, two of the three 
descriptors were related to polarity (rather than size and lipophilicity), possibly due to 
presence of the protonated compounds. In comparison, the equations (5-2, 5-4) 
derived from non-protonated compounds identified generic descriptors like size and 




5.3.4. 3D QSAR 
When a 3D model of the receptor is available or a proper alignment of ligands 
has been achieved, QSAR models based on molecular descriptors obtained from 3D 
structures may be derived. Comparative Molecular Field Analysis (CoMFA) is 
commonly employed for this purpose and its application has been described in 
Chapter 2.   
The success of a CoMFA model is critically dependent on the spatial 
alignment of the ligands.  In this case, the pharmacophore model described in Section 
5.3.1 was used for aligning the test ligands which consisted of 38 compounds 
(training set). The remaining nine compounds (1-4, 1-8, 3-4, 4-5, 4-9, 6-1, 6-3, 6-5, 6-
9) were reserved as the test set to validate the model derived from the training set.  
The main requirement of the test set was that it should be representative of the 
training set both in terms of structure and activity. In spite of the absence of 
compounds from Series 2 and 5 in the test set, this was made up by the presence of 4 
members from Series 6 which had variations at two positions on the scaffold, many of 
which overlapped with those observed in the missing series. The range of activity in 
the test set (0.6 M to > 100 M) was in line with that of the training set. The 









Figure 5-3. Alignment of compounds based on pharmacophore model. Figure 
created with PyMOL (DeLano Scientific, Palo Alto, CA, USA). 
Table 5-3. CoMFA and selected CoMSIA models. 
 CoMFA  CoMSIA 
q2 0.619 0.650 
SEP 0.485 0.467 
Optimal no. of components 3 4 
r2 0.873 0.892 
SEE 0.277 0.260 
F 77.992 67.909 
Field contribution   
Steric 0.480 0.176 
Electrostatic 0.520 0.301 
Hydrophobic - 0.241 
Donor - 0.171 
Acceptor - 0.111 
r2 pred a 0.824 0.796 
a Predictive r2 is based only on the 9 compounds not included in the training set. It is 
determined from r2 pred = (SD – PRESS)/SD where SD = sum of the squared 
deviations between IC50 values of compounds in test set and mean IC50 values of 
training set molecules, and PRESS is sum of the squared deviation between predicted 





To visualize the information content of the CoMFA model, the steric and 
electrostatic contour maps were generated. Figure 5-4 shows the stereoview of the 
steric contour maps generated for 7 representative compounds in the training set (1-1, 
2-2, 2-3, 3-5, 4-3, 5-1, 5-2) of this model. The green and yellow polyhedra described 
regions of space around the molecules where increases in steric bulk enhance or 
diminish Icmt inhibitory activity respectively. Swathes of yellow and green were 
found at both positions 1 and 3. At position 1, the location of a green zone at the distal 
end of the side chain and a yellow zone in the “middle” of the side chain implied a 
preference for a long side chain, corresponding to n-octyl and geranyl, but not shorter 
side chains like isoprenyl. Unlike the observations made with an earlier CoMFA 
model (Chapter 2), the yellow zone was not sandwiched between two green zones, 
possibly because shorter side chains that might have fallen within the proximal green 
zone were not represented in this study.   
Both green and yellow zones were observed at the side chain at position 3.  
These zones were on opposite sides of the side chain. A close examination of the 
zones suggested that there were different steric requirements for side chain amides 
(Series 3) and amines (Series 4), with bulk better tolerated by the shorter amines as 




Figure 5-4. CoMFA steric contour map. Green contours represent areas where 
steric bulk improves activity, while yellow contours correspond to regions to be kept 
unoccupied for increased activity. Compounds 1-1, 2-2, 2-3, 3-5, 4-3, 5-1, 5-2 were 
used as reference ligands for the CoMFA/CoMSIA contour 
Figure 5-5 depicts the electrostatic contours for the model. The blue contours 
represented regions where an increase in positive charge favours activity while the red 
contours represent regions where more negative charge is favoured. Electrostatic 
contours were found only at the side chain at position 3. The carbonyl oxygen of the 
amides and the lone pair of electrons on the amine nitrogen fell within the red zone. 
As these were H bond acceptors, the red zones corresponded to regions where H bond 
acceptors were sited. The blue zone was located at the opposite side of the side chain 
and it coincided with the amide nitrogen which was positively charged as a result of 
electron delocalization. The NH of the secondary amide 3-2 pointed towards the blue 





Figure 5-5. CoMFA electrostatic contour map. Blue contours represent regions 
where an increase in positive charge will enhance activity, while red contours 
correspond to areas where more negative charge is favoured. 
3D QSAR could also be explored with a related technique, comparative 
molecular similarity analysis (CoMSIA).94 CoMSIA has the advantage of addressing 
one of the key problems in CoMFA, namely small alignment shifts causing large 
changes in the molecular field at certain grid points. Instead of grid-based fields, 
CoMSIA is based on similarity indices obtained by using a functional form adapted 
from the SEAL algorithm.95 The similarity indices were calculated by a Gaussian-type 
distance dependence function, instead of the Lennard-Jones and the Coulomb 
potential. By this approach, the more or less arbitrary application of cut-off values 
used in CoMFA was avoided. But CoMSIA considers additional property fields 
(hydrophobic, H bond donor, H bond acceptor) besides those found in CoMFA (steric 
and electrostatic). As H bond acceptor and hydrophobic features were recognized in 
the pharmacophore model (Section 5.3.1), the use of CoMSIA instead of CoMFA to 
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may be more appropriate. On the other hand, the five property fields in CoMSIA are 
known to be highly interdependent. For example, the H bond donor and acceptor 
properties are implicitly considered in electrostatic interactions. Nonetheless, a 
CoMSIA model was derived using the five property fields (steric, electrostatic, 
hydrophobic, H bond donor and H bond acceptor). As shown in Table 5-3, the 
CoMSIA model (5-component) had comparable statistics to the CoMFA model (3-
component) but did not predict the activity of the test set (r2pred of 0.8) better than the 
CoMFA model. The H bond donor, H bond acceptor and hydrophobic contours of this 
CoMSIA model are given in Figures 5-6 and 5-7.   
Three zones were observed in Figure 5-6: a cyan zone where a H bond donor 
group was favoured, a purple zone where the H bond donor group was not favoured 
and a magenta zone where a H bond acceptor group was favoured. A close inspection 
showed that the magenta H bond acceptor zone coincided with the red contour in the 
CoMFA electrostatic map. The favoured H bond donor zone was located at nearly the 
same position as the blue contour in Figure 5-5, except for the difference in size of 
the two zones. There was no equivalent to a region where H bond donor was not 





Figure 5-6. Hydrogen bond donor/acceptor contour map. Cyan contour represents 
region where presence of a hydrogen bond donor group would enhance activity while 
purple contour represents area where hydrogen bond donor group is disfavoured. On 
the other hand, magenta contour indicates preference for hydrogen bond acceptor 
group at that region. 
As for the hydrophobic contours (Figure 5-6), an orange zone represented 
areas where hydrophobicity was favoured while the grey zone represented areas 
where hydrophilicity was favoured. The orange zone was located at the position of the 
5-phenyl ring, implying the need to maintain a hydrophobic residue at this position.  
The presence of the orange zone at this position rather than at position 1 was 
surprising as the absence of a substituent at position 1 resulted in a far greater loss in 
activity than the omission of a group at position 5 (Section 4.3.2). This anomaly may 
have arisen because there were far more compounds without a 5-substituent (six) than 
without a 1-substituent (one), thus skewing the hydrophobic contours in favour of 
position 5. The grey zone at the side chain located at position 3 reinforced the role of 
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Figure 5-7. CoMSIA hydrophobic contour map. Orange contour represents region 
where hydrophobicity is favoured while grey contour represents area where 
hydrophilicity is preferred. 
Taken together, the present findings showed that the additional information 
provided by CoMSIA was not as useful as anticipated and the same conclusions 




The objectives of this chapter were to establish a pharmacophore model for 
Icmt inhibition and to explain the structure-activity trends observed for the inhibitory 
activities of the indole analogues by quantitative means. In order to obtain the 
pharmacophore model, the test compounds were aligned in their non-protonated 
forms and with their side chains at position 1 restrained to a fixed conformation.  
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These conditions were imposed because the most active compounds had (i) amino 
groups in their side chains and these could interact with the enzyme in either the 
protonated or non-protonated state, and (ii) most of the compounds had highly 
flexible n-octyl side chains that could assume a large number of conformations. With 
these restrictions, a five point pharmacophore model was obtained. It comprised 3 
aromatic features, 1 hydrophobic feature and a H bond acceptor feature. The model 
had good accuracy (91.4 %) and identified all but one of the actives (IC50 value of < 5 
µM) and most of the inactives (9 out of 12). It was able to accommodate 5 known 
Icmt inhibitors that were not structurally related to cysmethynil.  
Three approaches were employed to analyze the SAR of the test compounds, 
namely multiple linear regression (MLR), partial least squares projection to latent 
structures (PLS) and a 3D approach based on CoMFA/CoMSIA. Both MLR and PLS 
identified size and hydrophobicity as the main determinants of activity. This was not 
unexpected given the presence of 3 aromatic and 1 hydrophobic feature in the 
pharmacophore model. Because some of the test compounds could interact with Icmt 
in their protonated or non-protonated states, MLR and PLS were carried out 
separately on protonated and non-protonated compounds. Regardless of the state of 
protonation, size and hydrophobicity were the main determinants of activity. 
However, more representative regression equations were derived when MLR and PLS 
were carried out on the protonated states, in that descriptors specific for the 
protonated amines were detected and their correlation to pIC50 value reflected the 
better activities of these compounds. The CoMFA model showed that the side chains 
at positions 1 was primarily responsible for the steric contributions to activity while 
the side chain at 3 was the sole determinant of polarity. 
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CHAPTER 6: INVESTIGATIONS INTO THE EFFECT OF 
SELECTED DERIVATIVES OF CYSMETHYNIL ON 
VIABILITY OF CANCER CELL LINES 
6.1. INTRODUCTION 
Several compounds have been proposed as promising substitutes of 
cysmethynil because they had comparable, if not better, Icmt inhibitory and cell 
growth inhibitory activities, besides having a more favourable physicochemical 
profile that might enhance its pharmacokinetic properties.  The most notable examples 
were the amino analogues 4-3, 6-4 and 6-5. These compounds were protonated at 
physiological pH and would be expected to be less lipophilic than cysmethynil. This 
might be true for 6-4 and 6-5 but not 4-3 as seen from their estimated SlogP values 
(Table 6-1). Nonetheless, the impressive activity of 4-3 still made it a worthwhile 
candidate for consideration.  
Previous investigations on cysmethynil showed that at moderate 
concentrations (20 M, close to its IC50 value), it inhibited the growth of human 
prostate cells but at higher concentrations (25, 30 M), this cytostatic profile was 
augmented with cytotoxic activity62. Cysmethynil arrested the cell cycle at the G1 
phase which might account for its cytostatic activity. Interesting, it also induced 
autophagic cell death. It was proposed that the inhibition of Icmt by cysmethynil led 
to a reduction of Ras and Rheb activity, which in turn reduced mTOR signaling, 
leading to cell cycle arrest and autophagy62. In this Chapter, 4-3 and 6-4 were 
investigated to determine if they mimicked cysmethynil in some of these activities, 
namely effects on the cell cycle and induction of autophagic cell death.  If similar 
effects were observed, this would provide useful information on the functional 
consequences of Icmt inhibition in tumor cells.  
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Table 6-1. Structures, IC50 values, ClogP and SlogP values of cysmethynil (1-1), 
4-3, 6-4 and 6-5. 
 
Cpd R1 R2 IC50 Icmt a IC50 antiproliferative a ClogPb SlogPc 
1-1 n-C8H17 -CH2CONH2 1.5 M 21.8 M 7.0 6.3 
4-3 n-C8H17 -CH2N(C2H5)2 0.7 M 3.6 M 9.6 6.9 
6-4 
 





2.1 M 3.9 M 7.7 5.7 
a From Table 4-1. IC50 antiproliferative were determined on MDA-MB-231 cells. 
b From Table 3-2, 3-5 and 3-7. Log of octanol /water partition coefficient calculated 
for non-protonated species with ChemDraw 9.0. 
c Log of octanol /water partition coefficient calculated from protonated form (except 
cysmethynil 1-1) with MOE 2008.1001. 
 
6.2 MATERIALS AND METHODS 
6.2.1. Materials 
Materials used were as described in Chapter 4. The PC3 prostate cancer cells 
were from American Type Cell Culture (ATCC, Rockville, MD). Antibodies directed 
against LC3 (MAP1LC3B) and GAPDH were purchased from Abgent (San Diego, 
CA) and Cell Signalling (Danvers, MA) respectively. Propidium iodide and 







6.2.2. Cell Viability Assay 
MDA-MB-231 human breast cancer cells and PC3 prostate cancer cells were 
grown in DMEM supplemented with 10 % fetal bovine serum, 50 U/ml penicillin and 
50 μg/ml streptomycin at 37 °C with 5 % CO2. Cells were subcultured at 80-90 % 
confluency and used within 10-25 passages for the cell-based assays.  
Cell viability assay was carried out as described in Chapter 4. Briefly, cells 
were seeded at 2400 cells per well in DMEM containing 5 % FBS in 96-well plates 
for 24 h prior to treatment with various concentrations of test compound or vehicle 
(media) for 72 h. Final concentration of DMSO in the media was maintained at 0.5 % 
v/v per well. The relative number of the live cells was determined using the 
CellTiter® 96 AQueous One Solution Cell Proliferation Assay (Promega). Each 
condition was performed in triplicate, and data presented represent that obtained from 
at least two separate experiments. 
 
6.2.3. Cell cycle analysis 
MDA-MB-231 and PC3 cells were seeded at 50,000 cells/ml in 100mm dishes 
in DMEM containing 5 % FBS and incubated for 24 h prior to treatment with specific 
compounds or vehicle for 48 h. Cells were harvested by trypsinization, washed with 
PBS, pelleted by centrifugation at 300 x g for 5 mins and fixed in ice cold 70 % 
ethanol overnight. The cells were then stained by resuspension in PBS containing 40 
µg/ml propidium iodide and 0.1 mg/ml ribonuclease A for 1 h at 37 °C. The stained 
cells were then analyzed for distribution in the G1, S and G2/M phases on a FC500 





6.2.4. Western blot analysis 
MDA-MB-231 and PC3 cells were seeded at 50,000 cells/ml in 100mm dishes 
in DMEM containing 5 % FBS and incubated for 24 h prior to treatment with various 
concentrations of test compound or vehicle for 48 h. Cells were lysed in plate by the 
addition of RIPA (radioimmunoprecipitation assay) lysis buffer (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA), transferred to 1.5 ml Eppendorf tubes and 
incubated on ice for 30 mins. The cell debris was removed by centrifugation (10,000 x 
g, 5 mins) and the supernatants were stored in aliquots at -20 °C. The protein content 
of the lysates was determined (BCA ® protein assay, ThermoScientific, Rockford, 
IL). The lysates were treated with Laemmli buffer (4x) and samples (10-20 μg 
protein) were resolved by 12 % SDS-PAGE gel electrophoresis at 110V for 90 mins. 
The resolved proteins were then transferred to polyvinylidene difluoride (PVDF) 
membranes (Amersham Hybond-P, GE Healthcare, UK) by wet transfer at 100 V for 
80 mins. Membranes were then treated with 5% blocking buffer (comprising of 
phosphate buffered saline (PBS) with 5% non-fat milk and 0.1% Tween-20) and 
probed with a specific antibody (GAPDH or LC3) by incubating the membranes in 
blocking buffer containing the antibody at 4 °C overnight. After washing in PBS with 
0.1% Tween 20 (PBST), the membranes previously probed with the primary antibody 
were reacted with secondary antibodies (horseradish peroxidase anti-mouse IgG) in 
blocking buffer at room temperature for 1 hour. They were then washed with PBST 
and developed using an enhanced chemiluminescence procedure (Amersham ECL 
Advanced Western Blotting Detection Kit, GE Healthcare, UK). Immunoblots were 
viewed using the ImageQuant RT-ECL imager (GE Healthcare) and the images 




6.3 RESULTS  
6.3.1.   Effect of 4-3 and 6-4 on viability of human prostate (PC3) and breast 
(MDA-MB-231) cancer cells.     
Both 4-3 and 6-4 were evaluated for their effects on the growth of MDA-MB-
231 cells (Section 4.3.5) and found to be more potent ( 6-fold) than cysmethynil in 
affecting cell viability although they were only comparable (6-4) or modestly more 
potent (4-3) than cysmethynil in terms of Icmt inhibitory activity. In this section, they 
were tested against another cancer cell line (PC3 prostate cancer cells) to confirm 
their effects on tumor cell growth. As seen from Figure 6-1, both compounds affected 
the viabilitiy of MDA-MB-231 and PC3 cells with comparable IC50 values. A similar 
observation was made for cysmethynil while 3-1 (analogue of cysmethynil which is 
not an Icmt inhibitor) did not affect the viability of either cell line. As pointed out in 
an earlier report,62 the results obtained with 3-1 provided strong evidence that the 
inhibition of Icmt contributed significantly to the effects on cell growth. 
  














































Figure 6-1. Effect of cysmethynil (●), 3-1 (▲), 4-3 (■) and 6-4 (×) on cell viability 
(72 h) of (A) MDA-MB-231 cells and (B) PC3 cells. IC50 PC3 values determined by 
the method described in Section 4.2.5 were 17.7 M (cysmethynil), 4.0 M (4-3) and 
3.6 M (6-4) compared to IC50 231 values of 21.8 M (cysmethynil), 3.6 M (4-3) and 
3.8 M (6-4). Cell viability was expressed in terms of % DMSO control. Data 











The compounds might affect cell viability by killing them (cytotoxic 
mechanism) or inhibiting their growth and proliferation (cytostatic effect). This could 
be investigated by monitoring the viability of cells treated with varying concentrations 
of the test compound over several days. The results are given in Figures 6-2 and 6-3. 
Broadly similar outcomes were observed on both cell lines. When tested at a 
concentration that corresponded to their IC50 Icmt value ( 3.8 M), 4-3 and 6-4 
maintained cell viability for the first 2 days, and up to 3 days for MDA-MD-231 cells, 
but not PC3 cells. At higher concentrations (5 and 10 M), both compounds showed 
concentration-dependent cytotoxic effects, with loss of cell viability observed after 24 
hours at 10 M. A similar profile was observed for cysmethynil on both cell lines 
which confirmed the earlier observation62 that it had a biphasic effect on cell growth 




























































































Figure 6-2. Effect of (A) cysmethynil (0, 10, 20, 25, 30 μM), (B) 4-3 (0, 1, 3.75, 5, 
10 μM), (C) 6-4 (0, 1, 3.75, 5, 10 μM) on viability of MDA-MB-231 cells over 3 
days.  Cell viability was expressed in terms of absorbance readings at 490 nm. Data 
represent the mean of triplicate determinations from a single experiment that was 
































































































Figure 6-3. Effect of (A) cysmethynil (0, 10, 20, 25, 30 μM), (B) 4-3 (0, 1, 3.75, 5, 
10 μM), (C) 6-4 (0, 1, 3.75, 5, 10 μM) on viability of PC3 cells over time 3 days. 
Cell viability was expressed in terms of absorbance readings at 490 nm. Data 
represent the mean of triplicate determinations from a single experiment that was 
repeated on 3 separate occasions. 
 
6.3.2. Effects of 4-3 and 6-4 on cell cycle of MDA-MB-231 and PC3 cells 
Cysmethynil was reported to arrest the cell cycle of PC3 cells at the G1 
phase62. This finding was prompted by the observation that, at concentrations 
approximating to its IC50 value, cysmethynil had a cystostatic effect. As 4-3 and 6-4 
were also cytostatic at their IC50 concentrations, this may suggest that they might also 
cause G1 arrest. Briefly, the G1 (gap 1) phase is one of the four phases that occur 
during cell growth and multiplication. At the G1 phase, the cell is actively growing 
and preparing to copy its DNA (2C) in response to various growth factors or internal 
signals. The next phase is the S (synthesis) phase where replication of DNA (4C) 
takes place. Once the chromosomes are copied, there is another gap or interval (G2, 




copies. Finally, there is mitosis (M) where cell division takes place to produce two 
daughter cells, each with their complement of 2C DNA. Cells may re-enter the G1 
phase to repeat the cycle or exit the G1 phase and enter into G0 to stop proliferation 
and if necessary, provide time for repair to take place, or for cell death to occur. 
Regulation of each step of the cycle is precise and complex, involving several proteins 
called cyclins, cylin dependent kinases (CDK) and CDK inhibitors.   
The effects of 4-3, 6-4 and 3-1 on the cell cycle were investigated by 
fluorescence activated cell sorter analysis (FACS) using flow cytometry. Figure 6-4 
shows the distribution of DNA/cells (MDA-MB-231) in the G1 and G2/M phases 
after incubation with the test compound for 24 hours. The first panel (i) shows the 
distribution of DNA in untreated cells. Cells treated with the inactive analogue 3-1 
(Panel (v) of Figure 6-4) showed a similar distribution pattern, indicating that it did 
not interfere with the cell cycle transverse.  In contrast, cells treated with cysmethynil, 
4-3 and 6-4 had a higher proportion of DNA/cells in the G1 phase and a lesser 
proportion in the G2 phase, compared to untreated cells examined at the same time 
point (Panel (i) of Figure 6-4). This was indicative of the arrest of the cell cycle at the 
G1 phase. The same experiments were carried out on PC3 cells (Figure 6-5) and 
similar observations were made. However, it was noted that G1 arrest was more 
noticeable in the treated MDA-MB-231 cells, as seen from the larger proportion of 
DNA/cells in the G1 phase, particularly for 6-4 (71 % in G1 phase versus 52 % in the 
control for MDA-MB-231 cells, as compared to 47 % in G1 phase versus 38 % in the 
control for PC3 cells). 4-3 and 6-4 were clearly more potent than cysmethynil in 
inducing G1 arrest as they were tested at lower concentrations (4 M) than 
cysmethynil (25 M) but caused similar changes in the distribution of cells in the G1 






     
Figure 6-4. DNA content analysis of MDA-MB-231 breast cancer cells, after 24 h 
incubation with (i) vehicle (DMSO), (ii) cysmethynil (25 μM); (iii) 4-3 (4 μM); 
(iv) 6-4 (4 μM) and (v) 3-1 (25 μM). The % of cells in the G1 and G2 phases are 
indicated in each panel. Experiments were repeated on two separate occasions and (i)-
(v) are representative diagrams.  
 
    
Figure 6-5. DNA content analysis of PC3 prostate cancer cells after 24 h 
incubation with (i) vehicle (DMSO), (ii) cysmethynil (25 μM); (iii) 4-3 (4 μM); 
(iv) 6-4 (4 μM) and (v) 3-1 (25 μM). The % of cells in the G1 and G2 phases are 
indicated in each panel. Experiments were repeated on two separate occasions and (i)-
(v) are representative diagrams.  
6.3.3. Effects of 4-3 and 6-4 on autophagic-induced cell death  
Wang et al reported that cysmethynil also induced cell death in addition to 
arresting the cell cycle at the G1 phase62. Although inhibition of CaaX protein 
processing had been linked to apoptosis in many cell types96, cysmethynil did not 
cause cell death by apoptosis even when PC3 cells were treated at concentrations that 
were cytotoxic to cells. Interestingly, cysmethynil was found to induce a non-
apoptotic form of cell death called autophagy (“self-eating”) which involved 
i) Vehicle      ii) 25µM Cysmeth   iii) 4µM 4-3         iv) 4µM 6-4        v) 25µM 3-1 
G1= 
   38.5%            42.6%            43.8%    47.3%         38.9% 
 
   G2 = 
      34.9%            34.5%    29.3%       22.3%           37.4% 
i) Vehicle      ii) 25µM Cysmeth   iii) 4µM 4-3         iv) 4µM 6-4        v) 25µM 3-1 
G1= 
   51.9%            61.3%            64.8%    71.1%         48.9% 
 
   G2 = 
      25.1%            21.3%    18.3%       15.9%           28.4% 
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lysosome-mediated degradation of proteins and cellular organelles, usually in 
response to starvation or stress.97 In view of these findings, it was of interest to 
determine if 4-3 and 6-4 behaved in like manner.  Both compounds were tested at two 
concentrations, namely 4 µM which corresponded to its IC50 value and a lower 
concentration of 1 µM. A preliminary experiment was carried out at 5 µM as this 
concentration displayed prominent cytotoxic effects by 48 h (which was the 
incubation time employed for this investigation) (Figures 6-2 and 6-3). However, 
almost all the cells were killed at this concentration and this led to the use of 4 µM for 
the experiments. The marked difference on cell viability observed with such a small 
difference in concentration (4 µM vs 5 µM) may be related to the steep rising portion 
of the concentration-viability curves of 4-3 and 6-4 (Figure 6-1). 
The microtubule-associated protein 1 light chain 3 (MAP1LC3, also known as 
LC3) was used as a marker for autophagy.98 Briefly, autophagy begins with the 
production of double-membrane bound structures inside an intact cell. As these 
membrane structures elongate and mature, LC3 is recruited to the membrane. Prior to 
its recruitment, LC3 undergoes ubiquitin-like post-translational modifications, 
although involving phospholipid rather than peptide attachment, so that it could target 
the membrane structures. The processed form is called LC3-I and it resides in the 
cytosol. When autophagy is induced, a portion of the LC3-I is conjugated to 
phosphatidylethanolamine to give LC3-II, which associates tightly with the 
autophagosomal membrane. On SDS-PAGE, LC3-II migrates faster than LC3-I.  
Hence, immunoblotting of LC3 results in two bands, LC3-I and LC3-II. The amount 
of LC3-II or the ratio of LC3-II/LC3-I is correlated to the number of autophagosomes, 
and hence represents the autophagic activity in the cell. If 4-3 and 6-4 induced 
autophagy, then the LC3-II band should be more pronounced than LC3-I. 
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Figure 6-6 and 6-7 shows the immunoblots of LC3-I and LC3-II obtained 
from MDA-MD-231 and PC3 cells that were exposed to test compounds. 
Cysmethynil was included as the positive control and the inactive analogue 3-1 was 
used as the negative control. Compounds 4-3 and 6-4 increased the content of LC3-II 
at 4 µM on both cell lines. The effect was concentration-dependent as seen from the 
less intense LC3-II bands detected at 1 µM of test compound. Compared to 
cysmethynil (25 µM), both 4-3 and 6-4 (at 4 µM) caused comparable or greater 
increases in LC3-II content.  The inactive analogue 3-1 did not increase LC3-II levels 
at either 10 µM or 25 µM. These observations were supported by densitometric 



























Figure 6-6. Effect of cysmethynil, 4-3, 6-4 and 3-1 on LC3-1 and LC3-II protein 
levels in MDA-MB-231 breast cancer cell lysates, determined by western blot 
analysis after 48 h of incubation. (A) Cell lysates (10-20 μg) were subjected to SDS-
PAGE and probed with anti-LC3-I and anti-LC3-II antibodies. GADPH was used as 
the loading control. Immunoblots are representative results from a single experiment 
that was repeated at least three times. (B) These observations were supported by 
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Figure 6-7. Effect of cysmethynil, 4-3, 6-4 and 3-1 on LC3-1 and LC3-II protein 
levels in PC3 prostate cancer cell lysates, determined by western blot analysis 
after 48 h of incubation. (A) Immunoblots are prepared as described in Figure 6-6. 
(B) Densitometric quantification of the blots to give the LC3-II/LC3-I ratios. 
 
6.4. DISCUSSION 
The purpose of this chapter was to determine if the Icmt inhibitors 4-3 and 6-4 
affected the growth and viability of cancer cells in a similar fashion as cysmethynil. 
An earlier study has shown that cysmethynil had biphasic effects on the growth of 
prostate cancer cells (PC3), namely a cytostatic effect at concentrations 
approximating to its IC50 value and a cytotoxic effect at higher concentrations.  
Cysmethynil was shown to interfere with the cell cycle transverse by arresting cells at 
the G1 phase in accord with its cytostatic action on cell growth. It enhanced 
autophagy and autophagic cell death. The findings in this chapter showed that 4-3 and 
6-4 exhibited a dual cytostatic-cytotoxic profile that was dependent on concentration. 
They caused G1 arrest at their antiproliferative IC50 values and increased the content 
of the autophagy biomarker (LC3-II) in PC3 and MDA-MD-231 cells in a 
concentration-dependent manner. While these effects were similar to that observed for 
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cysmethynil, 4-3 and 6-4 were evidently more potent in that they induced these effects 
at lower concentrations (4 µM for G1 arrest and increase in LC3-II content) compared 
to cysmethynil (25 µM for both effects). That the inhibition of Icmt was linked to 
these processes was inferred from 3-1 which neither inhibited Icmt nor interfered with 
the growth and viability of the PC3 and MDA-MD-231 cells. On the other hand, only 
4-3 but not 6-4 was a more potent inhibitor of Icmt in vitro (Table 6-1), albeit over a 
narrow 3-fold range (0.7 to 2.3 µM) that may not significantly impact their Icmt 
inhibitory properties. Rather the improved potencies of 4-3 and 6-4 on these cell-
based processes could be the result of structural or physicochemical features that 
favoured their access to the target site. These may be related to the protonated amino 
functionality present in both compounds which would influence properties (solubility, 
lipophilicity, protein binding characteristics) that are critical for passage across 
biological membranes.   
Wang et al proposed a model to explain how the inhibition of Icmt by 
cysmethynil resulted in G1 cell cycle arrest and autophagy in PC3 cells62.  In this 
model, it was proposed that inhibition of Ras- and possibly Rheb-methylation by Icmt 
activated the mTOR (mammalian target of rapamycin) pathway via a cascade of other 
regulatory proteins. mTOR had important effects on cell proliferation and autophagy. 
It promoted cell proliferation by reducing the levels of endogenous CDK2 inhibitors 
(such as p27kip1) and inhibited autophagy.  Thus when Icmt is inhibited, the defective 
Ras and/or Rheb diminished mTOR signalling which led to the induction of p27kip1 
and a block in the G1-S cell cycle progression. Inhibition of mTOR also led to the 
induction of autophagy.   
Whether the induction of autophagy favours or restricts cancer cell growth has 
been widely discussed97, 99-106. That autophagy has an anticancer role comes from the 
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observations that oncogenes inhibited autophagy, tumor suppressors induced 
autophagy, and that a bone fide autophagy regulator (Beclin-1) was itself a tumor 
suppressor107. On the other hand, autophagy may keep tumor cells alive by supplying 
them with macromolecular precursors like amino acids, fatty acids and nucleotides, 
thus overriding nutrient deprivation and hypoxia caused by limited angiogenesis. 
Cancer cells are also known to undergo “protective autophagy” to protect themselves 
from the effects of anticancer therapies. In this context, the inhibition of autophagy 
may be preferred. Many anticancer agents have been reported to induce autophagy. 
These include tamoxifen, rapamycin, arsenic trioxide, and etoposide. But it remained 
to be seen if autophagy played a key role in their mechanism of action. Because 
autophagy occurs in tumor cells before they are killed, it does not necessarily mean 
that it contributed to cell death.  It may be a mechanism by which the cells are striving 
to survive.  However, the finding by Wang et al that PC3 cells could be protected 
from the cytotoxic effect of cysmethynil by inhibiting the autophagy pathway argues 
strongly that, in the case of autophagy induced by Icmt inhibition, the autophagic 
response contributes to the cell killing activity of cysmethynil. 
 
6.5. CONCLUSION 
Taken together, the findings in this chapter showed that Icmt inhibition 
resulted in the arrest of the cell cycle at the G1 phase and the induction of autophagic 
cell death.  This was observed for the Icmt inhibitors 4-3 and 6-4 but not the inactive 
analogue 3-1. 4-3 and 6-4 were more potent than cysmethynil possibly due to an 




CHAPTER 7 CONCLUSION AND FUTURE WORK 
The aim of the thesis centred on the investigation of structure-activity 
relationships of the Icmt inhibitor cysmethynil. It was hypothesized that the anticancer 
activity of cysmethynil could be enhanced by undertaking structural changes at the 
primary amide side chain of the molecule, and by concurrently incorporating more 
drug or lead-like features in its structure. The focus on the primary amide side chain 
was prompted by the fact that this was the only position on cysmethynil that had not 
been previously investigated. Moreover, modifications at other pendant groups on the 
indole ring did not result in more potent compounds than cysmethynil. Although 
cysmethynil incorporated several “drug like” features (compliance to the number of H 
bond donors and acceptors, molecular weight), its estimated lipophilicity (ClogP >5) 
and rotatable bond count exceeded or bordered to the recommended threshold limits.  
Thus, one objective of this investigation was to propose less lipophilic/more soluble 
cysmethynil analogues for synthesis and to determine how far this could be achieved 
without compromising Icmt inhibitory activity. 
To achieve this objective, forty six analogues of cysmethynil were 
synthesized.  The design of these compounds, particularly modifications at positons 1 
and 5 of the scaffold, was aided in part by the analysis of structure-activity trends 
derived from the original library of indoleacetamides which gave cysmethynil. The 
analysis which was carried out with multiple linear regression (MLR), projection 
methods and comparative molecular field analysis (CoMFA), showed that there were 
contrasting steric and lipophilic requirements at positions 1 and 5, with more bulk and 
lipophilicity favoured at position 1 than 5. Notwithstanding the requirement for 
bulkiness and lipophilicity at position 1, the steric CoMFA fields showed two optimal 
lengths at this position, with a long side chain corresponding to n-octyl and a shorter 
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one typified by a trifluoromethylbenzyl side chain. Modifications at the acetamide 
side chain were guided by conventional analogue-based approaches like isosteric 
replacement, homologation and functional group changes. In all, 46 novel indole 
derivatives were synthesized and screened for Icmt inhibitory activity and cell 
viability effects on a human breast cancer cell line (MDA-MB-231).   
The Icmt inhibitory activity of cysmethynil was found to be critically 
dependent on the presence of the acetamide side chain. Omission of this side chain 
resulted in a significant loss of activity, far exceeding that observed when the 1-(n-
octyl) or the 5-substituted phenyl ring was omitted from the molecule. An analysis of 
the structure-activity relationships (SAR) of the series suggested that a lipophilic 
residue should be present at positon 1, a hydrogen (H) bond acceptor entity at position 
3 and a group equivalent to a phenyl ring at position 5. Modifications at the latter 
position resulted in mostly incremental changes in activity and could be explored in 
future work as a possible site for the introduction of functionalities to moderate drug-
likeness of the final compound.   
A significant correlation (Spearman rho value of 0.707, p< 0.01) was observed 
between IC50 values for Icmt inhibition and cell viability effects. With few exceptions, 
similar structural trends were observed for the two activities. The most promising 
compounds were the amine analogues of cysmethynil in which the acetamide side 
chain was replaced by an amino group. Most of the amines (notably 4-3) showed a 
modest improvement in Icmt inhibitory (2-fold) but were significantly more potent 
than cysmethynil (7-fold) in affecting cell viability. Other amines with isoprenyl 
sidechains (6-4, 6-5) that had comparable Icmt inhibitory activities as cysmethynil 
also showed improved antiproliferative activities. These compounds are proposed as 
more drug-like alternatives to cysmethynil in view of their protonated states at 
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physiological pH which could translate to lower lipophilicities and improved 
solubilities. In fact, their improved potencies on the cell based viability assay which 
involved passage across biological membranes might have stemmed from a more 
favourable physicochemical profile. 
Computational analysis of the Icmt inhibitory activities of the test compounds 
yielded a five point pharmacophore model comprising of  3 aromatic features (5-
phenyl and indole rings), 1 hydrophobic feature (side chain at position 1) and a polar 
H bond acceptor feature (at position 3). This model required the amino analogues to 
be represented in their non-protonated rather than protonated states. It may be that the 
physiologically relevant form of the compound (protonated state) need not be the 
“active” entity that interacted with the enzyme. Noting that Icmt is a membrane bound 
enzyme located in the hydrophobic environment of the endoplasmic reticulum, it may 
be that the protonated amine analogue lost a proton in this environment and finally 
interacted with the enzyme in its non-protonated state. Notwithstanding this proposal, 
it was noted that a more informative model was derived when quantitative analysis of 
structure-activity trends were applied to compounds in their protonated states. The 
resulting equations derived from stepwise MLR and PLS regression identified 
prominent contributions from size and hydrophobicity to activity, and a lesser input 
by descriptors that were specific to the protonated states of the test compounds. The 
CoMFA steric and electrostatic fields closely reflected the pharmacophore model with 
sterically favourable green zones at the side chain at position 1, and prominent red 
zones (electron density is favoured) in the region of the electron lone pair of the 
amide carbonyl or amino nitrogen. Taken together, these varied but complementary 
computational tools supported a prominent steric/lipophilic role and a small but still 
essential polar contribution for good Icmt inhibitory activity.   
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The consequences of Icmt inhibition were investigated with the more 
promising Icmt inhibitors 4-3 and 6-4. Both compounds were found to disrupt the G1 
phase of the cell cycle and to increase the content of the autophagic biomarker LC3-II 
in human and prostate cancer cell lines. These effects closely mimicked that observed 
for cysmethynil, except that 4-3 and 6-4 were approximately 6-times more potent than 
cysmethynil in inducing these effects. The observation that 3-1 which had negligible 
Icmt inhibition, did not disrupt the cell cycle or induced autophagy gave added 
evidence of a link between these effects and Icmt inhibition.  
The most promising compounds to emerge from this study were only modestly 
more potent than cysmethynil as Icmt inhibitors or antiproliferative agents. The 
improvement in their physicochemical profiles has not been rigorously tested in 
pharmacokinetic studies. The steep Hill slopes associated with their dose-response 
curves for Icmt inhibition and antiproliferative activity might imply that protein 
binding, a problem associated with cysmethynil, would still be present in the new 
compounds. Thus, there is still a need for Icmt inhibitors with improved 
physicochemical properties and greater potencies. The present findings are a useful 
starting point. In this context, the pharmacophore model constructed in this 
investigation, notwithstanding some limitations, would be a useful platform to screen 
against commercial databases of leadlike or druglike compounds. Promising leads 
would be tested for Icmt inhibitory activity and positive outcomes iteratively fed back 
to the model to improve it further. In this way, scaffolds other than the indole ring of 
cysmethynil might be discovered. Changes in the indole scaffold in cysmethynil have 
not been investigated to date.  This approach might yield novel leads with the desired 
characteristics of enhanced potency and drug-like features that would greatly aid in 
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APPENDIX 1. QSAR OF INDOLOACETAMIDES 
Table A1-1.  Descriptors of compounds in database. 
Comp σPh1 σN1 CLOGP2 Ph3 Ph23 N3 AREA4 PSA5 PV6 VOL7 CMR8 DM9 HOMO LUMO PL110 PB110 PB510 NL111 NB111 NB511 
1A1 -0.06 -0.015 4.75 0.50 2.38 1.92 647.537 106.277 161.757 1028.175 9.97 3.92 -0.357 0.101 6.58 1.85 4.46 5.15 1.71 4.66 
1B1 -0.06 0.013 4.27 0.50 2.39 1.44 646.709 106.790 163.014 1003.580 9.83 4.30 -0.358 0.104 6.58 1.85 4.46 5.03 1.70 4.70 
1C1 -0.06 -0.032 5.94 0.50 2.38 3.11 722.312 106.094 149.055 1133.590 10.90 3.56 -0.359 0.096 6.58 1.85 4.46 8.34 1.71 6.32 
1D -0.06 -0.032 7.00 0.50 2.39 4.17 778.714 106.772 116.062 1206.793 11.82 3.56 -0.359 0.096 6.58 1.85 4.46 10.43 1.70 7.82 
1E -0.06 0.058 5.07 0.50 2.39 2.24 666.768 102.688 140.091 1080.034 11.09 3.24 -0.362 0.099 6.58 1.85 4.46 5.37 1.70 6.26 
1G1 -0.06 0.078 5.95 0.50 2.39 3.12 714.462 102.309 163.132 1188.415 11.60 4.59 -0.365 0.088 6.58 1.85 4.46 5.47 1.70 7.61 
1H1 -0.06 0.078 6.24 0.50 2.39 3.41 720.039 102.892 159.963 1208.393 12.78 3.82 -0.359 0.060 6.58 1.85 4.46 6.82 1.70 8.02 
1I1 -0.06 0.008 5.45 0.50 2.39 2.62 780.725 114.912 160.671 1200.047 12.17 4.50 -0.362 0.102 6.58 1.85 4.46 10.15 1.70 5.85 
1J1 -0.06 0 2.83 0.50 2.39 0.00 566.562 148.468 163.555 835.525 8.11 4.15 -0.372 0.097 6.58 1.85 4.46 2.03 1.00 1.00 
2A1 0.34 -0.015 4.40 0.15 2.03 1.93 627.338 105.700 155.554 983.208 9.52 2.90 -0.362 0.091 6.37 1.78 3.83 5.15 1.71 4.66 
2B1 0.34 0.013 3.91 0.14 2.03 1.44 628.078 106.460 161.470 974.093 9.38 3.20 -0.363 0.095 6.37 1.78 3.83 5.03 1.70 4.70 
2C1 0.34 -0.032 5.59 0.15 2.03 3.12 702.381 106.772 146.134 1090.180 10.45 5.48 -0.364 0.086 6.37 1.78 3.83 8.34 1.71 6.32 
2D 0.34 -0.032 6.64 0.14 2.03 4.17 761.622 106.772 117.555 1184.861 11.38 5.47 -0.364 0.087 6.37 1.78 3.83 10.43 1.70 7.82 
2E 0.34 0.058 4.71 0.14 2.03 2.24 644.240 102.827 143.865 1050.181 10.64 5.13 -0.367 0.090 6.37 1.78 3.83 5.37 1.70 6.26 
2F1 0.34 0.058 6.53 0.14 2.03 4.06 745.225 102.827 134.772 1220.352 12.49 5.27 -0.363 0.088 6.37 1.78 3.83 6.66 1.70 8.80 
2G1 0.34 0.078 5.59 0.14 2.03 3.12 691.327 102.825 151.545 1149.016 11.15 5.85 -0.370 0.084 6.37 1.78 3.83 5.47 1.70 7.61 
2I1 0.34 0.008 5.09 0.14 2.03 2.62 759.188 114.640 169.934 1182.821 11.72 3.84 -0.365 0.090 6.37 1.78 3.83 10.15 1.70 5.85 
2J1 0.34 0 2.47 0.14 2.03 0.00 547.048 148.778 171.570 793.653 7.66 5.99 -0.377 0.089 6.37 1.78 3.83 2.03 1.00 1.00 
3A1 -0.12 -0.015 4.75 0.50 2.38 1.92 655.479 106.411 157.771 1019.079 9.97 3.61 -0.356 0.101 7.43 1.96 3.15 5.15 1.71 4.66 
3B1 -0.12 0.013 4.27 0.50 2.39 1.44 649.549 106.586 170.152 1016.847 9.83 4.03 -0.355 0.101 7.43 1.96 3.15 5.03 1.70 4.70 
3C1 -0.12 -0.032 5.94 0.50 2.38 3.11 732.607 106.068 152.426 1142.734 10.90 3.63 -0.358 0.097 7.43 1.96 3.15 8.34 1.71 6.32 
3D -0.12 -0.032 7.00 0.50 2.39 4.17 786.873 106.580 118.829 1205.092 11.82 3.63 -0.357 0.094 7.43 1.96 3.15 10.43 1.70 7.82 
3G1 -0.12 0.078 5.95 0.50 2.39 3.12 714.954 102.535 146.326 1167.301 11.60 4.05 -0.363 0.088 7.43 1.96 3.15 5.47 1.70 7.61 
3H1 -0.12 0.078 6.24 0.50 2.39 3.41 738.560 102.314 150.870 1217.364 12.78 3.57 -0.356 0.061 7.43 1.96 3.15 6.82 1.70 8.02 
3J1 -0.12 0 2.83 0.50 2.39 0.00 571.403 148.827 165.521 831.725 8.11 3.31 -0.365 0.098 7.43 1.96 3.15 2.03 1.00 1.00 
4A1 0.145 -0.015 4.70 0.45 2.33 1.92 697.719 115.598 164.406 1127.357 10.59 3.02 -0.357 0.102 7.37 1.78 6.45 5.15 1.71 4.66 
4B1 0.145 0.013 4.22 0.45 2.34 1.44 697.933 115.411 159.359 1115.983 10.45 4.38 -0.358 0.105 7.37 1.78 6.45 5.03 1.70 4.70 
4C1 0.145 -0.032 5.89 0.45 2.33 3.11 771.976 115.602 162.731 1221.646 11.51 4.02 -0.359 0.096 7.37 1.78 6.45 8.34 1.71 6.32 
4D 0.145 -0.032 6.95 0.45 2.34 4.17 839.363 115.474 105.805 1277.910 12.44 3.99 -0.359 0.096 7.37 1.78 6.45 10.43 1.70 7.82 
4E 0.145 0.058 5.01 0.44 2.33 2.23 726.759 112.452 185.304 1192.032 11.70 3.80 -0.359 0.098 7.37 1.78 6.45 5.37 1.70 6.26 
4F1 0.145 0.058 6.84 0.45 2.34 4.06 830.827 112.452 178.910 1369.584 13.56 3.84 -0.361 0.102 7.37 1.78 6.45 6.66 1.70 8.80 
4G1 0.145 0.078 5.90 0.45 2.34 3.12 760.459 111.913 194.929 1291.469 12.22 5.32 -0.364 0.088 7.37 1.78 6.45 5.47 1.70 7.61 
4H1 0.145 0.078 6.19 0.45 2.34 3.41 783.639 112.634 169.337 1310.430 13.39 4.04 -0.359 0.061 7.37 1.78 6.45 6.82 1.70 8.02 
4I1 0.145 0.008 5.40 0.45 2.34 2.62 833.325 123.496 157.568 1288.638 12.79 5.21 -0.362 0.103 7.37 1.78 6.45 10.15 1.70 5.85 








 Table A1-1. (cont’d) 
Comp σPh1 σN1 CLOGP2 Ph3 Ph23 N3 AREA4 PSA5 PV6 VOL7 CMR8 DM9 HOMO LUMO PL110 PB110 PB510 NL111 NB111 NB511 
5A1 0 -0.015 3.61 -0.64 1.24 1.92 638.413 113.356 193.822 1049.959 10.12 3.69 -0.352 0.112 4.77 1.78 5.18 5.15 1.71 4.66 
5B1 0 0.013 3.13 -0.64 1.25 1.44 635.850 113.738 194.288 1036.692 9.98 4.07 -0.351 0.110 4.77 1.78 5.18 5.03 1.70 4.70 
5C1 0 -0.032 4.80 -0.64 1.24 3.11 712.911 113.868 176.677 1138.920 11.05 3.04 -0.355 0.112 4.77 1.78 5.18 8.34 1.71 6.32 
5D 0 -0.032 5.86 -0.64 1.25 4.17 773.329 113.538 156.597 1234.810 11.98 3.06 -0.354 0.112 4.77 1.78 5.18 10.43 1.70 7.82 
5E 0 0.058 3.92 -0.65 1.24 2.23 660.567 109.586 173.154 1113.361 11.24 2.96 -0.355 0.106 4.77 1.78 5.18 5.37 1.70 6.26 
5G1 0 0.078 4.81 -0.64 1.25 3.12 706.159 109.855 183.797 1204.648 11.75 4.11 -0.361 0.088 4.77 1.78 5.18 5.47 1.70 7.61 
5H1 0 0.078 5.10 -0.64 1.25 3.41 722.257 109.268 172.104 1245.609 12.93 3.69 -0.351 0.062 4.77 1.78 5.18 6.82 1.70 8.02 
5I1 0 0.008 4.31 -0.64 1.25 2.62 770.949 121.659 190.050 1228.835 12.32 4.17 -0.354 0.107 7.43 1.96 3.15 10.15 1.70 5.85 
5J1 0 0 1.69 -0.64 1.25 0.00 556.712 155.670 181.851 845.831 8.27 3.20 -0.362 0.110 4.77 1.78 5.18 2.03 1.00 1.00 
6A1 0.44 -0.015 5.11 0.86 2.74 1.92 648.167 105.700 160.900 1025.737 10.01 3.90 -0.364 0.083 7.10 1.93 4.59 5.15 1.71 4.66 
6B1 0.44 0.013 4.63 0.86 2.75 1.44 647.486 106.460 170.254 1015.951 9.87 3.91 -0.365 0.087 7.10 1.93 4.59 5.03 1.70 4.70 
6C1 0.44 -0.032 6.30 0.86 2.74 3.11 722.912 106.772 143.339 1136.505 10.94 6.73 -0.366 0.079 7.10 1.93 4.59 8.34 1.71 6.32 
6D 0.44 -0.032 7.36 0.86 2.75 4.17 781.941 106.772 121.883 1217.625 11.87 6.74 -0.365 0.079 7.10 1.93 4.59 10.43 1.70 7.82 
6E 0.44 0.058 5.42 0.85 2.74 2.23 664.441 102.827 147.097 1086.489 11.13 5.12 -0.367 0.080 7.10 1.93 4.59 5.37 1.70 6.26 
6F1 0.44 0.058 7.25 0.86 2.75 4.06 765.726 102.827 130.091 1246.831 12.99 5.35 -0.365 0.080 7.10 1.93 4.59 6.66 1.70 8.80 
6G1 0.44 0.078 6.30 0.85 2.74 3.11 711.462 102.825 159.458 1185.140 11.64 5.16 -0.374 0.080 7.10 1.93 4.59 5.47 1.70 7.61 
6I1 0.44 0.008 5.80 0.85 2.74 2.61 779.260 114.640 163.019 1212.219 12.21 6.25 -0.368 0.085 7.10 1.93 4.59 10.15 1.70 5.85 
6J1 0.44 0 3.19 0.86 2.75 0.00 566.278 148.778 171.516 838.361 8.16 7.33 -0.379 0.081 7.10 1.93 4.59 2.03 1.00 1.00 
7A1 1.08 -0.015 6.02 1.77 3.65 1.92 721.521 106.231 139.487 1157.136 10.53 4.20 -0.372 0.066 7.10 2.50 5.08 5.15 1.71 4.66 
7B1 1.08 0.013 5.54 1.77 3.66 1.44 719.401 106.238 147.715 1141.248 10.39 4.39 -0.371 0.067 7.10 2.50 5.08 5.03 1.70 4.70 
7D 1.08 -0.032 8.27 1.77 3.66 4.17 851.836 106.531 121.774 1349.768 12.38 5.31 -0.373 0.062 7.10 2.50 5.08 10.43 1.70 7.82 
7E 1.08 0.058 6.33 1.76 3.65 2.23 738.974 102.531 134.787 1224.007 11.64 4.99 -0.374 0.061 7.10 2.50 5.08 5.37 1.70 6.26 
7F1 1.08 0.058 8.16 1.77 3.66 4.06 841.066 103.030 157.596 1417.819 13.50 5.10 -0.377 0.068 7.10 2.50 5.08 6.66 1.70 8.80 
7G1 1.08 0.078 7.22 1.77 3.66 3.12 784.656 102.510 148.107 1323.325 12.16 5.29 -0.383 0.064 7.10 2.50 5.08 5.47 1.70 7.61 
7H1 1.08 0.078 7.51 1.77 3.66 3.41 793.505 102.911 152.252 1359.324 13.33 4.10 -0.369 0.057 7.10 2.50 5.08 6.82 1.70 8.02 
7I1 1.08 0.008 6.72 1.77 3.66 2.62 859.179 115.329 146.925 1338.394 12.73 4.93 -0.377 0.068 7.10 2.50 5.08 10.15 1.70 5.85 
7J1 1.08 0 4.10 1.77 3.66 0.00 645.803 148.933 165.081 976.571 8.67 4.18 -0.385 0.063 7.10 2.50 5.08 2.03 1.00 1.00 
8A1 -0.208 -0.015 6.35 2.10 3.99 1.92 742.187 115.456 83.223 1172.695 12.17 2.77 -0.351 0.107 9.78 1.78 5.85 5.15 1.71 4.66 
8B1 -0.208 0.013 5.87 2.10 3.99 1.44 752.242 118.249 172.005 1202.720 12.03 3.04 -0.350 0.108 9.78 1.78 5.85 5.03 1.70 4.70 
8C1 -0.208 -0.032 7.54 2.10 3.98 3.11 830.958 118.813 204.669 1343.243 13.10 4.06 -0.353 0.104 9.78 1.78 5.85 8.34 1.71 6.32 
8E -0.208 0.058 6.66 2.09 3.98 2.23 781.580 114.735 127.490 1287.931 13.29 4.43 -0.354 0.103 9.78 1.78 5.85 5.37 1.70 6.26 
8G1 -0.208 0.078 7.55 2.10 3.99 3.12 823.508 115.016 166.532 1368.260 13.80 5.21 -0.357 0.088 9.78 1.78 5.85 5.47 1.70 7.61 
8H1 -0.208 0.078 7.84 2.10 3.99 3.41 837.961 116.160 183.067 1424.444 14.98 2.83 -0.355 0.058 9.78 1.78 5.85 6.82 1.70 8.02 
8I1 -0.208 0.008 7.05 2.10 3.99 2.62 885.516 128.038 181.519 1437.821 14.37 4.93 -0.377 0.068 9.78 1.78 5.85 10.15 1.70 5.85 









1Hammett sigma values of substituents on phenyl ring (σPh) and substituents on indole N (σN) 
2 log of the octanol/water partition coefficient, as calculated by the CLOGP program 
3Hansch  values of substituents on phenyl (Ph), substituted phenyl ring (Ph2) and indole N (N) 
4Total surface area 
5Polar surface area (By default, the surface computation includes all O, N, and S atoms as well as hydrogen atoms covalently bonded to these 
atoms. The surface is computed as a solvent accessible surface, essentially a van der Waals surface with inflated radii. The surface is affected by 
the molecule’s conformation, but is independent of atomic charges.) 
6Polar volume (By default, the volume computation includes all O, N, and S atoms as well as hydrogen atoms covalently bonded to these atoms.) 
7Total volume  
8Molar refractivity 
9Dipole moment 
10Sterimol parameters of substituted phenyl ring 
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A-1 A-2 1-8  
 
2-(5-Fluoro-1H-indol-3-yl)acetonitrile (A-1). Nitrile A-1 was prepared from 
5-fluoro-1H-indole-3-carbaldehyde following the method described for the synthesis 
of nitrile 1 (Section 3.4.2). Yield: 52 %; 1H NMR (300 MHz, CDCl3):  3.66 (s, 2H), 
6.90 (dt, J1 = 9 Hz, J2 = 2.1 Hz, 1 H), 7.08 (s, 1 H), 7.13-7.22 (m, 2 H), 8.4 (1H, NH); 
13C NMR  (75 MHz, CDCl3) δ 14.2, 102.8, 104.2, 111.0, 112.4, 118.3, 124.8, 126.2, 
132.8, 156.3. 
2-(5-Fluoro-1H-indol-3-yl)acetamide (A-2). Amide A-2 was obtained from 
nitrile A-1 following the method described for the synthesis of amide 2 (Section 
3.4.2). Yield: 61 %; 1H NMR (300 MHz, CDCl3):  3.69 (s, 2 H), 5.29 (s, 2 H), 6.98 
(dt, J1 = 9 Hz, J2 = 2.4 Hz, 1 H), 7.21 (s, 1 H), 7.25-7.33 (m, 2 H), 8.34 (s, 1 H). 
 2-(5-Fluoro-1-octyl-1H-indol-3-yl)acetamide) (1-8). Amide A-2 reacted 
with bromooctane according to the general procedure described for the synthesis of 
indole 6 (Section 3.4.4). Yield: 70 %; 1H NMR (300 MHz, CDCl3):  7.26 – 7.18 (m, 
2 H), 7.09 (s, 1 H), 6.97 (dt, J1 = 9 Hz, J2 = 2.4 Hz, 1 H), 5.73 (br. s, 2 H), 4.06 (t, J = 
7.2 Hz, 2 H), 3.65 (s, 2 H), 1.83 (t, J = 6.3 Hz, 2 H), 1.29-1.25 (m, 10 H), 0.86 (t, J = 
6.3 Hz, 3H); 13C NMR  (75 MHz, CDCl3) δ 174.10, 159.39, 156.27, 139.66, 133.03, 
128.67, 127.68, 127.55, 110.66, 117.23, 103.88, 46.63, 32.81, 31.70, 30.17, 29.09 























3-2, 3-74 5  
 
2-(5-Bromo-1-octyl-1H-indol-3-yl)-N-
methylacetamide (5e). Acid 4 was reacted with SOCl2 and 
methylamine as described in the general procedure for the 
synthesis of amide 5 (Section 3.4.3). Yield: 73 %; 1H NMR (300 MHz, CDCl3):  
0.87 (t, J = 6.9 Hz, 3 H), 1.26- 1.29 (m, 10 H), 1.82 (t, J = 6.9 Hz, 2 H), 2.74 (d, J = 
4.8 Hz, 3 H), 3.66 (s, 2 H), 4.07 (t, J = 7.2 Hz, 2 H), 7.04 (s, 1 H), 7.20- 7.34 ((m, 2 
H), 7.67 (s, 1 H); 13C NMR  (75 MHz, CDCl3) δ 14.0, 22.5, 26.4, 26.9, 29.1, 29.1, 
30.1, 31.6, 32.9, 46.5, 107.0, 111.1, 112.8, 121.4, 124.8, 128.4, 129.2, 135.0, 171.7. 
2-(5-Bromo-1-octyl-1H-indol-3-yl)-1-(4-
methylpiperazin-1-yl)ethanone (5f). Acid 4 was reacted 
with SOCl2 and N-methylpiperazine as described in the 
general procedure for the synthesis of amide 5 (Section 3.4.3). Yield: 58 %; 1H NMR 
(300 MHz, CDCl3): δ 0.85 (t, J = 6.9 Hz, 3 H), 1.23–1.25 (m, 10 H), 1.76 (t, J = 6.9 
Hz, 2 H), 2.20 (t, J = 6.3 Hz, 2 H), 2.23 (s, 3 H), 2.35 (t, J = 4.8 Hz, 2 H), 3.46 (t, J = 
4.8 Hz, 2 H), 3.66 (t, J = 4.5 Hz, 2 H), 3.74 (s, 2 H), 4.01 (t, J = 7.2 Hz, 2 H), 7.0 (s, 1 
H), 7.15 (d, J = 8.7 Hz, 1 H), 7.25 (d, J = 8.7 Hz, 1 H), 7.70 (s, 1 H); 13C NMR (75 
MHz, CDCl3): δ 14.0, 22.5, 26.8, 29.10, 29.12, 30.7, 31.7, 41.6, 45.9, 46.4, 54.5, 54.9, 
107.2, 110.9, 112.3, 121.3, 124.4, 127.2, 129.1, 134.8, 169.6.      
N-Methyl-2-(1-octyl-5-m-tolyl-1H-indol-3-yl)acetamide (3-2). Amide 5e 













synthesis of amide 3-3 (Section 3.4.3). Yield: 68 %; 1H NMR (300 MHz, CDCl3):  
7.72 (s, 1 H), 7.49-7.30 (m, 5 H), 7.12 (d, J = 6.6 Hz, 1 H), 7.01 (s, 1 H), 5.89 (bs, 1 
H), 4.06 (t, J = 6.6 Hz, 2 H), 2.68 (d, J = 4.5 Hz, 3 H), 2.41 (s, 3 H), 1.82 (t, J = 6.8 
Hz, 2 H), 1.39-1.25 (m, 10 H), 0.86 (t, J = 6.3 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 
174.10, 159.39, 156.27, 139.66, 133.03, 128.67, 127.68, 127.55, 110.66, 110.47, 
110.31, 107.52, 107.46, 103.88, 103.57; MS (APCI): m/z 391.8 [M + H]+; Found 
(calcd. for C26H34N2O) C 79.86 % (79.96); H 8.96 % (8.77). 
1-(4-Methylpiperazin-1-yl)-2-(1-octyl-5-m-tolyl-1H-indol-3-yl)ethanone 
(3-7). Amide 5f was reacted with m-tolylboronic acid as described in the general 
procedure for the synthesis of amide 3-3 (Section 3.4.3). The product is isolated as an 
amber oil. Yield: 45 %;  1H NMR (300 MHz, CDCl3):  7.75 (s, 1 H)7.46-7.29 (m, 5 
H), 7.12 (d, J = 6.9 Hz, 1 H), 7.02 (s, 1 H), 4.07 (t, J = 6.9 Hz, 2 H), 3.85 (s, 2 H) 3.68 
(t, J = 6.9 Hz, 2 H), 3.48 (t, J = 6.9 Hz, 2 H),  2.43 (s, 3 H), 2.36 (t, J = 6.9 Hz, 2 H), 
2.23 (s, 3 H), 2.20 (t, J = 6.9 Hz, 2 H), 1.81 (t, J = 6.9 Hz, 2 H), 1.29-1-25 (m, 10 H), 
0.87 (t, J = 6.9 Hz, 3 H); 13C NMR  (75 MHz, CDCl3) δ 172.54, 142.54, 138.15, 
135.60, 133.07, 132.13, 131.69, 128.41, 127.33, 127.06, 126.24, 124.52, 121.39, 
114.06, 109.74, 57.2, 53.3, 53.0, 46.3, 46.0, 31.7, 30.2, 29.2 (2C), 27.0, 22.6, 21.6, 
14.1; MS (APCI): m/z  460.5 [M + H]+.    
 



















Compound 3-1 was reacted with dimethylamine following the method described for 
the amine 4-3 (Section 3.4.4). The product is isolated as an amber oil. Yield: 61 %; 
1H NMR (300 MHz, CDCl3):  7.84 (s, 1 H), 7.46-7.42 (m, 3 H), 7.36 (s, 1 H), 7.32 
(d, 1 H J = 4.5 Hz), 7.11 (d, 1 H J = 7.5 Hz), 7.07 (s, 1 H), 4.09 (t, 2 H, J = 7.2 Hz), 
3.66 (s, 2 H), 2.43 (s, 3 H), 2.29 (s, 6 H), 1.84 (t, 2 H J = 6.6 Hz), 1.31-1.25 (m, 10 
H), 0.86 (t, 3 H J = 5.7 Hz). 13C NMR  (75 MHz, CDCl3): δ 142.7, 138.0, 135.7, 
132.6, 128.8, 128.4, 128.2, 127.9, 126.9, 125.5, 121.2, 117.8, 111.8, 109.4, 54.2, 46.3, 
45.2, 31.7, 30.2, 29.1, 29.1, 26.9, 22.5, 21.5, 14.0; MS (APCI): m/z  377.3 [M + H]+.  
N-isopropyl-N-((1-octyl-5-m-tolyl-1H-indol-3-yl)methyl)propan-2-amine 
(4-4). Compound 3-1 was reacted with diisopropylamine following the method 
described for the amine 4-3 (Section 3.4.4). The product is isolated as an amber oil. 
Yield:  62 %; 1H NMR (300 MHz, CDCl3):  8.08 (s, 1 H), 7.46-7.30 (m, 4 H), 7.1 (d, 
2 H J = 5.4 Hz), 7.01 (s, 1 H), 4.05 (t, 2 H J = 7.2 Hz), 3.85 (s, 2 H), 3.13 (p 2 H, J = 
6.6 Hz), 2.41 (s, 3 H), 1.80 (t, 2 H J = 5.7 Hz), 1.28-1.24 (m, 10 H), 1.07 (d, 12 H, J 
=6.3 Hz), 0.86 (t, 3 H, J = 6.9 Hz); 13C NMR  (75 MHz, CDCl3) δ 142.9, 138.0, 
136.1, 131.8, 128.5, 128.3, 128.1, 127.3, 126.7, 124.4, 120.9, 118.5, 115.7, 109.3, 
47.3, 46.3, 40.4, 31.7, 30.3, 29.2, 29.2, 27.0, 22.6, 21.6, 20.6, 14.0; MS (APCI): m/z  
433.0 [M + H]+. 
N-((1-Octyl-5-m-tolyl-1H-indol-3-yl)methyl)-N-propylpropan-1-amine (4-
5). Compound 3-1 was reacted with dipropylamine following the method described 
for the amine 4-3 (Section 3.4.4). The product is isolated as an amber oil. Yield: 65 
%; 1H NMR (300 MHz, CDCl3):  7.90 (s, 1 H), 7.46-7.41 (m, 3 H), 7.33 (d, 2 H, J = 
8.4 Hz), 7.11 (d, 1 H, J = 7.5 Hz), 7.02 (s, 1 H), 4.07 (t, 2 H, J = 7.2 Hz), 3.79 (s, 2 
H), 2.42 (s, 3 H), 2.42 (t, 2 H, J = 4.2 Hz), 1.82 (t, 2 H, J = 5.7 Hz), 1.54 (q, 4 H, J = 
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7.5 Hz), 1.28-1.24 (m, 10 H), 0.87 (t, 9 H, J = 7.2 Hz); 13C NMR  (75 MHz, CDCl3) δ 
142.7, 138.0, 135.8,132.2, 128.9, 128.4, 128.1, 127.6, 126.8, 124.4, 121.0, 118.2, 
112.6, 109.3, 55.8, 49.2, 46.3, 31.7, 30.2, 29.1, 29.1, 27.0, 22.6, 21.5, 20.3, 14.0, 12.0; 
MS (APCI): m/z 433.6 [M + H]+.  
N-methyl-N-((1-octyl-5-m-tolyl-1H-indol-3-yl)methyl)propan-2-amine (4-
6). Compound 3-1 was reacted with N-methylpropan-2-amine following the method 
described for the amine 4-3 (Section 3.4.4). The product is isolated as an amber oil. 
Yield: 52%; 1H NMR (300 MHz, CDCl3):   7.87 (s, 1 H), 7.46-7.41 (m, 3 H), 7.32 
(d, 2 H, J = 8.4 Hz), 7.10 (d, 1 H, J = 7.5 Hz), 7.07 (s, 1 H), 4.06 (t, 2 H, J 6.9 Hz), 
3.76 (s, 2 H), 2.98 (p, 1 H, J = 6.6 Hz), 2.42 (s, 3 H), 2.23 (s, 3 H), 1.81 (t, 2 H, J = 
6.3 Hz), 1.30-1.24 (m, 10 H), 1.11 (d, 6 H, J = 6.6 Hz), 0.86 (t, 3 H,  J = 6.9 Hz); 13C 
NMR  (75 MHz, CDCl3) δ 142.8, 138.0, 135.8, 132.5, 128.8, 128.5, 128.2, 127.8, 
126.9, 124.5, 121.2, 117.9, 112.6, 109.5, 52.7, 48.3, 46.3, 36.8, 31.7, 30.3, 29.2, 29.2, 
27.0, 22.6, 21.6, 18.0, 14.1; MS (APCI), m/z  = 405.5 [M +  H]+.  Found (calcd. for 
C28H40N2): C 83.12 (83.11);  H 9.59 (9.96). 
1-Octyl-3-(pyrrolidin-1-ylmethyl)-5-m-tolyl-1H-indole (4-7). Compound 3-
1 was reacted with pyrrolidine following the method described for the amine 4-3 
(Section 3.4.4). The product is isolated as an amber oil. Yield: 71 %; 1H NMR (300 
MHz, CDCl3):  7.85 (s, 1 H), 7.46-7.41 (m, 3 H), 7.32 (d, 2 H, J =  8.1 Hz), 7.10 (s, 
1 H), 7.01 (d, 1 H, J =  7.2 Hz), 4.04 (t, 2 H, J = 7.2 Hz), 3.87 (s, 2 H), 2.61 (br. s, 4 
H), 2.42 (s, 3 H), 1.78 (br. s, 6 H), 1.29-1.24 (m, 10 H), 0.86 (t, 3 H, J = 6.3 Hz); 13C 
NMR (75 MHz, CDCl3) δ 142.7, 138.1, 135.6, 132.6, 128.7, 128.5, 128.2, 127.9, 
127.0, 124.6, 121.2, 117.7, 112.0, 109.5, 54.0, 50.1, 46.4, 31.8, 30.3, 29.26, 29.22, 
27.0, 23.5, 22.6, 21.6, 14.1. MS (APCI): m/z 403.5 [M +  H]+.  
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1-Octyl-3-(piperidin-1-ylmethyl)-5-m-tolyl-1H-indole (4-8). Compound 3-1 
was reacted with piperidine following the method described for the amine 4-3 
(Section 3.4.4).  The product is isolated as an amber oil. Yield: 78%; 1H NMR (300 
MHz, CDCl3):  7.87 (s, 1 H), 7.46-7.41 (m, 3 H), 7.34-7.32 (m, 2 H), 7.11 (d, 1 H, J 
= 7.2Hz), 7.07 (s, 1 H), 4.06 (t, 2 H, J = 6.9 Hz), 3.72 (s, 2 H), 2.45 (s, 3 H), 2.46-2.43 
(m, 4 H), 1.84 (t, 2 H, J = 6.3 Hz), 1.58-1.55 (m, 4 H), 1.41-1.22 (m, 12 H), 0.86 (t, 3 
H, J = 6.9 Hz); 13C NMR  (75 MHz, CDCl3) δ 142.8, 138.1, 135.6, 132.5, 129.2, 
128.5, 128.28, 128.21, 126.9, 124.5, 121.8, 118.0, 111.2, 109.4, 60.3, 54.3, 53.8, 46.3, 
31.7, 30.2, 29.1, 27.0, 26.0, 24.4, 22.6, 21.6, 14.1. MS (APCI): m/z 417.5 [M +  H]+.   
3-((4-Methylpiperazin-1-yl)methyl)-1-octyl-5-m-tolyl-1H-indole (4-9). 
Compound 3-1 was reacted with 1-methylpiperazine following the method described 
for the amine 4-3 (Section 3.4.4). The product is isolated as an amber oil. Yield: 87 
%; 1H NMR (300 MHz, CDCl3):  7.89 (s, 1 H), 7.46-7.41 (m, 3 H), 7.33-7.29 (m, 2 
H), 7.05 (s, 1 H), 7.01 (d, 1 H, J = 7.2 Hz), 4.04 (t, 2 H, J = 6.9 Hz), 3.73 (s, 2 H), 
2.54-2.47 (m, 8 H), 2.42 (s, 3 H), 2.25 (s, 3 H), 1.80 (t, 2 H, J = 5.7 Hz), 1.28-1.24 (m, 
10 H), 0.86 (t, 3 H, J = 5.4 Hz); 13C NMR  (75 MHz, CDCl3) δ 142.7, 138.1, 135.8, 
132.6, 129.0, 128.5, 128.2, 128.0, 126.9, 124.5, 121.3, 118.1, 111.2, 109.5, 55.2, 53.3, 
53.0, 46.3, 46.0, 31.7, 30.2, 29.2(2C), 27.0, 22.6, 21.6, 14.1; MS (APCI): m/z 432.6 
[M +  H]+.  
4-((1-Octyl-5-m-tolyl-1H-indol-3-yl)methyl)morpholine (4-10). Compound 
3-1 was reacted with morpholine following the method described for the amine 4-3 
(Section 3.4.4). The product is isolated as an amber oil. Yield: 78 %; 1H NMR (300 
MHz, CDCl3):  7.90 (s, 1 H), 7.46 (m, 3 H), 7.33-7.28 (m, 2 H), 7.09 (d, 1 H, J = 7.5 
Hz), 7.01 (s, 1 H), 4.01 (t, 2 H, J = 6.9 Hz), 3.69 (s, 2 H), 3.68 (t, 4 H, J = 4.8 Hz), 
2.48 (t, 4 H, J = 4.8 Hz), 2.41 (s, 3 H), 1.78 (t, 2 H, J = 6 Hz), 1.27-1.21 (m, 10 H), 
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0.86 (t, 3 H, J = 6.9 Hz); 13C NMR  (75 MHz, CDCl3) δ  142.8, 138.1, 135.9, 132.7, 
129.0, 128.6, 128.3, 128.1,  127.1, 124.6, 121.4, 118.2, 110.9, 109.6, 67.2, 54.0, 53.7, 
46.4, 31.8, 30.3, 29.2, 29.2, 27.0, 22.7, 21.7, 14.2. MS (APCI): m/z 419.3 [M +  H]+. 
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1-Octyl-5-m-tolyl-1H-indole-3-carboxylic acid (A-3). Compound A-3 was 
synthesized according to the method described in Andreani et al108. Compound 9 
(0.573 mmol, 1 equiv) was dissolved in 10 mL of acetone and treated with a solution 
of potassium permanaganate (KMnO4, 1.5 mmol) in water (5 mL). The reaction 
mixture was stirred at room temperature for 5h, treated with 10 % H2O2 until the pink 
color of KMnO4 was not observed and then filtered. The solvent was removed under 
reduced pressure and the resulting residue was filtered again (if necessary), acidified 
with 2M HCl and extracted with Et2O.  The organic solvent was removed in vacuo 
and the residue was purified by column chromatography with hexane/EtOAc as 
eluting solvents. Yield: 62 %;  1H NMR (300 MHz, CDCl3): δ 8.84 (s, 1 H), 7.92 (s, 1 
H), 7.54-7.48 (m, 2 H), 7.41-7.29 (m, 3 H), 7.14 (d, J = 6.6 Hz, 1 H), 4.12 (t, J = 6.6 
Hz, 2 H), 2.44 (s, 3 H), 1.87 (t, J = 6.6 Hz, 3 H), 1.37-1.25 (m, 10 H), 0.86 (t, J = 6.6 
Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ 170.3, 142.3, 141.9, 138.4, 138.2, 136.1, 
136.0, 135.8, 128.5, 128.3, 127.4, 124.6, 120.3, 110.3, 106.3, 47.2, 31.7, 31.1, 29.8, 
29.1, 22.6, 21.5, 21.5, 14.0.   
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1-Octyl-5-m-tolyl-1H-indole-3-carboxamide (5-1). A mixture of A-3 (0.4 
mmol, 1 equiv.) and SOCl2 (1 mL, 13 equiv.) in dry benzene (5 mL) were refluxed for 
4 h.  Excess SOCl2 and benzene were removed by distillation under reduced pressure 
and the residue containing the acid chloride was dried in vacuo. It was dissolved in 
dry THF (4 ml) and ammonia gas was bubbled into the stirred solution for 30 min. 
THF was removed under vacuum, the residue was extracted with CH2Cl2, dried 
(anhydrous Na2SO4) and the solvent removed under reduced pressure to give 
carboxamide 5-1. Yield: 74 %; 1H NMR (300 MHz, CDCl3):   8.16 (s, 1 H), 7.74 (s, 
1 H), 7.49-7.13 (m, 6 H), 5.99 (bs, 2 H), 4.09 (t, J = 7.2 Hz), 2.42 (s, 3 H); 1.82 (t, J = 
6.8 Hz, 2 H), 1.28-1.24 (m, 10 H) 0.86 (t, J = 6.3 Hz, 3 H); 13C NMR  (75 MHz, 
CDCl3) δ 167.32, 141.92, 138.25, 136.07, 135.31, 132.61, 128.58, 128.29, 127.47, 
126.18, 124.60, 122.37, 118.94, 110.43, 110.00, 47.02, 31.71, 29.92, 29.11, 29.08, 





















MsCl (0.434 mmol, 1 equiv.) was added to a solution of amine 4-1 (0.434 mmol, 1 
equiv.) and triethylamine (0.651 mmol, 1.5 equiv.) in THF (4 mL) at 0 oC. The 
reaction mixture was stirred at room temperature for 1 h. The precipitate was removed 
by filtration, the filtrate was concentrated under reduced pressure and the residue 
purified by column chromatography with CH2Cl2 as eluting solvent to give 
sulfonamide 5-6 as an amber oil. Yield: 61 %; 1H NMR (300 MHz, CDCl3): δ 7.19 (s, 
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1 H), 7.50-7.31 (m, 7 H), 7.15 (s, 1 H), 4.54 (d, 2 H, J = 4.8 Hz), 4.10 (t, 2 H, J = 7.2 
Hz), 2.85 (s, 3 H), 2.44 (s, 3 H), 1.84 (t, 2 H, J =  6.3 Hz), 1.31-1.25 (m, 10 H), 0.87 
(t, 3 H, J = 7.2 Hz); 13C NMR  (75 MHz, CDCl3) δ 142.1, 138.2, 135.9, 133.3, 128.6, 
128.1, 127.8, 127.26, 127.22, 124.4, 121.9, 117.1, 110.1, 109.9, 60.4, 46.5, 40.8, 38.8, 
31.7, 30.2, 29.1, 26.9, 22.6, 21.5, 14.0; MS (APCI): m/z 427.3 [M + H]+.   
 




1-Octyl-5-o-tolyl-1H-indole (A-4a). Compound 6 was 
reacted with o-tolylboronic acid as described for 3-3 (Section 
3.4.3). Yield: 68 %; 1H NMR (300 MHz, CDCl3):   7.53 (d, J 
= 6.9 Hz, 1 H), 7.35-7.11 (m, 7 H), 6.49 (d, J = 2.7 Hz,1 H), 
4.11 (t, J = 6.3 Hz, 2 H), 2.30 (s, 3 H),1.85 (t, J = 6.9 Hz, 2 H), 1.31-1.25 (m,10 
H),0.86 (t, J =6.9 Hz, 3 H); 13C NMR  (75 MHz, CDCl3) δ 143.1, 135.7, 134.9, 133.0, 
130.3, 130.1, 128.3, 128.2, 126.5, 125.5, 123.0, 121.2, 108.7, 100.9, 46.5, 31.7, 30.2, 
29.1, 27.0, 22.6, 20.7, 14.0. 
1-Octyl-5-p-tolyl-1H-indole (A-4b). Compound 
A-4b was reacted with p-tolylboronic acid as described for 
3-3 (Section 3.4.3). Yield: 72 %; 1H NMR (300 MHz, 
CDCl3):  0.87 (t, J = 6.3 Hz, 3 H), 1.26-1.30 (m, 10 H), 1.83 (t, J = 6.3 Hz, 2 H), 
















H), 7.24 (d, J = 7.8 Hz, 2 H), 7.36-7.50 (m, 2 H), 7.55 (d, J = 7.8 Hz, 2 H), 7.81 (s, 1 
H); 13C NMR (75 MHz, CDCl3) δ 14.0, 20.7, 22.6, 27.0, 29.1(2C), 30.2, 31.7, 46.5, 
101.1, 109.5, 119.1, 121.1, 126.9, 127.1, 128.4, 128.6, 129.3, 132.6, 135.3, 135.7.  
N-ethyl-N-((1-octyl-5-o-tolyl-1H-indol-3-yl)methyl)ethanamine (6-1). 
Compound A-4a was reacted with diethylamine as described for the synthesis of 4-3 
(Section 3.4.4). The product is isolated as an amber oil. Yield: 72 %; 1H NMR (300 
MHz, CDCl3):  7.63 (s, 1 H,), 7.33-7.22 (m, 5 H, ), 7.16 (d, 1 H, J = 8.4 Hz), 7.08 (s, 
1 H), 4.09 (t, 2 H, J = 7.2 Hz), 7.39 (s, 2 H), 2.56 (q, 4 H, J = 7.2 Hz), 2.32 (s, 3 H), 
1.85 (t, 2 H, J = 6.9 Hz), 1.32-1.26 (m, 10 H), 1.08 (t, 6 H, J = 7.2 Hz), 0.87 (t, 3 H, J 
= 4.8 Hz); 13C NMR  (75 MHz, CDCl3) δ 143.2, 135.7, 135.2, 132.6, 130.3, 130.1, 
128.4, 127.7, 126.5, 125.5, 122.9, 119.9,111.5, 108.7, 47.7, 46.5, 46.3, 31.7, 30.2, 
29.1, 29.1, 27.0, 22.6, 20.7, 14.0, 11.9; MS (APCI): m/z 405.6 [M +  H]+. Found 
(calcd. for C28H48N2): C 83.01 (83.11), H 9.21 (9.96). 
N-Ethyl-N-((1-octyl-5-p-tolyl-1H-indol-3-yl)methyl)ethanamine (6-2). 
Compound A-4b was reacted with diethylamine as described for the synthesis of 
amine 4-3 (Section 3.4.4). The product is isolated as an amber oil. Yield: 65 %; 1H 
NMR (300 MHz, CDCl3):  7.87 (s, 1 H), 7.55 (d, 2 H, J = 7.8 Hz), 7.42 (d, 2H, J = 
8.1 Hz), 7.33 (d, 1 H, J = 8.4 Hz), 7.24 (d, 2 H, J = 7.8 Hz), 7.06 (s, 1 H), 4.08 (t, 2 H, 
J =6.9 Hz), 3.81 (s, 2 H), 2.54 (q, 4 H, J = 6.9 Hz), 2.39 (s, 2 H), 1.83 (t, 2 H, J = 6.6 
Hz), 1.31-1.29 (m, 10 H), 1.10 (t, 6 H, J = 7.2 Hz), 0.86 (t, 3 H, J = 6.9 Hz).  13C 
NMR  (75 MHz, CDCl3) δ 139.9, 135.7, 135.5 132.2, 129.3, 129.0, 127.8, 127.2, 
121.0, 117.7, 111.8, 109.4, 47.7, 46.8, 46.3, 31.7, 30.2, 29.1, 29.1,  26.9, 22.5, 21.0, 













6-4, 6-5, 6-6A-5 6-3  
 
 
5-Bromo-1-(3-methylbut-2-enyl)-1H-indole (A-5). Indole A-5 was prepared 
from 5-bromo-1H-indole and 1-chloro-3-methylbut-2-ene according to the method 
described for the synthesis of indole 6 (Section 3.4.4). Yield: 96 %; 1H NMR (300 
MHz, CDCl3):  7.32 (d, J = 1.5 Hz, 1H), 7.23 (d, J = 1.5 Hz), 7.23 (d, J = 1.5 Hz, 1 
H), 7.16 (s, 1 H), 7.06 (d, J = 3Hz, 1H), 6.39 (d, J = Hz, 1H), 5.32 (t, J = 6.9 Hz, 1 H), 
4.61 (d, J = 6.9 Hz, 2 H), 1.78 (s, 3H), 1.74 (s, 3H); 13C NMR  (75 MHz, CDCl3) δ 
136.7, 134.6, 130.4, 128.5, 124.1, 123.3, 119.5, 112.5, 110.9, 100.5, 44.3, 25.6, 18.0.  
1-(3-Methylbut-2-enyl)-5-m-tolyl-1H-indole (6-3). Indole A-5 was reacted 
with m-tolylboronic acid as described for the synthesis of amide 3-3 (Section 3.4.4). 
Yield: 75 %; 1H NMR (300 MHz, CDCl3):  7.87 (d, J = 0.9 Hz, 1 H), 7.45-7.28 (m, 5 
H), 7.11-7.09 (m, 2 H), 6.57 (dd, J1 = 3.0 Hz, J2 = 0.6 Hz, 1 H), 5.46-5.43 (m, 1 H), 
4.76 (d, J = 6.9 Hz, 2 H), 2.47 (s, 3 H), 1.89 (s, 3 H), 1.82 (s, 3 H); 13C NMR (75 
MHz, CDCl3) δ 142.70, 138.14, 136.34, 135.55, 132.98, 129.25, 128.57, 128.26, 
128.06, 127.01, 124.54, 121.31, 119.99, 119.47, 109.71, 101.39, 44.30, 25.70, 21.66, 
18.08. MS (APCI): m/z 276.5 [M + H]+.    
N-Ethyl-N-((1-(3-methylbut-2-enyl)-5-m-tolyl-1H-indol-3-
yl)methyl)ethanamine  (6-4). Indole 6-3 was reacted with diethylamine, as described 
for the synthesis of amine 4-3 (Section 3.4.4). The product is isolated as an amber oil. 
Yield: 70%; 1H NMR (300 MHz, CDCl3):   7.88 (s, 1 H), 7.46-7.41 (m, 3 H), 7.34-
7.29 (m, 2 H), 7.11 (d, 1 H, J = 7.2 Hz), 7.06 (s, 1 H), 5.38 (t, 1 H, J = 6.9 Hz), 4.67 
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(d, 2 H, J = 6.6 Hz), 3.80 (s, 2 H,), 2.57 (q, 4 H, J = 6.9 Hz), 2.43 (s, 3 H), 1.82 (s, 3 
H), 1.76 (s, 3 H), 1.09 (t, 6 H, J = 7.2 Hz). 13C NMR  (75 MHz, CDCl3) δ 142.7, 
138.1, 136.1, 135.6, 132.6, 129.2, 128.5, 128.2, 127.7, 126.9, 124.5, 121.2, 119.9, 
117.8, 111.6, 109.6, 47.7, 46.5, 44.1, 25.6, 21.6, 18.0, 11.7; MS (APCI): m/z 361.1 [M 
+  H]+; Found (calcd. for C25H32N2)  C 82.92% (83.28) H 8.85 (8.95). 
1-(3-Methylbut-2-enyl)-3-(piperidin-1-ylmethyl)-5-m-tolyl-1H-indole (6-
5). Compound 6-3 was reacted with piperidine as described for the synthesis of amine 
4-3 (Section 3.4.4). The product is isolated as an amber oil. Yield: 71 %; 1H NMR 
(300 MHz, CDCl3):   7.86  (s, 1 H), 7.46-7.42 (m, 3 H), 7.34 (d, 2 H, J = 7.2 Hz), 
7.12 (d, 1 H, J = 10.2 Hz), 7.03 (s, 1 H), 5.39 (t, 1 H,  J = 5.1 Hz), 4.68 (d, 2 H, J = 
6.6 Hz), 3.73 (s, 2 H), 2.49 (br. s, 4 H), 2.44 (s, 3 H), 1.83 (s, 3 H), 1.77 (s, 3 H), 1.42 
(m, 2 H), 0.86 (m, 4 H). 13C NMR  (75 MHz, CDCl3) δ 142.8, 138.1, 136.1, 135.6, 
132.6, 129.4, 128.5, 128.2, 127.8, 126.9, 124.5, 121.1, 120.0, 118.0, 111.4, 109.5, 
54.3, 53.8, 44.1, 26.0, 25.6, 24.4, 21.6, 18.0. MS (APCI): m/z 373.3  [M +  H]+: Found 
(calcd. for C26H32N2): C 83.62% (83.82) H 8.85 (8.66). 
4-((1-(3-methylbut-2-enyl)-5-m-tolyl-1H-indol-3-yl)methyl)morpholine (6-
6). The product is isolated as an amber oil. Compound 6-3 was reacted with 
morpholine as described for the synthesis of amine 4-3 (Section 3.4.4). Yield: 68 %; 
1H NMR (300 MHz, CDCl3):  7.76 (s, 1 H), 7.44-7.40 (m, 3 H), 7.34-7.30 (m, 3 H), 
7.10 (d, J = 7.5 Hz, 1 H), 5.35 (t, J = 6.6 Hz, 1 H), 4.67 (J = 6.6 Hz, 2 H), 3.93 (s, 2 
H), 2.68 (br. s, 2 H), 2.41 (s, 3 H), 1.80 (s, 3 H), 1.74 (s, 3 H), 1.71 (t, J = 8.7 Hz, 4 
H); 13C NMR (75 MHz, CDCl3) δ 142.45, 138.22, 136.60, 135.54, 133.33, 129.73, 
129.26, 128.58, 128.22, 127.17, 124.53, 121.56, 119.62, 117.27, 110.27, 110.02, 
100.61, 53.32, 44.41, 25.66, 24.69, 23.40, 21.59, 18.09. MS (APCI): m/z 375.4 [M + 














N-((1H-Indol-3-yl)methyl)-N-ethylethanamine (A-6).. Compound A-6 was 
reacted with diethylamine as described for the synthesis of amine 4-3 (Section 3.4.4). 
Yield: 64 %; 1H NMR (300 MHz, CDCl3):  1.07 (t, J = 6.0 Hz, 6 H), 2.55 (q, J = 6.0 
Hz, 4 H), 3.77 (s, 2 H), 6.95 (s, 1 H), 7.08- 7.16 (m, 2 H), 7.23 (d, J = 6.9 Hz, 1 H), 
7.67 (d, J = 7.8 Hz, 1 H);  13C NMR  (75 MHz, CDCl3) δ 11.5, 46.4, 50.0, 111.2, 
112.1, 119.0, 119.2, 121.6, 124.2, 128.1, 136.1.  
N-Ethyl-N-((1-(3-methylbut-2-enyl)-1H-indol-3-yl)methyl)ethanamine (6-
7). Amine 6-7 was prepared from indole A-6 and 1-chloro-3-methylbut-2-ene 
according to the method described for the synthesis of indole 6 (Section 3.4.4). The 
product is isolated as an amber oil. Yield: 62 %; 1H NMR (300 MHz, CDCl3):  7.69 
(d, J = 7.5 Hz, 1 H), 7.28 (d, J = 8.1 Hz, 1 H), 7.18 (t, J = 6.9 Hz, 1 H), 7.10 (d, J = 
7.2 Hz, 1 H), 7.04 (s, 1 H), 5.36 (t, J = 6.6 Hz, 1 H), 4.64 (d, J = 6.6 Hz, 2 H), 3.77 (s, 
2 H), 2.56 (q, J = 6 Hz, 4 H), 1.80 (s, 3 H), 1.74 (s, 3 H), 1.08 (t, J = 7.2 Hz, 6 H); 13C 
NMR  (75 MHz, CDCl3) δ 136.1, 135.9, 128.8, 126.8, 121.2, 120.1, 119.4, 118.8, 
111.6, 109.3, 47.8, 46.5, 44.0, 40.9, 25.6, 18.0, 11.8; MS (APCI): m/z 271.5 [M +  
H]+.  
2-(5-Fluoro-1-(3-methylbut-2-enyl)-1H-indol-3-yl)acetamide (6-8). Amide 
6-8 was prepared from indole A-6 and 1-chloro-3-methylbut-2-ene according to the 
method described for the synthesis of indole 6 (Section 3.4.4). The product is isolated 
as an amber oil. Yield: 67 %; 1H NMR (300 MHz, CDCl3):  7.26-7.23 (m, 2 H), 7.19 
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(s, 1 H), 6.98 (t, J = 9Hz, 1 H), 5.72 (br s, 2 H), 5.36 (t, J = 6 Hz, 1 H), 4.65 (d, J = 
6.6 Hz, 2 H), 3.65 (s, 2 H), 1.82 (s, 3 H), (1.79 s, 3 H); 13C NMR  (75 MHz, CDCl3) δ 
174.16, 137.04, 133.04, 128.29, 119.27, 110.62, 110.45, 110.27, 107.54, 103.86, 













5-Fluoro-1-octyl-1H-indole (A-7). Indole A-7 was prepared from 5-fluoro-
1H-indole and 1-bromooctane according to the method described for the synthesis of 
indole 6 (Section 3.4.4). Yield: 92%; 1H NMR (300 MHz, CDCl3):   7.27-7.19 (m, 2 
H), 7.10 (d, J = 3 Hz, 1 H), 6.93 (dt, J = 8.4 Hz, J2 = 2.1 Hz), 6.41 (d, J = 2.7 Hz, 1 
H), 4.06 (t, J = 6.9 Hz, 2 H), 1.79 (t, J = 6.6 Hz, 2 H), 1.28-1.24 (m, 10 H), 0.86 (t, J = 
6 Hz, 3 H); 1H NMR (300 MHz, CDCl3):   156.1, 132.6, 129.3, 109.8, 109.4, 105.6, 
105.3, 100.7, 46.6, 31.7, 30.2, 29.1, 26.9, 22.6, 14.0. 
N-Ethyl-N-[(5-fluoro-1-octyl-1H-indol-3-yl)methyl]ethanamine (6-9). 
Amine 6-9 was reacted with diethylamine as described for the synthesis of amine 4-3 
(Section 3.4.4). The product is isolated as an amber oil. Yield: 73 %; 1H NMR (300 
MHz, CDCl3):   7.35 (dd, 1 H, J1 = 10.5 Hz, J2 = 0.9 Hz), 7.18 (dd 1 H, J1=  9 Hz, J2 
= 4.2 Hz), 7.05 (s, 1 H), 6.91 (dt, 1 H, J1 = 9Hz, J2 = 2.4 Hz), 4.03 (t, 2 H, J = 6.9 Hz), 
3.70 (s, 2 H), 2.53 (q, 4 H, J = 6.9 Hz), 1.79 (t, 2 H, J = 6.9 Hz), 1.28-1.24 (m, 10 H), 
1.07 (t, 6 H, J = 7.2 Hz), 0.86 (t, 3 H, J = 6.3 Hz). 13C NMR  (75 MHz, CDCl3) δ  
159.0, 155.9, 132.8, 128.6, 111.9, 109.7, 109.3, 104.6, 47.9,46.5, 46.4, 31.7, 30.1, 
29.1, 29.1, 26.9, 22.5, 14.0, 11.8; MS (APCI): m/z 333.0 [M +  H]+; Found (calcd. for 















5-Fluoro-1-(3-methylbut-2-enyl)-1H-indole (A-8). Indole A-8 was prepared 
from 5-fluoro-1H-indole and 1-chloro-3-methylbut-2-ene according to the method 
described for the synthesis of indole 6 (Section 3.4.4). Yield: 89%; 1H NMR (300 
MHz, CDCl3):  7.29-7.20 (m, 2 H), 7.13 (d, J = 3.3 Hz, 1 H), 6.94 (dt, J1 = 9.3 Hz, J2 
= 2.7 Hz, 1 H), 6.44 (d, J = 3.0 Hz), 5.37 (t, J = 6.6 Hz, 1 H), 4.67 (d, J = 6.6 Hz, 2 
H), 1.82 (s, 3 H), 1.77 (s, 3 H); 13C NMR  (75 MHz, CDCl3) δ 156.2, 136.5, 132.6, 
128.9, 119.6, 110.0, 109.4, 105.6, 105.3, 100.7, 44.3, 25.6, 17.9. 
N-Ethyl-N-((5-fluoro-1-(3-methylbut-2-enyl)-1H-indol-3-
yl)methyl)ethanamine (6-10). Indole A-7 was reacted with diethylamine as described 
for the synthesis of amine 4-3 (Section 3.4.4). The product is isolated as an amber oil. 
Yield: 77 %; 1H NMR (300 MHz, CDCl3):  7.34 (dd, 1 H, J1 = 9.6 Hz, J2 = 2.1 Hz), 
7.17 (d, 1 H, J = 3.6 Hz), 7.09 (s, 1 H), 6.91 (dd, 1 H, J1 = 8.7 Hz, J2 = 4.2Hz), 5.34 (t, 
1 H, J = 6.6 Hz), 4.64 (d, 2 H, J = 6.9 Hz),3.84 (s, 2 H), 2.66 (q, 4 H, J = 7.2 Hz), 
1.81 (s, 3 H), 1.76 (s, 3 H), 1.16 (t, 6 H, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) δ 
159.1, 156.0, 136.3, 132.8, 128.4, 119.7, 111.6, 111.5, 110.0, 109.8, 109.7, 109.4, 




APPENDIX 3. HPLC PURITY DETERMINATION OF ALL SYNTHESIZED 
COMPOUNDS.  
Mobile Phase A Mobile Phase B Comp 
Compositiona RT (min)c Area (%)d Compositionb RT (min)c Area (%)d 
1-1 A1 5.3 98.5 B1 3.7 98.1 
1-2 A1 5.0 96.8 B1 3.7 96.5 
1-3 A1 5.4 96.5 B1 3.8 95.4 
1-4 A1 4.2 96.1 B1 3.1 95.5 
1-5 A1 4.9 95.5 B1 3.5 96.9 
1-6 A1 4.7 96.2 B1 3.3 96.3 
1-7 A1 2.9 95.4 B1 2.5 97.2 
1-8 A2 2.0 93.5 B2 2.1 93.3 
2-1 A1 1.8 97.7 B1 1.6 99.6 
2-2 A1 2.5 95.4 B1 2.1 95.4 
2-3 A1 2.8 98.0 B1 2.2 98.1 
2-4 A1 5.0 98.1 B1 3.4 98.4 
3-1 A1 16.0 98.8 B1 13.5 98.4 
3-2 Combustion Analysise Combustion Analysise 
3-3 A1 7.4 97.4 B1 5.4 95.7 
3-4 A1 9.9 96.7 B1 7.1 97.5 
3-5 A1 9.0 98.2 B1 6.3 97.6 
3-6 A1 10.8 95.4 B1 7.8 96.7 
3-7 A2 3.5 92.1 B2 4.0 92.8 
4-1 A3 1.9 96.9 B3 1.5 97.8 
4-2 A4 10.9 98.0 B2 14.9 98.1 
4-3 A3 2.1 98.3 B3 1.8 98.1 
4-4 A4 7.0 97.0 B2 9.8 96.9 
4-5 A4 8.1 97.3 B2 10.3 96.8 
4-6 Combustion Analysise Combustion Analysise 
4-7 A4 8.2 96.4 B2 10.0 95.5 
4-8 A4 6.1 97.2 B2 8.8 96.7 
4-9 A4 7.8 96.2 B2 10.7 95.2 
4-10 A4 6.8 93.5 B2 9.8 92.0 
5-1 A5 3.6 99.0 B6 3.4 99.0 
5-2 A1 6.0 97.5 B1 4.1 96.9 
5-3 A1 11.5 96.5 B1 7.6 97.0 
5-4 A1 13.8 98.1 B1 9.3 97.5 
5-5 A1 5.9 97.6 B1 4.2 980 
5-6 A4 2.7 98.3 B4 4.0 99.0 
6-1 A4 7.3 97.0 B2 9.9 96.6 
6-2 A4 8.0 95.4 B2 10.5 95.9 
6-3 A4 3.7 96.0 B5 5.8 95.3 
6-4 Combustion Analysise Combustion Analysise 
6-5 Combustion Analysise Combustion Analysise 
6-6 Combustion Analysise Combustion Analysise 
6-7 Combustion Analysise Combustion Analysise 
6-8 A2 1.8 93.2 B2 2.0 93.0 
6-9 Combustion Analysise Combustion Analysise 
6-10 A4 2.2 92.8 B2 3.4 93.2 
6-11 A1 7.0 95.6 B1 5.3 96.4 




a Composition of Mobile Phase A: Methanol and Water 
A1: 90% methanol 
A2: 95% methanol + 0.1% triethylamine (TEA) 
A3: 90% methanol + 0.1% TEA 
A4: 92% methanol + 0.1% TEA 
A5: 100 % methanol 
 
b Composition of Mobile Phase B: Acetonitrile and Water 
B1: 90% acetonitrile 
B2: 95% acetonitrile + 0.1% triethylamine (TEA) 
B3: 90% acetonitrile + 0.1% TEA 
B4: 95% acetonitrile 
B5: 92% acetonitrile + 0.1% TEA 
B6: 100% acetonitrile 
 
c Retention time of Major Peak in chromatogram. Chromatogram was run for at least 
15 min for the detection of the major peak 
 
d Area (%) of Major Peak = [Area of Major Peak / Total Area of All Peaks] x 100  
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Table A4-1. 2D Descriptors of Synthesized Compounds (non-protonated) 
Comp mr logP(o/w) SlogP vdw_area vdw_vol TPSA logS Weight lip_druglike lip_violation
1-1 11.774 7.190 6.271 410.237 575.378 48.02 -7.888 376.544 1 1 
1-2 11.777 7.151 6.271 410.237 575.378 48.02 -7.888 376.544 1 1 
1-3 11.774 7.153 6.271 410.237 575.378 48.02 -7.888 376.544 1 1 
1-4 11.991 6.848 5.972 425.240 586.040 57.25 -7.464 392.543 1 1 
1-5 12.451 7.189 6.362 442.472 610.469 57.25 -7.791 406.570 1 1 
1-6 11.333 6.855 5.963 393.004 550.949 48.02 -7.414 362.517 1 1 
1-7 8.847 4.858 4.296 322.506 435.975 48.02 -4.987 286.419 1 0 
1-8 8.927 5.048 4.435 326.915 439.118 48.02 -5.282 304.409 1 0 
2-1 8.055 3.635 3.171 262.333 378.329 58.88 -4.889 264.328 1 0 
2-2 11.605 6.785 6.289 390.570 553.204 48.02 -7.607 422.450 1 1 
2-3 10.308 4.839 4.877 357.117 496.189 48.02 -5.940 332.447 1 0 
2-4 12.569 5.703 6.604 441.854 612.433 48.02 -7.794 400.566 1 1 
3-1 10.415 8.162 7.244 356.911 510.670 4.93 -7.574 319.492 1 1 
3-2 12.265 7.546 6.532 431.138 601.423 34.03 -7.782 390.571 1 1 
3-3 12.704 7.743 6.874 458.417 627.468 25.24 -7.676 404.598 1 1 
3-4 13.640 8.425 7.654 492.881 676.327 25.24 -8.330 432.652 1 1 
3-5 13.445 8.275 7.408 464.258 662.431 25.24 -8.228 430.636 1 1 
3-6 13.909 8.717 7.799 481.490 686.860 25.24 -8.430 444.663 1 1 
3-7 14.207 7.268 6.560 509.275 704.763 28.48 -7.723 459.678 1 1 
4-1 11.171 7.415 6.969 388.211 549.770 30.95 -7.239 348.534 1 1 
4-2 12.087 8.208 7.572 436.392 601.860 8.17 -7.446 376.588 1 1 
4-3 13.021 8.890 8.352 470.856 650.719 8.17 -8.100 404.642 1 1 
4-4 13.881 9.814 9.129 505.320 699.577 8.17 -8.754 432.696 1 1 
4-5 13.945 10.118 9.132 505.320 699.577 8.17 -8.504 432.696 1 1 
4-6 12.984 9.011 8.350 470.856 650.719 8.17 -8.100 404.642 1 1 
4-7 12.827 8.740 8.106 442.232 636.823 8.17 -7.998 402.626 1 1 
4-8 13.290 9.182 8.496 459.464 661.252 8.17 -8.200 416.653 1 1 
4-9 13.586 7.733 7.257 487.249 679.155 11.41 -7.492 431.668 1 1 
4-10 13.072 7.774 7.342 457.236 647.484 17.40 -7.737 418.625 1 1 
5-1 11.311 7.102 6.343 393.004 550.949 48.02 -7.826 362.517 1 1 
5-2 12.238 7.278 6.661 427.469 599.808 48.02 -7.770 390.571 1 1 
5-3 12.151 8.188 6.959 428.404 595.798 31.23 -8.017 391.555 1 1 
5-4 12.609 8.529 7.349 445.636 620.227 31.23 -8.345 405.582 1 1 
5-5 12.256 7.584 7.146 431.138 601.423 34.03 -7.728 390.571 1 1 
5-6 12.667 7.388 6.559 451.113 614.467 51.10 -7.356 426.625 1 1 
6-1 13.025 8.851 8.352 470.856 650.719 8.17 -8.100 404.642 1 1 
6-2 13.021 8.853 8.352 470.856 650.719 8.17 -8.100 404.642 1 1 
6-3 8.957 5.811 5.849 303.791 431.481 4.93 -5.626 275.395 1 1 
6-4 11.567 6.539 6.958 417.736 571.529 8.17 -6.152 360.545 1 1 
6-5 11.834 6.831 7.102 406.345 582.063 8.17 -6.252 372.556 1 1 
6-6 11.611 5.423 5.948 404.116 568.295 17.40 -5.789 374.528 1 1 
6-7 8.646 4.207 4.982 330.006 432.126 8.17 -3.252 270.420 1 0 
6-8 7.452 2.697 3.041 273.796 359.928 48.02 -3.334 260.312 1 0 
6-9 10.183 6.748 6.516 387.535 514.458 8.17 -5.495 332.507 1 1 
6-10 8.725 4.397 5.121 334.415 435.269 8.17 -3.547 288.410 1 1 
6-11 13.862 8.083 7.355 507.885 686.988 34.47 -7.907 448.651 1 1 
6-12 14.321 8.424 7.745 525.117 711.417 34.47 -8.234 462.678 1 1 
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Table A4-1 (cont’d) 
 
Comp b_count b_rotN b_1rotN b_rotR b_1rotR a_acc A_don a_base vsa_acc vsa_don vsa_hyd vsa_pol
1-1 62 10 10 0.333 0.333 1 1 0 13.567 17.742 338.477 31.309
1-2 62 10 10 0.333 0.333 1 1 0 13.567 17.742 338.477 31.309
1-3 62 10 10 0.333 0.333 1 1 0 13.567 17.742 338.477 31.309
1-4 63 11 11 0.355 0.355 2 1 0 16.071 17.742 350.977 33.813
1-5 66 12 12 0.375 0.375 2 1 0 16.071 17.742 366.786 33.813
1-6 59 10 10 0.345 0.345 1 1 0 13.567 17.742 322.669 31.309
1-7 48 9 9 0.409 0.409 1 1 0 13.567 17.742 255.018 31.309
1-8 48 9 9 0.391 0.391 1 1 0 13.567 17.742 260.139 31.309
2-1 38 3 3 0.136 0.136 1 2 0 13.567 23.425 193.918 36.992
2-2 55 6 5 0.176 0.147 1 1 0 13.567 17.742 326.640 31.309
2-3 51 5 5 0.185 0.185 1 1 0 13.567 17.742 291.052 31.309
2-4 64 8 8 0.250 0.250 1 1 0 13.567 17.742 370.094 31.309
3-1 55 8 8 0.308 0.308 0 0 0 0.000 0.000 336.269 0.000
3-2 65 11 10 0.355 0.323 1 1 0 13.567 5.683 372.377 19.249
3-3 68 11 11 0.344 0.344 1 0 0 13.567 0.000 406.276 13.567
3-4 74 13 13 0.382 0.382 1 0 0 13.567 0.000 437.893 13.567
3-5 73 11 11 0.314 0.314 1 0 0 13.567 0.000 410.693 13.567
3-6 76 11 11 0.306 0.306 1 0 0 13.567 0.000 426.502 13.567
3-7 78 11 11 0.297 0.297 2 0 0 13.567 0.000 453.575 13.567
4-1 60 9 9 0.321 0.321 1 1 0 0.000 0.000 342.968 17.742
4-2 66 10 10 0.333 0.333 1 0 0 0.000 0.000 410.767 0.000
4-3 72 12 12 0.375 0.375 1 0 0 0.000 0.000 442.384 0.000
4-4 78 12 12 0.353 0.353 1 0 0 0.000 0.000 474.001 0.000
4-5 78 14 14 0.412 0.412 1 0 0 0.000 0.000 474.001 0.000
4-6 72 11 11 0.344 0.344 1 0 0 0.000 0.000 442.384 0.000
4-7 71 10 10 0.303 0.303 1 0 0 0.000 0.000 415.184 0.000
4-8 74 10 10 0.294 0.294 1 0 0 0.000 0.000 430.993 0.000
4-9 76 10 10 0.286 0.286 2 0 0 0.000 0.000 458.066 0.000
4-10 72 10 10 0.294 0.294 2 0 0 2.504 0.000 427.684 2.504
5-1 59 9 9 0.310 0.310 1 1 0 13.567 17.742 322.669 31.309
5-2 65 11 11 0.355 0.355 1 1 0 13.567 17.742 354.286 31.309
5-3 64 11 10 0.355 0.323 1 0 0 13.567 0.000 374.136 13.567
5-4 67 12 11 0.375 0.344 1 0 0 13.567 0.000 389.944 13.567
5-5 65 11 10 0.355 0.323 1 1 0 13.567 5.683 372.377 19.249
5-6 66 11 11 0.344 0.344 2 1 0 32.017 8.075 374.353 40.092
6-1 72 12 12 0.375 0.375 1 0 0 0.000 0.000 442.384 0.000
6-2 72 12 12 0.375 0.375 1 0 0 0.000 0.000 442.384 0.000
6-3 44 3 3 0.130 0.130 0 0 0 0.000 0.000 288.843 0.000
6-4 61 7 7 0.241 0.241 1 0 0 0.000 0.000 394.959 0.000
6-5 63 5 5 0.161 0.161 1 0 0 0.000 0.000 383.567 0.000
6-6 61 5 5 0.161 0.161 2 0 0 2.504 0.000 380.259 2.504
6-7 47 6 6 0.286 0.286 1 0 0 0.000 0.000 311.499 0.000
6-8 37 4 4 0.200 0.200 1 1 0 13.567 17.742 212.713 31.309
6-9 58 11 11 0.440 0.440 1 0 0 0.000 0.000 364.045 0.000
6-10 47 6 6 0.273 0.273 1 0 0 0.000 0.000 316.620 0.000
6-11 75 14 14 0.400 0.400 2 0 0 16.071 0.000 450.393 16.071
6-12 78 15 15 0.417 0.417 2 0 0 16.071 0.000 466.201 16.071
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Table A4-2. 3D Descriptors for Synthesized Compounds (non-protonated) 
Comp PM3_E PM3_Eele PM3_HOMO PM3_LUMO PM3_IP PM3_HF PM3_dipole VSA vol 
1-1 -93967.1 -802835 -8.401 -0.132 8.401 -27.163 5.744 466.566 413.375
1-2 -93965.3 -808437 -8.463 -0.107 8.463 -25.382 6.105 467.341 414.625
1-3 -93966.5 -796794 -8.301 -0.069 8.301 -26.600 5.614 466.244 414.875
1-4 -100727.3 -856201 -8.426 -0.150 8.426 -55.325 6.919 474.798 421.000
1-5 -104176.2 -899924 -8.403 -0.122 8.403 -61.285 5.277 497.788 438.875
1-6 -90514.4 -753086 -8.394 -0.139 8.394 -17.570 6.007 445.458 397.750
1-7 -72709.3 -541570 -8.428 -0.036 8.428 -42.255 5.947 368.404 315.250
1-8 -82507.6 -591475 -8.618 -0.318 8.618 -77.748 7.445 370.609 315.750
2-1 -66382.5 -467564 -8.528 -0.175 8.528 14.831 4.942 303.260 269.625
2-2 -120493.0 -946854 -8.495 -0.812 8.495 -96.640 4.209 436.559 393.125
2-3 -82892.3 -673906 -8.284 -0.033 8.284 11.263 6.039 397.244 356.500
2-4 -99404.8 -878781 -8.303 -0.038 8.303 30.541 6.275 491.387 438.125
3-1 -76909.7 -610810 -8.270 0.073 8.270 24.992 2.411 411.543 364.875
3-2 -97411.9 -856358 -8.390 -0.124 8.390 -28.084 5.431 490.140 431.125
3-3 -100854.1 -915406 -8.287 -0.022 8.287 -28.180 5.107 504.560 451.000
3-4 -107751.4 -1022892 -8.227 0.045 8.227 -39.319 5.131 542.640 486.375
3-5 -107038.1 -1003048 -8.251 0.020 8.251 -33.207 5.340 526.654 475.625
3-6 -110485.6 -1072204 -8.237 0.030 8.237 -37.623 5.156 538.294 490.875
3-7 -114575.9 -1105719 -8.256 0.029 8.256 -26.657 3.212 562.900 506.375
4-1 -84455.3 -709901 -8.201 0.090 8.201 46.321 3.378 449.144 393.125
4-2 -91345.1 -813941 -8.171 0.109 8.171 17.070 2.654 486.505 431.250
4-3 -98240.9 -927323 -8.171 0.113 8.171 3.215 2.787 524.443 467.750
4-4 -105140.8 -1049912 -8.133 0.130 8.133 -10.517 2.575 560.674 501.500
4-5 -105139.7 -1035346 -8.154 0.117 8.154 -9.181 2.933 565.826 502.000
4-6 -98241.8 -925836 -8.139 0.128 8.139 2.576 2.496 521.719 465.750
4-7 -97528.7 -902286 -8.153 0.116 8.153 8.277 2.979 507.478 455.500
4-8 -100977.8 -959677 -8.161 0.115 8.161 2.252 2.725 525.390 472.500
4-9 -105067.1 -1014552 -8.168 0.105 8.168 14.353 3.547 543.130 487.000
4-10 -104292.3 -966304 -8.225 0.049 8.225 -13.196 2.971 516.625 462.750
5-1 -90517.8 -748233 -8.438 -0.195 8.438 -21.097 5.434 447.115 396.000
5-2 -97412.8 -846752 -8.273 -0.012 8.273 -29.991 4.936 483.839 429.500
5-3 -100083.7 -854378 -8.295 -0.005 8.295 -70.176 2.386 485.247 426.875
5-4 -103532.1 -904322 -8.274 0.002 8.274 -75.172 2.305 506.663 446.750
5-5 -97413.1 -839602 -8.418 -0.134 8.418 -29.794 5.081 490.718 433.250
5-6 -105733.7 -916523 -8.448 -0.288 8.448 -53.096 4.835 501.902 444.750
6-1 -98240.9 -936451 -8.183 0.180 8.183 3.271 3.173 521.365 464.750
6-2 -98243.3 -923728 -8.094 0.109 8.094 0.916 2.651 522.359 469.000
6-3 -65835.5 -497690 -8.216 0.114 8.216 55.608 2.711 341.106 309.000
6-4 -87168.8 -797941 -8.105 0.166 8.105 40.958 2.556 455.391 405.625
6-5 -89902.1 -830230 -8.119 0.162 8.119 41.590 2.935 457.985 415.625
6-6 -93217.8 -829402 -8.242 0.072 8.242 14.767 3.209 449.350 405.250
6-7 -65911.1 -528620 -8.114 0.280 8.114 23.805 2.498 355.527 311.250
6-8 -71433.4 -476757 -8.540 -0.253 8.540 -47.797 7.679 298.185 260.875
6-9 -86782.1 -703565 -8.406 -0.074 8.406 -56.118 4.369 428.180 372.500
6-10 -75710.0 -580928 -8.314 -0.001 8.314 -20.392 4.194 360.944 316.000
6-11 -114512.2 -1072357 -8.309 -0.059 8.309 -68.195 3.823 558.791 494.875
6-12 -117959.7 -1142324 -8.290 -0.025 8.290 -72.595 6.370 575.456 510.125
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Table A4-2 (cont’d) 
 
Comp E E_ele E_sol E_str E_strain E_tor E_vdw ASA_H ASA_P dipole 
1-1 43.566 -4.315 -13.525 5.896 0.011 -5.624 44.092 622.977 121.307 1.218
1-2 45.897 -4.042 -13.901 6.022 0.011 -3.030 43.289 622.756 123.193 1.276
1-3 44.157 -3.666 -15.197 5.977 0.350 -6.214 44.309 633.692 125.401 1.173
1-4 50.162 -8.041 -14.157 5.743 0.021 -4.910 47.609 610.340 161.182 1.623
1-5 50.112 -7.510 -12.690 5.898 0.024 -7.624 47.552 653.792 143.977 1.013
1-6 41.930 -3.426 -15.528 5.824 0.324 -6.157 42.195 605.441 124.591 1.238
1-7 18.116 -3.931 -14.014 3.240 0.008 -10.042 25.679 470.366 122.647 1.277
1-8 15.202 -6.547 -12.565 3.103 0.033 -10.137 25.522 471.807 123.243 1.664
2-1 43.865 -4.433 -16.053 4.805 0.006 8.142 33.133 367.345 153.500 1.127
2-2 81.016 8.487 -14.714 7.349 0.083 8.458 52.672 475.295 222.117 1.124
2-3 55.776 1.767 -15.471 5.821 0.013 1.566 41.853 506.115 141.792 1.159
2-4 64.185 5.249 -15.517 6.974 0.028 -4.570 49.594 634.276 152.122 1.140
3-1 41.546 1.098 -5.162 5.325 0.007 -8.723 41.583 652.854 24.301 0.462
3-2 43.610 -1.977 -12.804 6.083 0.029 -9.479 45.892 693.507 95.245 1.238
3-3 55.086 -1.458 -10.796 6.562 0.011 -8.452 51.707 701.565 90.740 1.255
3-4 51.845 -0.608 -10.500 7.315 0.013 -14.286 52.945 805.667 51.638 1.227
3-5 55.985 -0.307 -10.867 6.780 0.017 -9.988 49.081 771.090 64.038 1.241
3-6 52.907 -1.311 -10.440 7.284 0.033 -16.558 56.280 798.704 54.494 1.257
3-7 80.662 17.616 -10.346 7.656 2.367 -13.409 59.318 794.142 101.258 0.953
4-1 39.390 -1.847 -7.418 5.512 0.082 -9.763 43.185 647.422 87.045 0.650
4-2 51.755 0.297 -3.652 6.048 0.028 -8.590 49.688 717.162 59.866 0.589
4-3 48.823 0.314 -1.933 6.481 0.027 -16.340 52.428 782.858 30.968 0.558
4-4 54.540 0.437 -1.292 7.388 0.022 -22.646 57.565 838.761 18.205 0.505
4-5 49.930 0.610 -2.603 6.647 0.051 -22.169 53.898 848.766 22.942 0.477
4-6 53.565 0.328 -2.288 7.151 0.091 -16.321 55.920 774.548 37.202 0.556
4-7 52.768 0.295 -2.625 6.312 0.017 -9.837 49.884 774.691 35.402 0.594
4-8 47.978 0.358 -2.301 6.686 0.019 -21.133 54.723 787.231 30.944 0.549
4-9 80.389 20.128 -6.517 7.546 0.015 -14.845 58.522 777.595 67.659 0.840
4-10 74.127 17.305 -5.523 6.945 0.073 -12.696 54.870 739.395 74.161 0.698
5-1 37.102 -10.259 -12.297 6.142 0.025 -8.443 45.676 605.770 122.013 1.254
5-2 36.536 -12.880 -15.700 6.032 0.027 -8.292 46.834 668.690 114.895 1.080
5-3 49.389 1.770 -5.894 5.908 0.047 -9.321 47.205 693.361 92.840 0.490
5-4 47.459 1.969 -5.532 6.022 0.030 -12.600 47.566 752.831 65.676 0.501
5-5 33.058 -12.511 -12.776 5.705 0.048 -9.612 46.556 715.633 77.608 1.189
5-6 16.267 -30.746 -13.208 5.743 0.021 -5.577 43.572 703.050 114.033 1.140
6-1 50.019 0.340 -2.500 6.546 0.071 -17.963 52.229 771.363 27.058 0.598
6-2 48.069 0.256 -2.582 6.389 0.128 -19.611 52.913 785.700 28.148 0.533
6-3 53.119 6.316 -6.588 5.168 0.017 -1.073 39.286 538.742 39.287 0.480
6-4 58.956 5.602 -2.959 6.501 0.011 -10.965 50.780 658.618 41.381 0.567
6-5 56.191 5.473 -2.443 6.454 0.014 -14.184 52.142 681.750 42.498 0.567
6-6 81.967 22.145 -2.984 6.770 0.024 -6.153 52.690 628.508 85.162 0.637
6-7 33.824 6.625 -5.723 3.884 0.009 -15.791 32.401 517.812 42.234 0.583
6-8 27.045 -0.683 -14.730 2.922 0.042 -2.930 23.255 358.993 138.971 1.612
6-9 20.393 -1.816 -2.702 3.805 0.021 -21.622 34.158 645.261 28.621 0.999
6-10 30.571 3.421 -3.423 3.761 0.009 -15.769 32.439 526.147 43.929 0.996
6-11 59.690 -3.336 -12.851 6.962 1.104 -12.841 56.279 769.096 96.012 1.143
6-12 55.742 -4.803 -9.833 7.017 0.019 -16.046 56.763 829.927 64.147 1.628
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Table A4-3. 2D Descriptors of Synthesized Compounds (protonated) 
Comp mr logP(o/w) SlogP vdw_area vdw_vol TPSA logS Weight lip_druglike lip_violation
1-1 11.774 7.190 6.271 410.237 575.378 48.02 -7.888 376.544 1 1 
1-2 11.777 7.151 6.271 410.237 575.378 48.02 -7.888 376.544 1 1 
1-3 11.774 7.153 6.271 410.237 575.378 48.02 -7.888 376.544 1 1 
1-4 11.991 6.848 5.972 425.240 586.040 57.25 -7.464 392.543 1 1 
1-5 12.451 7.189 6.362 442.472 610.469 57.25 -7.791 406.570 1 1 
1-6 11.333 6.855 5.963 393.004 550.949 48.02 -7.414 362.517 1 1 
1-7 8.847 4.858 4.296 322.506 435.975 48.02 -4.987 286.419 1 0 
1-8 8.927 5.048 4.435 326.915 439.118 48.02 -5.282 304.409 1 0 
2-1 8.055 3.635 3.171 262.333 378.329 58.88 -4.889 264.328 1 0 
2-2 11.605 6.785 6.289 390.570 553.204 48.02 -7.607 422.450 1 1 
2-3 10.308 4.839 4.877 357.117 496.189 48.02 -5.940 332.447 1 0 
2-4 12.569 5.703 6.604 441.854 612.433 48.02 -7.794 400.566 1 1 
3-1 10.415 8.162 7.244 356.911 510.670 4.93 -7.574 319.492 1 1 
3-2 12.265 7.546 6.532 431.138 601.423 34.03 -7.782 390.571 1 1 
3-3 12.704 7.743 6.874 458.417 627.468 25.24 -7.676 404.598 1 1 
3-4 13.640 8.425 7.654 492.881 676.327 25.24 -8.330 432.652 1 1 
3-5 13.445 8.275 7.408 464.258 662.431 25.24 -8.228 430.636 1 1 
3-6 13.909 8.717 7.799 481.490 686.860 25.24 -8.430 444.663 1 1 
3-7 14.245 7.268 5.143 517.894 708.647 29.68 -7.698 460.686 1 1 
4-1 11.217 7.415 6.252 391.284 553.655 32.57 -7.215 349.542 1 1 
4-2 12.124 8.208 6.155 445.011 605.745 9.37 -7.421 377.596 1 1 
4-3 13.059 8.890 6.935 479.475 654.603 9.37 -8.076 405.650 1 1 
4-4 13.920 9.814 7.712 513.939 703.461 9.37 -8.730 433.704 1 1 
4-5 13.983 10.118 7.715 513.939 703.461 9.37 -8.479 433.704 1 1 
4-6 13.022 9.011 6.933 479.475 654.603 9.37 -8.076 405.650 1 1 
4-7 12.866 8.740 6.689 450.851 640.707 9.37 -7.974 403.634 1 1 
4-8 13.328 9.182 7.079 468.083 665.136 9.37 -8.175 417.661 1 1 
4-9 13.663 7.733 4.423 504.487 686.923 13.81 -7.444 433.684 1 0 
4-10 13.111 7.774 5.925 465.855 651.368 18.60 -7.713 419.633 1 1 
5-1 11.311 7.102 6.343 393.004 550.949 48.02 -7.826 362.517 1 1 
5-2 12.238 7.278 6.661 427.469 599.808 48.02 -7.770 390.571 1 1 
5-3 12.151 8.188 6.959 428.404 595.798 31.23 -8.017 391.555 1 1 
5-4 12.609 8.529 7.349 445.636 620.227 31.23 -8.345 405.582 1 1 
5-5 12.256 7.584 7.146 431.138 601.423 34.03 -7.728 390.571 1 1 
5-6 12.667 7.388 6.559 451.113 614.467 51.10 -7.356 426.625 1 1 
6-1 13.063 8.851 6.935 479.475 654.603 9.37 -8.076 405.650 1 1 
6-2 13.059 8.853 6.935 479.475 654.603 9.37 -8.076 405.650 1 1 
6-3 8.957 5.811 5.849 303.791 431.481 4.93 -5.626 275.395 1 1 
6-4 11.606 6.539 5.540 426.355 575.414 9.37 -6.128 361.553 1 1 
6-5 11.874 6.831 5.685 414.964 585.947 9.37 -6.227 373.564 1 1 
6-6 11.652 5.423 4.531 412.735 572.179 18.60 -5.765 375.536 1 0 
6-7 8.685 4.207 3.565 338.625 436.011 9.37 -3.227 271.428 1 0 
6-8 7.452 2.697 3.041 273.796 359.928 48.02 -3.334 260.312 1 0 
6-9 10.221 6.748 5.098 396.154 518.342 9.37 -5.470 333.515 1 1 
6-10 8.765 4.397 3.704 343.034 439.153 9.37 -3.522 289.418 1 0 
6-11 13.862 8.083 7.355 507.885 686.988 34.47 -7.907 448.651 1 1 
6-12 14.321 8.424 7.745 525.117 711.417 34.47 -8.234 462.678 1 1 
APPENDICES 
 186
Table A4-3 (cont’d) 
 
Comp b_count b_rotN b_1rotN b_rotR b_1rotR a_acc a_don a_base vsa_acc vsa_don vsa_hyd vsa_pol
1-1 62 10 10 0.333 0.333 1 1 0 13.567 17.742 338.477 31.309
1-2 62 10 10 0.333 0.333 1 1 0 13.567 17.742 338.477 31.309
1-3 62 10 10 0.333 0.333 1 1 0 13.567 17.742 338.477 31.309
1-4 63 11 11 0.355 0.355 2 1 0 16.071 17.742 350.977 33.813
1-5 66 12 12 0.375 0.375 2 1 0 16.071 17.742 366.786 33.813
1-6 59 10 10 0.345 0.345 1 1 0 13.567 17.742 322.669 31.309
1-7 48 9 9 0.409 0.409 1 1 0 13.567 17.742 255.018 31.309
1-8 48 9 9 0.391 0.391 1 1 0 13.567 17.742 260.139 31.309
2-1 38 3 3 0.136 0.136 1 2 0 13.567 23.425 193.918 36.992
2-2 55 6 5 0.176 0.147 1 1 0 13.567 17.742 326.640 31.309
2-3 51 5 5 0.185 0.185 1 1 0 13.567 17.742 291.052 31.309
2-4 64 8 8 0.250 0.250 1 1 0 13.567 17.742 370.094 31.309
3-1 55 8 8 0.308 0.308 0 0 0 0.000 0.000 336.269 0.000
3-2 65 11 10 0.355 0.323 1 1 0 13.567 5.683 372.377 19.249
3-3 68 11 11 0.344 0.344 1 0 0 13.567 0.000 406.276 13.567
3-4 74 13 13 0.382 0.382 1 0 0 13.567 0.000 437.893 13.567
3-5 73 11 11 0.314 0.314 1 0 0 13.567 0.000 410.693 13.567
3-6 76 11 11 0.306 0.306 1 0 0 13.567 0.000 426.502 13.567
3-7 79 11 11 0.297 0.297 1 0 1 13.567 0.000 453.575 13.567
4-1 61 9 9 0.321 0.321 0 0 1 0.000 17.742 342.968 17.742
4-2 67 10 10 0.333 0.333 0 0 1 0.000 0.000 410.767 0.000
4-3 73 12 12 0.375 0.375 0 0 1 0.000 0.000 442.384 0.000
4-4 79 12 12 0.353 0.353 0 0 1 0.000 0.000 474.001 0.000
4-5 79 14 14 0.412 0.412 0 0 1 0.000 0.000 474.001 0.000
4-6 73 11 11 0.344 0.344 0 0 1 0.000 0.000 442.384 0.000
4-7 72 10 10 0.303 0.303 0 0 1 0.000 0.000 415.184 0.000
4-8 75 10 10 0.294 0.294 0 0 1 0.000 0.000 430.993 0.000
4-9 78 10 10 0.286 0.286 0 0 2 0.000 0.000 458.066 0.000
4-10 73 10 10 0.294 0.294 1 0 1 2.504 0.000 427.684 2.504
5-1 59 9 9 0.310 0.310 1 1 0 13.567 17.742 322.669 31.309
5-2 65 11 11 0.355 0.355 1 1 0 13.567 17.742 354.286 31.309
5-3 64 11 10 0.355 0.323 1 0 0 13.567 0.000 374.136 13.567
5-4 67 12 11 0.375 0.344 1 0 0 13.567 0.000 389.944 13.567
5-5 65 11 10 0.355 0.323 1 1 0 13.567 5.683 372.377 19.249
5-6 66 11 11 0.344 0.344 2 1 0 32.017 8.075 374.353 40.092
6-1 73 12 12 0.375 0.375 0 0 1 0.000 0.000 442.384 0.000
6-2 73 12 12 0.375 0.375 0 0 1 0.000 0.000 442.384 0.000
6-3 44 3 3 0.130 0.130 0 0 0 0.000 0.000 288.843 0.000
6-4 62 7 7 0.241 0.241 0 0 1 0.000 0.000 394.959 0.000
6-5 64 5 5 0.161 0.161 0 0 1 0.000 0.000 383.567 0.000
6-6 62 5 5 0.161 0.161 1 0 1 2.504 0.000 380.259 2.504
6-7 48 6 6 0.286 0.286 0 0 1 0.000 0.000 311.499 0.000
6-8 37 4 4 0.200 0.200 1 1 0 13.567 17.742 212.713 31.309
6-9 59 11 11 0.440 0.440 0 0 1 0.000 0.000 364.045 0.000
6-10 48 6 6 0.273 0.273 0 0 1 0.000 0.000 316.620 0.000
6-11 75 14 14 0.400 0.400 2 0 0 16.071 0.000 450.393 16.071
6-12 78 15 15 0.417 0.417 2 0 0 16.071 0.000 466.201 16.071
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Table A4-4. 3D Descriptors for Synthesized Compounds (protonated) 
Comp PM3_E PM3_Eele PM3_HOMO PM3_LUMO PM3_IP PM3_HF PM3_dipole VSA vol 
1-1 -93967.0 -802952 -8.383 -0.112 8.383 -27.139 5.706 467.784 414.250
1-2 -93965.3 -809218 -8.459 -0.099 8.459 -25.399 6.080 467.473 414.625
1-3 -93966.7 -797032 -8.339 -0.108 8.339 -26.601 5.690 465.154 413.125
1-4 -100727.4 -856963 -8.453 -0.185 8.453 -55.571 6.938 474.798 421.125
1-5 -104176.3 -900474 -8.418 -0.137 8.418 -61.325 5.297 497.479 438.875
1-6 -90514.4 -753086 -8.394 -0.139 8.394 -17.570 6.007 445.458 397.750
1-7 -72709.3 -541570 -8.428 -0.036 8.428 -42.255 5.947 368.404 315.250
1-8 -82507.6 -591475 -8.618 -0.318 8.618 -77.748 7.445 370.609 315.750
2-1 -66382.6 -467374 -8.541 -0.197 8.541 12.720 4.922 302.951 269.875
2-2 -120493.1 -946202 -8.577 -0.847 8.577 -117.771 3.397 436.704 396.625
2-3 -82892.1 -674633 -8.336 -0.078 8.336 11.441 6.234 397.760 356.500
2-4 -99404.8 -878781 -8.303 -0.038 8.303 30.541 6.275 491.387 438.125
3-1 -76909.7 -610810 -8.270 0.073 8.270 24.992 2.411 411.543 364.875
3-2 -97411.9 -856495 -8.390 -0.124 8.390 -28.087 5.429 490.929 429.125
3-3 -100854.1 -915406 -8.287 -0.022 8.287 -28.180 5.107 504.560 451.000
3-4 -107751.4 -1022892 -8.227 0.045 8.227 -39.319 5.131 542.640 486.375
3-5 -107038.1 -1003048 -8.251 0.020 8.251 -33.207 5.340 526.654 475.625
3-6 -110485.6 -1072204 -8.237 0.030 8.237 -37.623 5.156 538.294 490.875
3-7 -114771.2 -1133621 -10.288 -4.370 10.288 131.647 24.005 564.800 506.500
4-1 -84667.0 -719196 -11.322 -4.124 11.322 158.449 16.379 450.894 396.625
4-2 -91552.4 -823764 -11.246 -3.926 11.246 159.216 15.378 490.838 438.000
4-3 -98453.5 -934653 -11.202 -3.778 11.202 144.202 14.423 526.283 469.625
4-4 -105353.1 -1059673 -11.170 -3.657 11.170 130.799 13.040 562.641 506.000
4-5 -105350.3 -1047212 -11.199 -3.693 11.199 133.632 13.193 568.909 506.125
4-6 -98453.1 -934408 -11.224 -3.793 11.224 144.614 14.461 522.404 471.750
4-7 -97738.1 -913427 -11.200 -3.739 11.200 152.452 14.614 512.332 461.875
4-8 -101187.0 -970802 -11.184 -3.702 11.184 146.706 13.719 529.371 477.375
4-9 -105389.1 -1034314 -13.013 -8.010 13.013 399.347 36.845 549.357 493.125
4-10 -104497.3 -976611 -11.253 -3.942 11.253 125.254 11.898 520.442 467.250
5-1 -90517.6 -747965 -8.422 -0.203 8.422 -20.964 5.605 443.873 397.500
5-2 -97412.8 -845614 -8.264 -0.011 8.264 -3.638 4.968 484.599 429.250
5-3 -100083.7 -853449 -8.284 0.001 8.284 -60.770 2.497 484.458 426.125
5-4 -103531.7 -900712 -8.277 -0.015 8.277 -74.661 2.046 506.346 448.000
5-5 -97413.1 -839488 -8.416 -0.135 8.416 -29.789 5.050 490.902 433.250
5-6 -105733.9 -919890 -8.443 -0.303 8.443 -58.097 5.116 502.294 444.125
6-1 -98450.7 -944231 -11.388 -3.781 11.388 179.831 14.534 522.424 469.875
6-2 -98453.4 -934728 -11.085 -3.775 11.085 144.366 14.290 523.619 468.250
6-3 -65835.6 -497851 -8.224 0.111 8.224 55.589 2.685 341.066 309.000
6-4 -87381.3 -806787 -11.166 -3.710 11.166 180.092 12.016 457.592 412.125
6-5 -90115.1 -839803 -11.183 -3.652 11.183 201.271 11.515 461.249 417.125
6-6 -93425.1 -838924 -11.210 -3.887 11.210 161.124 9.840 454.149 408.625
6-7 -66123.0 -537143 -11.494 -3.771 11.494 165.473 9.550 356.926 315.875
6-8 -71433.4 -476757 -8.540 -0.253 8.540 -47.797 7.679 298.185 260.875
6-9 -86992.1 -708446 -11.769 -3.934 11.769 87.494 14.542 434.137 375.625
6-10 -75920.0 -588872 -11.679 -3.859 11.679 125.574 10.238 360.883 318.000
6-11 -114511.5 -1068743 -8.285 -0.019 8.285 -67.531 3.870 558.753 494.875
6-12 -117959.7 -1142324 -8.290 -0.025 8.290 -72.595 6.370 575.456 510.125
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Table A4-4 (cont’d) 
 
Comp E E_ele E_sol E_str E_strain E_tor E_vdw ASA_H ASA_P dipole 
1-1 43.567 -4.281 -13.432 5.975 0.012 -5.616 43.976 624.497 122.644 1.215
1-2 45.896 -4.044 -13.906 6.018 0.010 -3.031 43.294 622.653 123.193 1.276
1-3 44.127 -3.690 -15.306 5.941 0.320 -5.999 44.258 628.010 124.202 1.189
1-4 50.162 -8.041 -14.157 5.742 0.021 -4.909 47.617 610.340 161.182 1.623
1-5 50.110 -7.506 -12.702 5.885 0.022 -7.617 47.548 653.593 144.289 1.013
1-6 41.930 -3.426 -15.528 5.824 0.324 -6.157 42.195 605.441 124.591 1.238
1-7 18.116 -3.931 -14.014 3.240 0.008 -10.042 25.679 470.366 122.647 1.277
1-8 15.202 -6.547 -12.565 3.103 0.033 -10.137 25.522 471.807 123.243 1.664
2-1 43.863 -4.434 -16.016 4.858 0.005 8.141 33.076 368.081 153.443 1.128
2-2 80.941 8.088 -13.243 7.158 0.008 9.125 52.510 479.013 221.820 1.073
2-3 55.774 1.776 -15.521 5.798 0.012 1.539 41.893 506.330 141.186 1.159
2-4 64.185 5.249 -15.517 6.974 0.028 -4.570 49.594 634.276 152.122 1.140
3-1 41.546 1.098 -5.162 5.325 0.007 -8.723 41.583 652.854 24.301 0.462
3-2 43.606 -1.970 -12.886 6.070 0.025 -9.432 45.853 685.860 94.114 1.236
3-3 55.086 -1.458 -10.796 6.562 0.011 -8.452 51.707 701.565 90.740 1.255
3-4 51.845 -0.608 -10.500 7.315 0.013 -14.286 52.945 805.667 51.638 1.227
3-5 55.985 -0.307 -10.867 6.780 0.017 -9.988 49.081 771.090 64.038 1.241
3-6 52.907 -1.311 -10.440 7.284 0.033 -16.558 56.280 798.704 54.494 1.257
3-7 87.284 23.471 -74.117 8.531 0.746 -13.009 58.875 767.975 102.009 6.096
4-1 35.414 -6.906 -67.250 5.403 0.014 -8.411 42.916 642.116 94.387 4.387
4-2 44.536 -5.648 -54.115 6.180 0.014 -8.445 48.230 710.013 68.247 4.195
4-3 45.366 -5.754 -51.548 6.787 0.030 -11.844 50.974 788.044 33.703 3.936
4-4 56.223 -5.782 -50.293 8.039 0.011 -12.409 56.095 836.266 19.137 3.421
4-5 46.713 -5.976 -51.543 6.921 0.014 -17.045 53.022 855.194 27.008 3.440
4-6 51.277 -5.812 -51.291 7.384 0.014 -10.276 54.030 770.896 40.602 3.825
4-7 45.864 -5.728 -51.799 6.374 0.017 -9.022 47.741 776.036 37.203 3.903
4-8 43.351 -5.760 -51.154 6.652 0.013 -16.491 52.649 785.835 38.396 3.630
4-9 108.923 49.221 -198.431 8.590 0.025 -12.449 54.296 764.379 83.369 9.272
4-10 73.540 17.541 -57.783 7.091 0.030 -10.927 52.956 735.537 82.540 3.265
5-1 37.089 -10.248 -12.428 6.113 0.012 -8.469 45.688 599.832 122.635 1.252
5-2 36.537 -12.884 -15.701 6.042 0.027 -8.299 46.835 668.778 114.895 1.079
5-3 49.354 1.795 -5.985 5.954 0.012 -9.448 47.178 693.921 91.897 0.498
5-4 47.080 1.867 -5.869 6.013 0.021 -12.217 47.532 756.173 64.303 0.486
5-5 33.058 -12.511 -12.775 5.706 0.048 -9.613 46.558 715.633 77.608 1.189
5-6 16.280 -30.701 -13.417 5.817 0.034 -5.686 43.593 707.643 113.606 1.142
6-1 47.372 -5.447 -53.227 6.961 0.014 -12.189 50.571 776.521 33.706 3.861
6-2 45.452 -5.122 -54.968 6.442 0.008 -13.144 50.613 790.898 31.882 3.829
6-3 53.118 6.316 -6.587 5.156 0.017 -1.073 39.290 538.468 39.287 0.480
6-4 56.060 -0.522 -51.958 6.637 0.018 -5.388 49.084 668.614 43.798 3.485
6-5 52.843 -0.668 -50.428 6.473 0.012 -9.015 50.203 674.083 45.256 3.313
6-6 82.852 22.273 -53.680 6.886 0.012 -2.823 50.182 622.059 89.335 2.636
6-7 31.001 0.478 -58.153 4.060 0.008 -10.246 30.690 521.912 44.557 3.025
6-8 27.045 -0.683 -14.730 2.922 0.042 -2.930 23.255 358.993 138.971 1.612
6-9 18.143 -6.653 -59.132 4.174 0.014 -17.230 32.734 638.146 31.875 3.950
6-10 28.849 -1.593 -58.322 4.027 0.008 -10.239 30.577 528.260 44.245 3.136
6-11 59.690 -3.336 -12.847 6.965 1.104 -12.842 56.281 769.096 96.012 1.143
6-12 55.742 -4.803 -9.833 7.017 0.019 -16.046 56.763 829.927 64.147 1.628
  
Table A4-5. Spearman Rho Correlation Coefficient of Descriptors employed in developing Equations 5-2 and 5-4 (non-protonated 
compounds) 
  ICMT b_1rotN b_1rotR b_count b_rotN b_rotR weight lip_ violation E E_ele E_sol E_str E_strain E_tor 
Correlation Coefficient .601** 1.000                         
b_1rotN 
Sig. (2-tailed) 0.000 .                         
Correlation Coefficient .387** .801** 1.000                       
b_1rotR 
Sig. (2-tailed) 0.007 0.000 .                       
Correlation Coefficient .672** .812** .394** 1.000                     
b_count 
Sig. (2-tailed) 0.000 0.000 0.006 .                     
Correlation Coefficient .528** .979** .790** .794** 1.000                   
b_rotN 
Sig. (2-tailed) 0.000 0.000 0.000 0.000 .                   
Correlation Coefficient .307* .778** .972** .387** .813** 1.000                 
b_rotR 
Sig. (2-tailed) 0.036 0.000 0.000 0.007 0.000 .                 
Correlation Coefficient .580** .767** .337* .926** .758** .338* 1.000               
weight 
Sig. (2-tailed) 0.000 0.000 0.020 0.000 0.000 0.020 .               
Correlation Coefficient .432** .460** 0.148 .544** .465** 0.148 .550** 1.000             
lip_violation 
Sig. (2-tailed) 0.002 0.001 0.320 0.000 0.001 0.320 0.000 .             
Correlation Coefficient 0.238 0.103 -.303* .475** 0.072 -.327* .533** .348* 1.000           
E 
Sig. (2-tailed) 0.106 0.489 0.038 0.001 0.631 0.025 0.000 0.017 .           
Correlation Coefficient -0.171 -.299* -.545** 0.069 -.294* -.520** 0.070 0.089 .582** 1.000         
E_ele 
Sig. (2-tailed) 0.251 0.041 0.000 0.646 0.045 0.000 0.640 0.551 0.000 .         
Correlation Coefficient 0.222 0.239 0.071 .393** 0.228 0.072 0.215 .343* 0.201 .503** 1.000       
E_sol 
Sig. (2-tailed) 0.134 0.105 0.634 0.006 0.124 0.632 0.146 0.018 0.175 0.000 .       
Correlation Coefficient .503** .449** 0.001 .788** .421** -0.023 .818** .522** .793** .377** .296* 1.000     
E_str 
Sig. (2-tailed) 0.000 0.002 0.997 0.000 0.003 0.880 0.000 0.000 0.000 0.009 0.043 .     
Correlation Coefficient 0.269 .318* 0.225 .312* .357* 0.264 .366* 0.273 0.115 -0.004 0.003 0.276 1.000   
E_strain 
Sig. (2-tailed) 0.067 0.030 0.129 0.033 0.014 0.073 0.011 0.064 0.442 0.978 0.986 0.061 .   
Correlation Coefficient -.332* -.541** -.407** -.588** -.525** -.416** -.419** -0.207 -0.046 -0.230 -.755** -.365* -0.127 1.000 E_tor 








Table A4-5 (cont’d) 
 
  ICMT b_1rotN b_1rotR b_count b_rotN b_rotR weight lip_ violation E E_ele E_sol E_str E_strain E_tor 
Correlation Coefficient .554** .565** 0.115 .873** .539** 0.098 .859** .555** .748** .336* .443** .936** .328* -.498** 
E_vdw 
Sig. (2-tailed) 0.000 0.000 0.441 0.000 0.000 0.514 0.000 0.000 0.000 0.021 0.002 0.000 0.024 0.000 
Correlation Coefficient -.545** -.733** -.413** -.801** -.754** -.434** -.770** -.545** -0.287 0.060 -.288* -.647** -.307* .431** 
logS 
Sig. (2-tailed) 0.000 0.000 0.004 0.000 0.000 0.002 0.000 0.000 0.050 0.689 0.050 0.000 0.036 0.002 
Correlation Coefficient .654** .791** .353* .989** .777** .352* .951** .555** .519** 0.087 .336* .817** .325* -.529** 
mr 
Sig. (2-tailed) 0.000 0.000 0.015 0.000 0.000 0.015 0.000 0.000 0.000 0.563 0.021 0.000 0.026 0.000 
Correlation Coefficient -0.047 0.004 0.178 -0.161 -0.017 0.154 -0.062 -0.287 -0.189 -.622** -.716** -0.142 -0.069 .364* 
dipole 
Sig. (2-tailed) 0.752 0.978 0.231 0.281 0.908 0.300 0.680 0.051 0.202 0.000 0.000 0.343 0.644 0.012 
Correlation Coefficient 0.270 .351* 0.164 .408** .315* 0.138 .499** 0.134 .347* -0.074 -0.099 .336* 0.202 -0.046 
a_acc 
Sig. (2-tailed) 0.066 0.016 0.270 0.004 0.031 0.356 0.000 0.370 0.017 0.621 0.507 0.021 0.173 0.758 
Correlation Coefficient -0.149 -.327* -0.042 -.512** -.303* -0.042 -.383** -.371* -.436** -.610** -.819** -.463** 0.030 .699** 
a_don 
Sig. (2-tailed) 0.316 0.025 0.778 0.000 0.038 0.778 0.008 0.010 0.002 0.000 0.000 0.001 0.844 0.000 
Correlation Coefficient -0.108 0.183 0.219 0.003 0.216 0.245 0.206 -0.118 -0.054 -.581** -.777** -0.048 0.104 .501** 
vsa_acc 
Sig. (2-tailed) 0.471 0.218 0.138 0.985 0.145 0.096 0.165 0.430 0.721 0.000 0.000 0.748 0.487 0.000 
Correlation Coefficient -0.213 -.313* -0.031 -.509** -.308* -0.052 -.365* -.416** -.363* -.560** -.835** -.412** -0.031 .710** 
vsa_don 
Sig. (2-tailed) 0.150 0.032 0.835 0.000 0.035 0.728 0.012 0.004 0.012 0.000 0.000 0.004 0.836 0.000 
Correlation Coefficient .649** .733** .329* .946** .715** .321* .843** .569** .545** 0.248 .593** .799** .297* -.673** 
vsa_hyd 
Sig. (2-tailed) 0.000 0.000 0.024 0.000 0.000 0.028 0.000 0.000 0.000 0.093 0.000 0.000 0.042 0.000 
Correlation Coefficient -0.152 -0.115 0.068 -.316* -0.098 0.067 -0.122 -.297* -0.262 -.642** -.903** -.292* 0.067 .704** 
vsa_pol 
Sig. (2-tailed) 0.308 0.440 0.650 0.030 0.513 0.654 0.414 0.043 0.075 0.000 0.000 0.046 0.653 0.000 
Correlation Coefficient -0.012 -0.060 0.139 -0.229 -0.090 0.103 -0.129 -.291* -0.199 -.596** -.761** -0.207 -0.061 .458** 
PM3_dipole 
Sig. (2-tailed) 0.935 0.690 0.352 0.121 0.549 0.490 0.387 0.047 0.180 0.000 0.000 0.163 0.684 0.001 
Correlation Coefficient -.491** -.710** -.299* -.844** -.711** -.310* -.977** -.531** -.528** -0.035 -0.089 -.785** -.363* .293* 
PM3_E 
Sig. (2-tailed) 0.000 0.000 0.041 0.000 0.000 0.034 0.000 0.000 0.000 0.814 0.553 0.000 0.012 0.045 
Correlation Coefficient -.600** -.746** -.307* -.941** -.735** -.309* -.985** -.545** -.583** -0.143 -.296* -.867** -.361* .489** PM3_Eele 








Table A4-5 (cont’d) 
 
  ICMT b_1rotN b_1rotR b_count b_rotN b_rotR weight lip_ violation E E_ele E_sol E_str E_strain E_tor 
Correlation Coefficient 0.115 -.423** -.509** -0.139 -.474** -.568** -.334* 0.014 0.208 .470** .361* 0.029 -0.237 -0.028 
PM3_HF 
Sig. (2-tailed) 0.440 0.003 0.000 0.353 0.001 0.000 0.022 0.925 0.160 0.001 0.013 0.845 0.108 0.850 
Correlation Coefficient .369* 0.194 -0.094 .471** 0.154 -0.127 0.267 .291* .428** .577** .753** .459** 0.008 -.601** 
PM3_HOMO 
Sig. (2-tailed) 0.011 0.191 0.529 0.001 0.300 0.396 0.070 0.047 0.003 0.000 0.000 0.001 0.959 0.000 
Correlation Coefficient -.369* -0.194 0.094 -.471** -0.154 0.127 -0.267 -.291* -.428** -.577** -.753** -.459** -0.008 .601** 
PM3_IP 
Sig. (2-tailed) 0.011 0.191 0.529 0.001 0.300 0.396 0.070 0.047 0.003 0.000 0.000 0.001 0.959 0.000 
Correlation Coefficient .289* 0.132 -0.099 .381** 0.094 -0.128 0.165 0.226 .361* .615** .805** .363* -0.096 -.618** 
PM3_LUMO 
Sig. (2-tailed) 0.049 0.378 0.507 0.008 0.531 0.391 0.267 0.127 0.013 0.000 0.000 0.012 0.522 0.000 
Correlation Coefficient .636** .669** .330* .845** .668** .339* .720** .578** .343* 0.164 .649** .653** 0.267 -.682** 
SlogP 
Sig. (2-tailed) 0.000 0.000 0.024 0.000 0.000 0.020 0.000 0.000 0.018 0.270 0.000 0.000 0.069 0.000 
Correlation Coefficient .619** .763** .357* .953** .758** .369* .832** .569** .389** 0.142 .568** .715** 0.259 -.692** 
ASA_H 
Sig. (2-tailed) 0.000 0.000 0.014 0.000 0.000 0.011 0.000 0.000 0.007 0.341 0.000 0.000 0.078 0.000 
Correlation Coefficient -0.235 -.308* -0.144 -.403** -.293* -0.143 -0.200 -.334* -0.073 -.390** -.894** -0.237 0.092 .775** 
ASA_P 
Sig. (2-tailed) 0.112 0.035 0.335 0.005 0.046 0.337 0.177 0.022 0.626 0.007 0.000 0.109 0.540 0.000 
Correlation Coefficient .684** .820** .404** .994** .807** .404** .937** .545** .476** 0.057 .362* .790** .316* -.564** 
VSA 
Sig. (2-tailed) 0.000 0.000 0.005 0.000 0.000 0.005 0.000 0.000 0.001 0.702 0.012 0.000 0.031 0.000 
Correlation Coefficient -0.115 -0.067 0.096 -0.252 -0.048 0.099 -0.061 -.300* -0.213 -.614** -.880** -0.230 0.089 .646** 
TPSA 
Sig. (2-tailed) 0.443 0.653 0.520 0.088 0.746 0.510 0.686 0.040 0.150 0.000 0.000 0.120 0.553 0.000 
Correlation Coefficient .669** .832** .411** .985** .817** .404** .934** .550** .493** 0.072 .362* .801** .333* -.561** 
vdw_area 
Sig. (2-tailed) 0.000 0.000 0.004 0.000 0.000 0.005 0.000 0.000 0.000 0.631 0.012 0.000 0.022 0.000 
Correlation Coefficient .674** .807** .384** .995** .790** .378** .944** .546** .505** 0.078 .362* .814** .321* -.562
** 
vdw_vol 
Sig. (2-tailed) 0.000 0.000 0.008 0.000 0.000 0.009 0.000 0.000 0.000 0.602 0.012 0.000 0.028 0.000 
Correlation Coefficient .675** .814** .387** .995** .797** .382** .938** .555** .490** 0.068 .366* .800** .324* -.570** 
vol 
Sig. (2-tailed) 0.000 0.000 0.007 0.000 0.000 0.008 0.000 0.000 0.000 0.650 0.011 0.000 0.026 0.000 
Correlation Coefficient .607** .744** .439** .843** .755** .453** .731** .564** 0.220 0.022 .548** .573** .306* -.592** logP 









Table A4-5 (cont’d) 
 
 E_vdw logS mr dipole a_acc a_don vsa_acc vsa_don vsa_hyd vsa_pol PM3_ dipole PM3_E PM3_Eele 
Correlation Coefficient 1.000                         
E_vdw 
Sig. (2-tailed) .                         
Correlation Coefficient -.659** 1.000                       
logS 
Sig. (2-tailed) 0.000 .                       
Correlation Coefficient .880** -.813** 1.000                     
mr 
Sig. (2-tailed) 0.000 0.000 .                     
Correlation Coefficient -0.248 0.153 -0.127 1.000                   
dipole 
Sig. (2-tailed) 0.093 0.305 0.395 .                   
Correlation Coefficient .438** -0.027 .410** 0.251 1.000                 
a_acc 
Sig. (2-tailed) 0.002 0.855 0.004 0.089 .                 
Correlation Coefficient -.561** .333* -.485** .576** -0.002 1.000               
a_don 
Sig. (2-tailed) 0.000 0.022 0.001 0.000 0.990 .               
Correlation Coefficient -0.107 -0.060 0.063 .722** .437** .559** 1.000             
vsa_acc 
Sig. (2-tailed) 0.475 0.687 0.674 0.000 0.002 0.000 .             
Correlation Coefficient -.525** .301* -.474** .599** 0.001 .945** .597** 1.000           
vsa_don 
Sig. (2-tailed) 0.000 0.039 0.001 0.000 0.996 0.000 0.000 .           
Correlation Coefficient .907** -.704** .925** -.337* .378** -.670** -0.213 -.673** 1.000         
vsa_hyd 
Sig. (2-tailed) 0.000 0.000 0.000 0.020 0.009 0.000 0.150 0.000 .         
Correlation Coefficient -.388** 0.181 -0.267 .716** 0.253 .885** .863** .873** -.524** 1.000       
vsa_pol 
Sig. (2-tailed) 0.007 0.224 0.069 0.000 0.086 0.000 0.000 0.000 0.000 .       
Correlation Coefficient -.321* 0.171 -0.186 .932** 0.200 .689** .682** .721** -.412** .764** 1.000     
PM3_dipole 
Sig. (2-tailed) 0.028 0.249 0.212 0.000 0.179 0.000 0.000 0.000 0.004 0.000 .     
Correlation Coefficient -.803** .721** -.883** -0.034 -.525** 0.285 -.336* 0.260 -.744** -0.011 0.041 1.000   
PM3_E 
Sig. (2-tailed) 0.000 0.000 0.000 0.822 0.000 0.052 0.021 0.078 0.000 0.942 0.783 .   
Correlation Coefficient -.908** .768** -.965** 0.092 -.467** .455** -0.113 .437** -.889** 0.217 0.169 .950** 1.000 PM3_Eele 









Table A4-5 (cont’d) 
 
 E_vdw logS mr dipole a_acc a_don vsa_acc vsa_don vsa_hyd vsa_pol PM3_ dipole PM3_E PM3_Eele 
Correlation Coefficient 0.010 0.216 -0.162 -.521** -.323* -0.208 -.709** -0.269 0.018 -.486** -.413** .449** 0.261 
PM3_HF 
Sig. (2-tailed) 0.947 0.144 0.276 0.000 0.027 0.162 0.000 0.067 0.906 0.001 0.004 0.002 0.077 
Correlation Coefficient .540** -.322* .426** -.697** -0.121 -.735** -.729** -.760** .616** -.817** -.716** -0.128 -.350* 
PM3_HOMO 
Sig. (2-tailed) 0.000 0.028 0.003 0.000 0.418 0.000 0.000 0.000 0.000 0.000 0.000 0.393 0.016 
Correlation Coefficient -.540** .322* -.426** .697** 0.121 .735** .729** .760** -.616** .817** .716** 0.128 .350* 
PM3_IP 
Sig. (2-tailed) 0.000 0.028 0.003 0.000 0.418 0.000 0.000 0.000 0.000 0.000 0.000 0.393 0.016 
Correlation Coefficient .444** -0.254 .335* -.729** -0.193 -.772** -.788** -.787** .544** -.868** -.748** -0.017 -0.255 
PM3_LUMO 
Sig. (2-tailed) 0.002 0.085 0.021 0.000 0.195 0.000 0.000 0.000 0.000 0.000 0.000 0.909 0.083 
Correlation Coefficient .755** -.792** .819** -.454** 0.019 -.628** -.357* -.664** .882** -.581** -.511** -.612** -.764** 
SlogP 
Sig. (2-tailed) 0.000 0.000 0.000 0.001 0.898 0.000 0.014 0.000 0.000 0.000 0.000 0.000 0.000 
Correlation Coefficient .823** -.780** .931** -.335* 0.229 -.637** -0.198 -.664** .952** -.503** -.406** -.726** -.861** 
ASA_H 
Sig. (2-tailed) 0.000 0.000 0.000 0.021 0.121 0.000 0.183 0.000 0.000 0.000 0.005 0.000 0.000 
Correlation Coefficient -.353* .341* -.356* .664** .299* .819** .769** .841** -.564** .918** .713** 0.056 0.276 
ASA_P 
Sig. (2-tailed) 0.015 0.019 0.014 0.000 0.041 0.000 0.000 0.000 0.000 0.000 0.000 0.710 0.060 
Correlation Coefficient .864** -.819** .992** -0.137 .414** -.485** 0.041 -.482** .938** -0.281 -0.198 -.863** -.948** 
VSA 
Sig. (2-tailed) 0.000 0.000 0.000 0.358 0.004 0.001 0.782 0.001 0.000 0.056 0.183 0.000 0.000 
Correlation Coefficient -.314* 0.145 -0.211 .715** .346* .850** .871** .858** -.453** .984** .756** -0.071 0.154 
TPSA 
Sig. (2-tailed) 0.031 0.329 0.155 0.000 0.017 0.000 0.000 0.000 0.001 0.000 0.000 0.635 0.302 
Correlation Coefficient .874** -.794** .983** -0.140 .432** -.502** 0.049 -.490** .944** -.288* -0.213 -.862** -.947** 
vdw_area 
Sig. (2-tailed) 0.000 0.000 0.000 0.348 0.002 0.000 0.744 0.000 0.000 0.050 0.151 0.000 0.000 
Correlation Coefficient .882** -.810** .995** -0.135 .411** -.498** 0.040 -.484** .941** -.289* -0.201 -.872** -.959
** 
vdw_vol 
Sig. (2-tailed) 0.000 0.000 0.000 0.365 0.004 0.000 0.791 0.001 0.000 0.049 0.176 0.000 0.000 
Correlation Coefficient .875** -.808** .993** -0.139 .414** -.501** 0.037 -.489** .940** -.293* -0.202 -.864** -.951** 
vol 
Sig. (2-tailed) 0.000 0.000 0.000 0.351 0.004 0.000 0.804 0.000 0.000 0.046 0.174 0.000 0.000 
Correlation Coefficient .679** -.861** .817** -.377** 0.011 -.532** -0.222 -.565** .818** -.452** -.444** -.636** -.750** logP 









Table A4-5 (cont’d) 
 
 PM3_HF PM3_ HOMO PM3_IP 
PM3_ 
LUMO SlogP ASA_H ASA_P VSA TPSA vdw_area vdw_vol vol logP 
Correlation Coefficient 1.000                         
PM3_HF 
Sig. (2-tailed) .                         
Correlation Coefficient .610** 1.000                       
PM3_HOMO 
Sig. (2-tailed) 0.000 .                       
Correlation Coefficient -.610** -1.000** 1.000                     
PM3_IP 
Sig. (2-tailed) 0.000 . .                     
Correlation Coefficient .633** .956** -.956** 1.000                   
PM3_LUMO 
Sig. (2-tailed) 0.000 0.000 0.000 .                   
Correlation Coefficient 0.100 .658** -.658** .601** 1.000                 
SlogP 
Sig. (2-tailed) 0.503 0.000 0.000 0.000 .                 
Correlation Coefficient -0.013 .605** -.605** .530** .924** 1.000               
ASA_H 
Sig. (2-tailed) 0.929 0.000 0.000 0.000 0.000 .               
Correlation Coefficient -.375** -.766** .766** -.816** -.693** -.617** 1.000             
ASA_P 
Sig. (2-tailed) 0.009 0.000 0.000 0.000 0.000 0.000 .             
Correlation Coefficient -0.162 .433** -.433** .343* .833** .941** -.373** 1.000           
VSA 
Sig. (2-tailed) 0.277 0.002 0.002 0.018 0.000 0.000 0.010 .           
Correlation Coefficient -.526** -.799** .799** -.857** -.550** -.459** .930** -0.216 1.000         
TPSA 
Sig. (2-tailed) 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.145 .         
Correlation Coefficient -0.161 .439** -.439** .346* .819** .931** -.369* .991** -0.221 1.000       
vdw_area 
Sig. (2-tailed) 0.278 0.002 0.002 0.017 0.000 0.000 0.011 0.000 0.135 .       
Correlation Coefficient -0.160 .440** -.440** .349* .833** .938** -.371* .997** -0.224 .991** 1.000     
vdw_vol 
Sig. (2-tailed) 0.282 0.002 0.002 0.016 0.000 0.000 0.010 0.000 0.130 0.000 .     
Correlation Coefficient -0.155 .444** -.444** .349* .833** .943** -.378** .997** -0.228 .992** .998** 1.000   
vol 
Sig. (2-tailed) 0.298 0.002 0.002 0.016 0.000 0.000 0.009 0.000 0.123 0.000 0.000 .   
Correlation Coefficient -0.049 .528** -.528** .468** .939** .898** -.601** .833** -.429** .812** .824** .824** 1.000 logP 









Table A4-6. Spearman Rho Correlation Coefficient of Descriptors employed in developing Equations 5-3 and 5-5 (protonated 
compounds) 
  ICMT b_1rotN b_1rotR b_count b_rotN b_rotR weight lip_ violation E E_ele E_sol E_str E_strain E_tor 
Correlation Coefficient .601** 1                         
b_1rotN 
Sig. (2-tailed) 0 .                         
Correlation Coefficient .387** .801** 1                       
b_1rotR 
Sig. (2-tailed) 0.007 0 .                       
Correlation Coefficient .670** .798** .373** 1                     
b_count 
Sig. (2-tailed) 0 0 0.01 .                     
Correlation Coefficient .528** .979** .790** .779** 1                   
b_rotN 
Sig. (2-tailed) 0 0 0 0 .                   
Correlation Coefficient .307* .778** .972** .366* .813** 1                 
b_rotR 
Sig. (2-tailed) 0.036 0 0 0.011 0 .                 
Correlation Coefficient .600** .767** .337* .919** .754** .334* 1               
weight 
Sig. (2-tailed) 0 0 0.021 0 0 0.022 .               
Correlation Coefficient .399** .534** .309* .490** .548** .313* .503** 1             
lip_violation 
Sig. (2-tailed) 0.006 0 0.034 0 0 0.032 0 .             
Correlation Coefficient 0.178 0.154 -0.257 .488** 0.135 -0.27 .563** 0.191 1           
E 
Sig. (2-tailed) 0.232 0.302 0.081 0.001 0.367 0.067 0 0.198 .           
Correlation Coefficient -.379** -.386** -.576** -0.071 -.361* -.529** -0.005 -0.243 .583** 1         
E_ele 
Sig. (2-tailed) 0.009 0.007 0 0.636 0.013 0 0.974 0.1 0 .         
Correlation Coefficient -.302* 0.088 0.151 -0.086 0.167 0.222 0.07 0.239 -0.01 0.033 1       
E_sol 
Sig. (2-tailed) 0.039 0.556 0.31 0.567 0.263 0.134 0.64 0.105 0.946 0.825 .       
Correlation Coefficient .529** .475** 0.035 .810** .443** 0.007 .823** .399** .767** 0.253 -0.126 1     
E_str 
Sig. (2-tailed) 0 0.001 0.816 0 0.002 0.963 0 0.006 0 0.086 0.399 .     
Correlation Coefficient 0.205 .294* 0.183 .295* .298* 0.203 .303* 0.223 0.054 -0.094 0.039 0.133 1   
E_strain 
Sig. (2-tailed) 0.167 0.045 0.218 0.044 0.042 0.172 0.038 0.131 0.72 0.53 0.795 0.375 .   
Correlation Coefficient -.302* -.646** -.505** -.668** -.647** -.540** -.536** -0.175 -0.019 0.108 0.147 -.395** -0.123 1 E_tor 








Table A4-6 (cont’d) 
   ICMT b_1rotN b_1rotR b_count b_rotN b_rotR weight lip_ violation E E_ele E_sol E_str E_strain E_tor 
E_vdw Correlation Coefficient .554** .589** 0.141 .886** .564** 0.123 .883** .446** .738** 0.145 -0.093 .945** 0.179 -.490** 
 Sig. (2-tailed) 0 0 0.345 0 0 0.411 0 0.002 0 0.33 0.536 0 0.229 0 
logS Correlation Coefficient -.543** -.734** -.417** -.778** -.756** -.439** -.760** -.634** -.325* 0.147 -0.279 -.648** -0.11 .506** 
 Sig. (2-tailed) 0 0 0.004 0 0 0.002 0 0 0.026 0.325 0.057 0 0.462 0 
mr Correlation Coefficient .655** .790** .352* .986** .776** .350* .950** .514** .537** -0.02 0.011 .826** .320* -.618** 
 Sig. (2-tailed) 0 0 0.015 0 0 0.016 0 0 0 0.893 0.941 0 0.028 0 
dipole Correlation Coefficient .442** 0.177 0.107 .351* 0.098 0.041 0.141 -0.072 0.034 -0.156 -.780** .289* 0.018 -.459** 
 Sig. (2-tailed) 0.002 0.234 0.475 0.016 0.514 0.786 0.343 0.632 0.821 0.294 0 0.049 0.904 0.001 
a_acc Correlation Coefficient -0.119 0.167 0.187 -0.025 0.195 0.21 0.207 0.02 0.1 -0.023 .554** -0.05 .361* 0.268 
 Sig. (2-tailed) 0.426 0.261 0.208 0.87 0.188 0.156 0.163 0.894 0.504 0.878 0 0.741 0.013 0.068 
a_base Correlation Coefficient .332* 0.058 -0.105 .330* 0.001 -0.148 0.124 -0.075 0.148 0.02 -.856** .328* -0.124 -.413** 
 Sig. (2-tailed) 0.023 0.699 0.484 0.023 0.996 0.32 0.405 0.619 0.322 0.893 0 0.024 0.407 0.004 
a_don Correlation Coefficient -0.21 -.299* -0.032 -.510** -0.275 -0.032 -.344* -0.202 -.354* -0.278 0.262 -.438** 0.11 .617** 
 Sig. (2-tailed) 0.157 0.041 0.832 0 0.062 0.832 0.018 0.173 0.015 0.059 0.075 0.002 0.462 0 
vsa_acc Correlation Coefficient -0.108 0.183 0.219 -0.042 0.216 0.245 0.192 0.046 0.031 -0.075 .604** -0.093 .351* 0.264 
 Sig. (2-tailed) 0.471 0.218 0.138 0.781 0.145 0.096 0.196 0.761 0.837 0.614 0 0.534 0.016 0.073 
vsa_don Correlation Coefficient -0.15 -.343* -0.042 -.564** -.339* -0.064 -.405** -0.206 -.361* -.296* 0.172 -.469** 0.056 .648** 
 Sig. (2-tailed) 0.315 0.018 0.777 0 0.02 0.669 0.005 0.164 0.013 0.043 0.249 0.001 0.71 0 
vsa_hyd Correlation Coefficient .649** .733** .329* .959** .715** .321* .849** .459** .529** -0.012 -0.206 .826** 0.221 -.668** 
 Sig. (2-tailed) 0 0 0.024 0 0 0.028 0 0.001 0 0.938 0.166 0 0.135 0 
vsa_pol Correlation Coefficient -0.152 -0.115 0.068 -.355* -0.098 0.067 -0.13 -0.105 -0.194 -0.203 .414** -.326* 0.221 .542** 
 Sig. (2-tailed) 0.308 0.44 0.65 0.014 0.513 0.654 0.383 0.481 0.192 0.171 0.004 0.026 0.135 0 
PM3_dipole Correlation Coefficient .449** 0.098 0.039 0.282 0.012 -0.037 0.085 -0.104 0.052 -0.139 -.843** 0.251 0.044 -.332* 
 Sig. (2-tailed) 0.002 0.512 0.794 0.055 0.935 0.803 0.571 0.488 0.728 0.351 0 0.088 0.77 0.023 
PM3_E Correlation Coefficient -.492** -.706** -.294* -.829** -.707** -.305* -.973** -.490** -.569** -0.051 -0.175 -.769** -.304* .434** 
 Sig. (2-tailed) 0 0 0.045 0 0 0.037 0 0 0 0.734 0.24 0 0.038 0.002 
PM3_Eele Correlation Coefficient -.604** -.740** -.297* -.936** -.725** -.296* -.986** -.486** -.605** -0.047 -0.013 -.869** -0.267 .573** 








Table A4-6 (cont’d) 
 
   ICMT b_1rotN b_1rotR b_count b_rotN b_rotR weight lip_ violation E E_ele E_sol E_str E_strain E_tor 
Correlation Coefficient 0.273 -0.185 -.322* 0.127 -0.252 -.384** -0.131 -0.076 0.116 0.083 -.788** 0.217 -0.214 -0.12 
PM3_HF 
Sig. (2-tailed) 0.063 0.213 0.027 0.393 0.088 0.008 0.378 0.613 0.438 0.581 0 0.143 0.149 0.422 
Correlation Coefficient -0.21 0.115 0.088 -0.022 0.166 0.134 0.097 0.283 0.107 0.154 .863** -0.049 0.155 0.191 
PM3_HOMO 
Sig. (2-tailed) 0.157 0.441 0.558 0.883 0.264 0.368 0.515 0.054 0.474 0.301 0 0.743 0.299 0.199 
Correlation Coefficient 0.21 -0.115 -0.088 0.022 -0.166 -0.134 -0.097 -0.283 -0.107 -0.154 -.863** 0.049 -0.155 -0.19 
PM3_IP 
Sig. (2-tailed) 0.157 0.441 0.558 0.883 0.264 0.368 0.515 0.054 0.474 0.301 0 0.743 0.299 0.199 
Correlation Coefficient -0.248 0.063 0.115 -0.113 0.116 0.161 -0.009 0.191 0.015 0.121 .887** -0.153 0.002 0.184 
PM3_LUMO 
Sig. (2-tailed) 0.093 0.674 0.442 0.449 0.438 0.279 0.954 0.198 0.92 0.419 0 0.306 0.989 0.215 
Correlation Coefficient .454** .700** .442** .683** .742** .482** .689** .682** 0.204 -0.214 .460** .498** 0.091 -.462** 
SlogP 
Sig. (2-tailed) 0.001 0 0.002 0 0 0.001 0 0 0.169 0.148 0.001 0 0.543 0.001 
Correlation Coefficient .639** .784** .396** .944** .782** .407** .821** .554** .351* -0.129 -0.042 .710** 0.207 -.718** 
ASA_H 
Sig. (2-tailed) 0 0 0.006 0 0 0.004 0 0 0.016 0.388 0.779 0 0.163 0 
Correlation Coefficient -0.2 -.309* -0.148 -.416** -.300* -0.154 -0.199 -0.247 -0.021 0.039 0.224 -0.258 0.203 .634** 
ASA_P 
Sig. (2-tailed) 0.178 0.034 0.322 0.004 0.04 0.301 0.181 0.094 0.889 0.793 0.129 0.08 0.172 0 
Correlation Coefficient .689** .822** .408** .990** .808** .405** .938** .502** .487** -0.071 -0.019 .802** .317* -.648** 
VSA 
Sig. (2-tailed) 0 0 0.004 0 0 0.005 0 0 0.001 0.636 0.897 0 0.03 0 
Correlation Coefficient -0.105 -0.071 0.095 -.292* -0.054 0.095 -0.073 -0.145 -0.146 -0.194 .347* -0.263 0.241 .483** 
TPSA 
Sig. (2-tailed) 0.482 0.637 0.526 0.047 0.72 0.524 0.627 0.332 0.329 0.192 0.017 0.074 0.102 0.001 
Correlation Coefficient .663** .816** .396** .989** .799** .389** .924** .487** .509** -0.056 -0.078 .820** .311* -.658** 
vdw_area 
Sig. (2-tailed) 0 0 0.006 0 0 0.007 0 0.001 0 0.71 0.602 0 0.033 0 
Correlation Coefficient .680** .798** .365* .992** .782** .361* .940** .503** .517** -0.048 -0.045 .824** .307* -.644** 
vdw_vol 
Sig. (2-tailed) 0 0 0.012 0 0 0.013 0 0 0 0.747 0.765 0 0.036 0 
Correlation Coefficient .679** .809** .378** .992** .790** .370* .939** .502** .505** -0.061 -0.035 .818** .308* -.645** 
vol 
Sig. (2-tailed) 0 0 0.009 0 0 0.011 0 0 0 0.686 0.817 0 0.035 0 
Correlation Coefficient .607** .744** .439** .842** .755** .453** .733** .606** 0.212 -0.22 0.067 .602** 0.092 -.631** logP 









Table A4-6 (cont’d) 
   E_vdw logS mr dipole a_acc a_base a_don vsa_acc vsa_don vsa_hyd vsa_pol PM3_ dipole PM3_E PM3_Eele 
E_vdw Correlation Coefficient 1                           
 Sig. (2-tailed) .                           
logS Correlation Coefficient -.670** 1                         
 Sig. (2-tailed) 0 .                         
mr Correlation Coefficient .890** -.805** 1                       
 Sig. (2-tailed) 0 0 .                       
dipole Correlation Coefficient .305* 0.002 0.247 1                     
 Sig. (2-tailed) 0.037 0.99 0.094 .                     
a_acc Correlation Coefficient -0.005 -0.05 0.071 -.578** 1                   
 Sig. (2-tailed) 0.973 0.75 0.633 0 .                   
a_base Correlation Coefficient .331* 0.025 0.221 .856** -.754** 1                 
 Sig. (2-tailed) 0.023 0.87 0.136 0 0 .                 
a_don Correlation Coefficient -.504** .295* -.451** -.497** .569** -.641** 1               
 Sig. (2-tailed) 0 0.044 0.001 0 0 0 .               
vsa_acc Correlation Coefficient -0.049 -0.07 0.055 -.607** .981** -.811** .614** 1             
 Sig. (2-tailed) 0.743 0.658 0.715 0 0 0 0 .             
vsa_don Correlation Coefficient -.534** .329* -.516** -.406** .493** -.571** .938** .537** 1           
 Sig. (2-tailed) 0 0.024 0 0.005 0 0 0 0 .           
vsa_hyd Correlation Coefficient .896** -.699** .929** .468** -0.18 .492** -.650** -0.213 -.693** 1         
 Sig. (2-tailed) 0 0 0 0.001 0.224 0 0 0.15 0 .         
vsa_pol Correlation Coefficient -.345* 0.175 -0.27 -.569** .835** -.766** .876** .863** .879** -.524** 1       
 Sig. (2-tailed) 0.018 0.239 0.062 0 0 0 0 0 0 0 .       
PM3_dipole Correlation Coefficient 0.238 0.045 0.187 .952** -.575** .856** -.388** -.608** -.288* .396** -.503** 1     
 Sig. (2-tailed) 0.108 0.763 0.208 0 0 0 0.007 0 0.05 0.006 0 .     
PM3_E Correlation Coefficient -.828** .712** -.877** -0.01 -.349* 0.015 0.242 -.336* .305* -.744** -0.011 0.049 1   
 Sig. (2-tailed) 0 0 0 0.946 0.016 0.921 0.101 0.021 0.037 0 0.942 0.742 .   
PM3_Eele Correlation Coefficient -.926** .756** -.962** -0.22 -0.13 -0.205 .424** -0.102 .480** -.891** 0.225 -0.153 .947** 1 








Table A4-6 (cont’d) 
 
   E_vdw logS mr dipole a_acc a_base a_don vsa_acc vsa_don vsa_hyd vsa_pol PM3_ dipole PM3_E PM3_Eele 
Correlation Coefficient 0.153 0.132 0.033 .678** -.809** .856** -.482** -.849** -.411** 0.278 -.695** .723** 0.285 0.042 
PM3_HF 
Sig. (2-tailed) 0.304 0.376 0.827 0 0 0 0.001 0 0.004 0.059 0 0 0.052 0.778 
Correlation Coefficient -0.037 -0.28 0.08 -.801** .577** -.856** 0.271 .631** 0.203 -0.168 .450** -.824** -0.19 -0.047 
PM3_HOMO 
Sig. (2-tailed) 0.803 0.053 0.592 0 0 0 0.066 0 0.171 0.26 0.002 0 0.202 0.755 
Correlation Coefficient 0.037 0.284 -0.08 .801** -.577** .856** -0.27 -.631** -0.203 0.168 -.450** .824** 0.19 0.047 
PM3_IP 
Sig. (2-tailed) 0.803 0.053 0.592 0 0 0 0.066 0 0.171 0.26 0.002 0 0.202 0.755 
Correlation Coefficient -0.141 -0.25 -0.02 -.816** .497** -.856** 0.268 .557** 0.198 -0.247 .398** -.848** -0.077 0.051 
PM3_LUMO 
Sig. (2-tailed) 0.344 0.093 0.919 0 0 0 0.069 0 0.183 0.094 0.006 0 0.608 0.731 
Correlation Coefficient .570** -.894** .719** -0.18 0.078 -0.169 -.316* 0.109 -.363* .618** -0.168 -0.255 -.656** -.677** 
SlogP 
Sig. (2-tailed) 0 0 0 0.233 0.603 0.256 0.031 0.466 0.012 0 0.259 0.084 0 0 
Correlation Coefficient .791** -.808** .922** .344* -0.19 .356* -.620** -0.197 -.668** .940** -.501** 0.257 -.710** -.849** 
ASA_H 
Sig. (2-tailed) 0 0 0 0.018 0.194 0.014 0 0.185 0 0 0 0.081 0 0 
Correlation Coefficient -.301* .340* -.351* -.447** .735** -.606** .810** .745** .842** -.548** .909** -.356* 0.05 0.272 
ASA_P 
Sig. (2-tailed) 0.04 0.019 0.015 0.002 0 0 0 0 0 0 0 0.014 0.736 0.064 
Correlation Coefficient .871** -.813** .993** 0.287 0.049 0.247 -.454** 0.039 -.508** .937** -0.281 0.226 -.860** -.947** 
VSA 
Sig. (2-tailed) 0 0 0 0.051 0.744 0.094 0.001 0.796 0 0 0.056 0.126 0 0 
Correlation Coefficient -0.278 0.147 -0.22 -.499** .840** -.702** .854** .866** .858** -.456** .985** -.433** -0.068 0.164 
TPSA 
Sig. (2-tailed) 0.058 0.324 0.138 0 0 0 0 0 0 0.001 0 0.002 0.652 0.27 
Correlation Coefficient .891** -.765** .982** .338* 0.006 .315* -.509** -0.011 -.574** .966** -.346* 0.274 -.838** -.939** 
vdw_area 
Sig. (2-tailed) 0 0 0 0.02 0.969 0.031 0 0.941 0 0 0.017 0.062 0 0 
Correlation Coefficient .895** -.792** .993** .308* 0.02 0.281 -.489** 0.009 -.542** .951** -.316* 0.246 -.862** -.954** 
vdw_vol 
Sig. (2-tailed) 0 0 0 0.035 0.893 0.056 0 0.951 0 0 0.03 0.096 0 0 
Correlation Coefficient .887** -.800** .993** .295* 0.034 0.267 -.474** 0.023 -.534** .943** -.305* 0.234 -.859** -.949** 
vol 
Sig. (2-tailed) 0 0 0 0.044 0.82 0.07 0.001 0.876 0 0 0.037 0.113 0 0 
Correlation Coefficient .675** -.859** .816** 0.251 -0.23 0.263 -.539** -0.222 -.557** .818** -.452** 0.165 -.631** -.746** logP 









Table A4-6 (cont’d) 
 
   PM3_HF PM3_ HOMO PM3_IP 
PM3_ 
LUMO SlogP ASA_H ASA_P VSA TPSA vdw_area vdw_vol vol logP 
Correlation Coefficient 1                         
PM3_HF 
Sig. (2-tailed) .                         
Correlation Coefficient -.675** 1                       
PM3_HOMO 
Sig. (2-tailed) 0 .                       
Correlation Coefficient .675** -1.000** 1                     
PM3_IP 
Sig. (2-tailed) 0 . .                     
Correlation Coefficient -.662** .953** -.953** 1                   
PM3_LUMO 
Sig. (2-tailed) 0 0 0 .                   
Correlation Coefficient -0.243 .432** -.432** .416** 1                 
SlogP 
Sig. (2-tailed) 0.1 0.002 0.002 0.004 .                 
Correlation Coefficient 0.182 -0.006 0.006 -0.066 .780** 1               
ASA_H 
Sig. (2-tailed) 0.22 0.967 0.967 0.658 0 .               
Correlation Coefficient -.530** 0.286 -0.286 0.224 -.403** -.628** 1             
ASA_P 
Sig. (2-tailed) 0 0.051 0.051 0.13 0.005 0 .             
Correlation Coefficient 0.044 0.045 -0.045 -0.047 .718** .931** -.363* 1           
VSA 
Sig. (2-tailed) 0.769 0.762 0.762 0.754 0 0 0.012 .           
Correlation Coefficient -.673** .381** -.381** .330* -0.19 -.464** .924** -0.22 1         
TPSA 
Sig. (2-tailed) 0 0.008 0.008 0.023 0.214 0.001 0 0.139 .         
Correlation Coefficient 0.105 -0.016 0.016 -0.113 .679** .936** -.410** .987** -0.28 1       
vdw_area 
Sig. (2-tailed) 0.483 0.914 0.914 0.45 0 0 0.004 0 0.056 .       
Correlation Coefficient 0.077 0.021 -0.021 -0.073 .706** .934** -.381** .996** -0.25 .992** 1     
vdw_vol 
Sig. (2-tailed) 0.605 0.89 0.89 0.624 0 0 0.008 0 0.086 0 .     
Correlation Coefficient 0.07 0.029 -0.029 -0.061 .708** .930** -.373** .996** -0.24 .991** .997** 1   
vol 
Sig. (2-tailed) 0.638 0.846 0.846 0.685 0 0 0.01 0 0.102 0 0 .   
Correlation Coefficient 0.108 0.028 -0.028 -0.007 .838** .921** -.589** .832** -.432** .814** .823** .824** 1 logP 
Sig. (2-tailed) 0.468 0.851 0.851 0.964 0 0 0 0 0.002 0 0 0 . 
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